## Alzheimer Disease in the US Population

Archives of Neurology 60, 1119

DOI: 10.1001/archneur.60.8.1119

Citation Report

#	Article	IF	CITATIONS
2	Alzheimer's disease caregiving information and skills. Part I: Care recipient issues and concerns. Research in Nursing and Health, 2003, 26, 366-375.	0.8	31
3	Emerging Therapeutics for Alzheimer's Disease: An Avenue of Hope. CNS Spectrums, 2003, 8, 834-845.	0.7	8
5	Linking lipids, Alzheimer's and LXRs?. Nuclear Receptor Signaling, 2004, 2, nrs.02001.	1.0	9
6	Testing the amyloid toxicity hypothesis of alzheimer's disease in transgenic Caenorhabditis elegans model. Frontiers in Bioscience - Landmark, 2004, 9, 3333.	3.0	12
7	Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion, 2004, 20, 517-524.	0.9	39
8	Memantine: An antiglutamatergic option for dementia. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 10-18.	0.9	16
9	Homocysteine and cognitive function in elderly people. Cmaj, 2004, 171, 897-904.	0.9	105
10	Consortium for the Assessment of Research on Progestins and Estrogens (CARPE) Fort Worth, Texas August 1–3, 2003. Journal of Women's Health, 2004, 13, 1165-1168.	1.5	8
11	Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice. Journal of Neuroscience, 2004, 24, 2527-2534.	1.7	342
12	Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil. JAMA - Journal of the American Medical Association, 2004, 291, 317.	3.8	1,186
13	Addressing the Ethical, Legal, and Social Issues Raised by Voting by Persons With Dementia. JAMA - Journal of the American Medical Association, 2004, 292, 1345.	3.8	42
14	Year 2000 Prevalence of Alzheimer Disease in the United States. Archives of Neurology, 2004, 61, 802.	4.9	8
15	Working with organization to implement dementia awareness training for public contact staff. American Journal of Alzheimer's Disease and Other Dementias, 2004, 19, 166-171.	0.9	6
16	Validation of a 26-Point Telephone Version of the Mini-Mental State Examination. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 81-87.	1.2	157
17	Relation of Apolipoprotein(a) Size to Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 18, 189-196.	0.7	21
18	Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1327-1330.	0.9	47
19	Brain Inflammation and Alzheimer's-Like Pathology in Individuals Exposed to Severe Air Pollution. Toxicologic Pathology, 2004, 32, 650-658.	0.9	456
20	Utilizing combination therapy in the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2004, 4, 799-808.	1.4	18

#	ARTICLE	IF	Citations
21	Terminal Care for Persons with Advanced Dementia in the Nursing Home and Home Care Settings. Journal of Palliative Medicine, 2004, 7, 808-816.	0.6	122
22	Student Scholarship Presentation Abstracts. Journal of Neurotherapy, 2004, 8, 107-118.	0.9	2
23	Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Current Medical Research and Opinion, 2004, 20, 1605-1612.	0.9	48
24	Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women <subtitle>Women's Health Initiative Memory Study</subtitle> . JAMA - Journal of the American Medical Association, 2004, 291, 2947.	3.8	1,149
25	State-specific projections through 2025 of Alzheimer disease prevalence. Neurology, 2004, 62, 1645-1645.	1.5	70
26	Post mortem sampling of the brain and other tissues in neurodegenerative disease. Histopathology, 2004, 44, 309-317.	1.6	28
27	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nature Medicine, 2004, 10, 1055-1063.	15.2	624
28	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Molecular Psychiatry, 2004, 9, 664-683.	4.1	248
29	The Effect of Dementia on Outcomes and Process of Care for Medicare Beneficiaries Admitted with Acute Myocardial Infarction. Journal of the American Geriatrics Society, 2004, 52, 173-181.	1.3	79
30	The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurology, The, 2004, 3, 627-630.	4.9	98
31	Apolipoprotein E: Diversity of Cellular Origins, Structural and Biophysical Properties, and Effects in Alzheimer's Disease. Journal of Molecular Neuroscience, 2004, 23, 189-204.	1.1	184
32	Microglia as a Potential Bridge between the Amyloid Â-Peptide and Tau. Annals of the New York Academy of Sciences, 2004, 1035, 85-103.	1.8	140
33	Hypertension and dementia: Does blood pressure control favorably affect cognition?. Current Hypertension Reports, 2004, 6, 357-362.	1.5	10
34	Microscale fractionation facilitates detection of differentially expressed proteins in Alzheimer's disease brain samples. Electrophoresis, 2004, 25, 2557-2563.	1.3	10
36	The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opinion on Drug Safety, 2004, 3, 425-440.	1.0	86
37	Efficacy of an Educational Program for Relatives of Persons in the Early Stages of Alzheimer's Disease. Journal of Gerontological Social Work, 2004, 42, 109-130.	0.6	41
38	Dementia and serious coexisting medical conditions: a double whammy. Nursing Clinics of North America, 2004, 39, 561-579.	0.7	32
39	Analyses of gender differences in profiles of nursing home residents with Alzheimer's disease. Gender Medicine, 2004, 1, 48-59.	1.4	31

#	Article	IF	Citations
40	Overview of Alzheimer's disease. Nursing Clinics of North America, 2004, 39, 545-559.	0.7	6
41	Sensitivity to Alzheimer's disease. Optometry - Journal of the American Optometric Association, 2004, 75, 541-542.	0.6	0
42	Dietâ€induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB Journal, 2004, 18, 902-904.	0.2	583
43	Pain assessment and management in persons with dementia. Nursing Clinics of North America, 2004, 39, 593-606.	0.7	73
44	Alzheimer's Disease. New England Journal of Medicine, 2004, 351, 56-67.	13.9	1,221
45	Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie, 2004, 86, 589-600.	1.3	47
46	Women's cognitive health: postmenopausal dementia and the women's health initiative memory study. Women's Health Issues, 2004, 14, 71-74.	0.9	3
47	Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Progress in Neurobiology, 2004, 74, 249-270.	2.8	141
48	Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiology of Aging, 2004, 25, 651-660.	1.5	113
49	Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neuroscience Letters, 2004, 371, 199-204.	1.0	12
50	Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. American Journal of Geriatric Pharmacotherapy, 2004, 2, 119-132.	3.0	39
51	Neurochemical imaging of dementias. Seminars in Nuclear Medicine, 2004, 34, 70-82.	2.5	19
52	Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clinical Therapeutics, 2004, 26, 615-630.	1.1	106
53	What Are the Challenges Faced by Psychiatrists in the Management of Alzheimer's Disease?. CNS Spectrums, 2004, 9, 13-15.	0.7	5
54	Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women: Women???s Health Initiative Memory Study. Obstetrical and Gynecological Survey, 2004, 59, 711.	0.2	4
56	The Participation of Cognitively Impaired Elderly in Research. Care Management Journals: Journal of Case Management; the Journal of Long Term Home Health Care, 2004, 5, 245-257.	0.5	3
57	Stimulating Creativity in All Elders: A Continuum of Interventions. Care Management Journals: Journal of Case Management; the Journal of Long Term Home Health Care, 2004, 5, 175-182.	0.5	13
58	Bathing Patients with Dementia. American Journal of Nursing, 2004, 104, 30-32.	0.2	13

#	Article	IF	Citations
59	Anaesthesia in patients with dementia. Current Opinion in Anaesthesiology, 2004, 17, 277-283.	0.9	11
60	Delirium and Dementia. Focus (American Psychiatric Publishing), 2004, 2, 210-220.	0.4	3
61	Comparisons Between Alzheimer Disease, Frontotemporal Lobar Degeneration, and Normal Aging With Brain Mapping. Topics in Magnetic Resonance Imaging, 2005, 16, 409-425.	0.7	71
62	Grief and Mourning from the Perspective of the Person with a Dementing Illness: Beginning the Dialogue. Omega: Journal of Death and Dying, 2005, 50, 165-179.	0.7	11
63	BEHAVIORS ASSOCIATED WITH DEMENTIA. American Journal of Nursing, 2005, 105, 40-52.	0.2	53
64	Reduction of Caregiver Burden in Alzheimer's Disease by Treatment with Galantamine. CNS Spectrums, 2005, 10, 481-488.	0.7	15
65	Therapy of vascular dementia: perspectives and milestones. Therapy: Open Access in Clinical Medicine, 2005, 2, 649-658.	0.2	5
66	Dementia Update 2005. Alzheimer Disease and Associated Disorders, 2005, 19, 100-117.	0.6	58
67	The Validation of a Caregiver Assessment of Dementia. Alzheimer Disease and Associated Disorders, 2005, 19, 186-194.	0.6	15
68	Taking care of the caregivers. Current Opinion in Psychiatry, 2005, 18, 633-639.	3.1	36
69	The Effect of a Memory Screening Program on the Early Diagnosis of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 1-7.	0.6	32
70	A Novel Interactive Voice Response (IVR) System for Dementia Screening, Education, and Referral: One-Year Summary. Alzheimer Disease and Associated Disorders, 2005, 19, 143-147.	0.6	14
71	Cultural Diversity in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 250-255.	0.6	30
72	Alzheimer's Disease: Current and Future Treatments. , 2005, , 329-354.		1
73	Predictors of Preclinical Alzheimer Disease and Dementia. Archives of Neurology, 2005, 62, 758.	4.9	190
75	CE TEST: Behaviors Associated with Dementia. American Journal of Nursing, 2005, 105, 52-53.	0.2	0
76	BACE Inhibitors for the Treatment of Alzheimer's Disease. Annual Reports in Medicinal Chemistry, 2005, 40, 35-48.	0.5	15
77	Are the benefits of NSAIDs to decrease the risk of Alzheimer's disease a MIRAGE?. Therapy: Open Access in Clinical Medicine, 2005, 2, 375-380.	0.2	1

#	ARTICLE	IF	Citations
78	Chemiluminescent high-throughput microassay for evaluation of acetylcholinesterase inhibitors. Analytica Chimica Acta, 2005, 535, 139-144.	2.6	24
79	Estrogen Bows to a New Master: The Role of Gonadotropins in Alzheimer Pathogenesis. Annals of the New York Academy of Sciences, 2005, 1052, 201-209.	1.8	43
80	Is Hypercholesterolemia a Risk Factor for Alzheimer's Disease?. Molecular Neurobiology, 2005, 31, 185-192.	1.9	32
82	A self-reported survey of Alzheimer's centers in Southwestern Pennsylvania. Special Care in Dentistry, 2005, 25, 164-170.	0.4	3
83	Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clinical Microbiology and Infection, 2005, 11, 788-800.	2.8	77
84	A National Study of the Location of Death for Older Persons with Dementia. Journal of the American Geriatrics Society, 2005, 53, 299-305.	1.3	334
85	Decisions to Hospitalize Nursing Home Residents Dying with Advanced Dementia. Journal of the American Geriatrics Society, 2005, 53, 1396-1401.	1.3	119
86	Cognitive function among physically independent very old people in an urban Japanese community. Geriatrics and Gerontology International, 2005, 5, 248-253.	0.7	3
87	Statins — a cure-all for the brain?. Nature Reviews Neuroscience, 2005, 6, 325-331.	4.9	104
88	Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Journal, 2005, 272, 2347-2361.	2.2	87
89	Dementia and Driving: Autonomy Versus Safety. Journal of the American Academy of Nurse Practitioners, 2005, 17, 393-402.	1.4	30
90	Dementia treatment update. Geriatric Nursing, 2005, 26, 74-78.	0.9	4
91	Development of nurse competencies to improve dementia care. Geriatric Nursing, 2005, 26, 98-105.	0.9	35
92	Genetically engineered livestock: closer than we think?. Trends in Biotechnology, 2005, 23, 533-535.	4.9	15
93	En route to early diagnosis of Alzheimer's disease – are we there yet?. Trends in Biotechnology, 2005, 23, 531-533.	4.9	23
94	Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotoxicity Research, 2005, 8, 25-50.	1.3	66
95	Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings. Journal of Managed Care Pharmacy, 2005, 11, 231-239.	2.2	57
96	Genetic Mouse Models of Alzheimer's Disease. Neural Plasticity, 2005, 12, 299-310.	1.0	20

#	Article	IF	Citations
97	Widows, Women, and the Bioethics of Care. Christian Bioethics, 2005, 11, 77-92.	0.1	0
98	The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment., 2005,, 166-175.		1
100	Alzheimer's Disease Pathways to Practice: Assessing Diagnosis and Outcome Measures. CNS Spectrums, 2005, 10, 5-5.	0.7	6
101	Nutrition, Brain Aging, and Alzheimers Disease. Current Nutrition and Food Science, 2005, 1, 215-229.	0.3	0
102	An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease. Current Alzheimer Research, 2005, 2, 281-290.	0.7	118
103	Phosphodiesterase Inhibitors for Cognitive Enhancement. Current Pharmaceutical Design, 2005, 11, 3329-3334.	0.9	120
104	Increasing Testosterone Levels and Effects on Cognitive Functions in Elderly Men and Women: A Review. CNS and Neurological Disorders, 2005, 4, 531-540.	4.3	47
105	Widows, Women, and the Bioethics of Care. Christian Bioethics, 2005, 11, 77-92.	0.1	1
106	High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein–Bound Mass Signatures. Clinical Chemistry, 2005, 51, 1946-1954.	1.5	137
107	Caregiver Psychological Adjustment and Institutionalization of Persons With Alzheimer's Disease. Journal of Aging and Health, 2005, 17, 172-189.	0.9	27
108	Genetic Testing For Alzheimer's Disease And Its Impact On Insurance Purchasing Behavior. Health Affairs, 2005, 24, 483-490.	2.5	127
109	Characterization of the APP proximal promoter and 5′â€untranslated regions: identification of cellâ€type specific domains and implications in APP gene expression and Alzheimer's disease. FASEB Journal, 2005, 19, 1-26.	0.2	39
110	Evaluating hospital care for individuals with Alzheimer's disease using inpatient quality indicators. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 27-36.	0.9	21
111	The Rush Memory and Aging Project: Study Design and Baseline Characteristics of the Study Cohort. Neuroepidemiology, 2005, 25, 163-175.	1.1	352
112	The Capacity to Vote of Persons With Alzheimer's Disease. American Journal of Psychiatry, 2005, 162, 2094-2100.	4.0	62
113	Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Current Medical Research and Opinion, 2005, 21, 1631-1639.	0.9	21
114	Factors Associated with Self- and Caregiver Report of Pain among Community-Dwelling Persons with Dementia. Journal of Palliative Medicine, 2005, 8, 567-575.	0.6	23
115	Modeling Ageâ€Related Diseases in Drosophila: Can this Fly?. Current Topics in Developmental Biology, 2005, 71, 199-223.	1.0	13

#	Article	IF	Citations
116	Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy. Journal of Health Services Research and Policy, 2005, 10, 232-238.	0.8	68
118	Compounds That Bind APP and Inhibit $\hat{Al^2}$ Processing in Vitro Suggest a Novel Approach to Alzheimer Disease Therapeutics. Journal of Biological Chemistry, 2005, 280, 17792-17797.	1.6	32
119	Nursing home residents with Alzheimer's disease in special care units compared to other residents with Alzheimer's disease. Dementia, 2005, 4, 249-267.	1.0	7
120	Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. American Journal of Alzheimer's Disease and Other Dementias, 2005, 20, 77-85.	0.9	97
121	The Effect of Adult Day Care Services on Time to Nursing Home Placement in Older Adults With Alzheimer's Disease. Gerontologist, The, 2005, 45, 754-763.	2.3	84
122	Children of Alzheimer Patients: An Overview. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 181-186.	1.2	17
123	Neurogenetics II: complex disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 623-631.	0.9	14
124	Effect of Domain Interaction on Apolipoprotein E Levels in Mouse Brain. Journal of Neuroscience, 2005, 25, 10658-10663.	1.7	75
125	Poststroke Fatigue: Characteristics and Related Factors. Cerebrovascular Diseases, 2005, 19, 84-90.	0.8	222
126	Blood Mercury Levels and Neurobehavioral Function. JAMA - Journal of the American Medical Association, 2005, 293, 1875.	3.8	89
127	Prevalence of Dementia among Veterans Affairs Medical Care System Users. Dementia and Geriatric Cognitive Disorders, 2005, 20, 245-253.	0.7	68
128	Mechanical Testing of Human Cardiac Tissue: Some Implications for MRI Safety. Journal of Cardiovascular Magnetic Resonance, 2005, 7, 835-840.	1.6	38
129	Memantine Blocks α7* Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1195-1205.	1.3	185
130	Longitudinal Models of Growth and Survival Applied to the Early Detection of Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 234-241.	1.2	45
131	Lowering the risk of Alzheimer's disease: Evidence-based practices emerge from new research. , 2005, $1$ , 152-160.		32
132	Undertreatment of patients with Alzheimer's disease in an elderly United States population. , 2005, 1, $136-144$ .		8
133	Age- and sex-related effects on the neuroanatomy of healthy elderly. NeuroImage, 2005, 26, 900-911.	2.1	257
134	Current Status and Future Promise of Pharmacotherapeutic Strategies for Alzheimer's Disease. Journal of the American Medical Directors Association, 2005, 6, 194-199.	1.2	5

#	Article	IF	CITATIONS
135	Clinical Diagnosis and Management of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 767-777.	0.5	10
136	The Use of the Occupational Disruptiveness Scale of the Neuropsychiatric Inventory-Nursing Home Version to Measure the Impact of Rivastigmine on the Disruptive Behavior of Nursing Home Residents With Alzheimer's Disease. Journal of the American Medical Directors Association, 2005, 6, 238-245.	1.2	17
137	Approaches to the Office Care of the Older Adult and the Specter of Dementia. Primary Care - Clinics in Office Practice, 2005, 32, 599-618.	0.7	4
138	End-of-Life Care: An Agenda for Policy Improvement. Clinics in Geriatric Medicine, 2005, 21, 255-272.	1.0	22
139	Dementia and Elder Abuse. Clinics in Geriatric Medicine, 2005, 21, 315-332.	1.0	57
140	Participation in Novelty-Seeking Leisure Activities and Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2005, 18, 134-141.	1.2	66
141	Clinical aspects of inflammation in Alzheimer's disease. International Review of Psychiatry, 2005, 17, 503-514.	1.4	126
142	A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine. Annual Review of Genetics, 2005, 39, 359-407.	3.2	2,836
143	Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. Medical Hypotheses, 2005, 64, 53-58.	0.8	22
144	Cognitive Function, Aging, and Ethical Decisions: Recognizing Change. Dental Clinics of North America, 2005, 49, 389-410.	0.8	8
145	Aging, stress and the hippocampus. Ageing Research Reviews, 2005, 4, 123-140.	5.0	182
146	Emergency medicine and older adults: continuing challenges and opportunities. American Journal of Emergency Medicine, 2005, 23, 556-560.	0.7	65
147	A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutrition and Metabolism, 2005, 2, 28.	1.3	259
148	Transgenic models of Alzheimer's disease: Learning from animals. NeuroRx, 2005, 2, 423-437.	6.0	180
149	Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing??Home Patients with Alzheimer???s Disease. Clinical Drug Investigation, 2005, 25, 507-515.	1.1	17
150	Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Current Medical Research and Opinion, 2005, 21, 1547-1554.	0.9	25
151	Alzheimer Disease Subjects with Psychosis Have Increased Schizotypal Symptoms Before Dementia Onset. Biological Psychiatry, 2005, 58, 325-330.	0.7	5
152	Pathophysiology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 727-753.	0.5	68

#	Article	IF	CITATIONS
153	Mass Spectrometry-Based Screening for Inhibitors of $\hat{l}^2$ -Amyloid Protein Aggregation. Analytical Chemistry, 2005, 77, 7012-7015.	3.2	68
154	Predicting Cognitive Decline in Healthy Older Adults. American Journal of Geriatric Psychiatry, 2005, 13, 735-740.	0.6	54
155	Drug Persistency of Two Cholinesterase Inhibitors. Drugs and Aging, 2005, 22, 695-707.	1.3	44
157	Ruffled hair and fever in an old woman with Alzheimer's disease. Aging Clinical and Experimental Research, 2005, 17, 62-66.	1.4	1
158	Validation of a Brief Screen for Cognitive Impairment (BSCI) Administered by Telephone for Use in the Medicare Population. Disease Management: DM, 2005, 8, 223-234.	1.0	33
159	Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly. Drugs and Aging, 2006, 23, 877-886.	1.3	25
160	Abuse and Neglect in Older Adults with Alzheimer's Disease. Nursing Clinics of North America, 2006, 41, 43-55.	0.7	26
161	Evaluating Best Practices for Social Model Programs for Adults with Alzheimer's Disease in South Carolina. Home Health Care Services Quarterly, 2006, 24, 21-46.	0.3	7
162	Assessing Therapeutic Efficacy in a Progressive Disease. CNS Drugs, 2006, 20, 311-325.	2.7	57
163	Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology, 2006, 67, 1208-1214.	1.5	432
166	Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer's Disease as a Case Study. , 2006, , 60-81.		3
167	Psychiatric Aspects of Parkinson's Disease. , 2006, , 163-176.		0
168	Intervenciones en deterioro cognitivo grave. Revista Espanola De Geriatria Y Gerontologia, 2006, 41, 42-48.	0.2	1
169	Position Statement of the American Association for Geriatric Psychiatry Regarding Principles of Care for Patients With Dementia Resulting From Alzheimer Disease. American Journal of Geriatric Psychiatry, 2006, 14, 561-573.	0.6	236
170	Cognitive Impairment. Medical Clinics of North America, 2006, 90, 769-787.	1.1	35
171	Current Status and Future Promise of Pharmacotherapeutic Strategies for Alzheimer's Disease. Journal of the American Medical Directors Association, 2006, 7, S46-S51.	1.2	4
172	Alzheimer's Treatment in Nursing Homes: Room for Improvement. Journal of the American Medical Directors Association, 2006, 7, 90-95.	1.2	9
173	Improving the Recognition and Management of Dementia in Long-term Care: Obstacles and Opportunities. Journal of the American Medical Directors Association, 2006, 7, 128-130.	1.2	11

#	Article	IF	CITATIONS
174	Initiation of Acetylcholinesterase Inhibitors and Complications of Chronic Airways Disorders in Elderly Patients. Drug Safety, 2006, 29, 1077-1085.	1.4	12
175	Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration. PLoS Medicine, 2006, 3, e310.	3.9	211
176	Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial. American Journal of Geriatric Psychiatry, 2006, 14, 704-715.	0.6	260
177	Current Pharmacotherapy for Alzheimer's Disease. Annual Review of Medicine, 2006, 57, 513-533.	5.0	285
178	Aminoethylenes:Â A Tetrahedral Intermediate Isostere Yielding Potent Inhibitors of the Aspartyl Protease BACE-1. Journal of Medicinal Chemistry, 2006, 49, 839-842.	2.9	61
179	lmaging and In Vivo Quantitation of β-Amyloid: An Exemplary Biomarker for Alzheimer's Disease?. Biological Psychiatry, 2006, 59, 940-947.	0.7	25
180	Low Folate and the Risk of Cognitive and Functional Deficits in the Very Old: The Monzino 80-plus Study. Journal of the American College of Nutrition, 2006, 25, 502-508.	1.1	25
181	Body mass index in older persons is associated with Alzheimer disease pathology. Neurology, 2006, 67, 1949-1954.	1.5	112
182	Alzheimer's Disease: Issues and Challenges in Primary Care. Nursing Clinics of North America, 2006, 41, 83-93.	0.7	19
183	Single Chain Fv Antibodies against the 25â^'35 Aβ Fragment Inhibit Aggregation and Toxicity of Aβ42â€. Biochemistry, 2006, 45, 11532-11539.	1.2	43
184	Recommendations for best practices in the treatment of Alzheimer's disease in managed care. American Journal of Geriatric Pharmacotherapy, 2006, 4, S9-S24.	3.0	83
185	Alzheimer's disease and endocytic dysfunction: Clues from the Down syndrome-related proteins, DSCR1 and ITSN1. Ageing Research Reviews, 2006, 5, 388-401.	5.0	65
186	Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Experimental Neurology, 2006, 197, 330-340.	2.0	164
187	Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clinical Therapeutics, 2006, 28, 365-372.	1.1	16
188	Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: A retrospective study. Clinical Therapeutics, 2006, 28, 1695-1700.	1.1	13
189	Attenuation of $\hat{I}^2$ -amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1802-1809.	1.1	59
190	Metal exposure and Alzheimer's pathogenesis. Journal of Structural Biology, 2006, 155, 45-51.	1.3	121
191	Voting rights for older Americans with dementia: Implications for health care providers. Nursing Outlook, 2006, 54, 68-73.	1.5	5

#	Article	IF	CITATIONS
192	Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Progress in Neurobiology, 2006, 80, 114-128.	2.8	80
193	Decreased phosphatidylethanolamine binding protein expression correlates with ${\sf A}^2$ accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 614-623.	1.5	67
194	Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 1372-1384.	1.5	854
195	Estrogen-containing hormone therapy and Alzheimer's disease risk: Understanding discrepant inferences from observational and experimental research. Neuroscience, 2006, 138, 1031-1039.	1.1	191
196	Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience, 2006, 140, 879-888.	1.1	91
197	Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evidence, 2006, Volume 1-Issues 3 & 4, 0-0.	4.7	10
198	The Use of Anticholinergic Medications in Homebound Elderly Patients with Dementia. The Consultant Pharmacist, 2006, 21, 391-399.	0.4	10
199	The Benefits of Consumer-Directed Services for Caregivers of Persons with Alzheimer's Disease. Families in Society, 2006, 87, 583-589.	0.6	3
201	The search for antecedent biomarkers of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 347-358.	1.2	23
203	Memantine in the treatment of Alzheimer's disease. Aging Health, 2006, 2, 891-904.	0.3	1
204	Mens Sana in Corpore Sano. Annals of Internal Medicine, 2006, 144, 135.	2.0	13
205	Drug Treatment: Memantine. , 2006, , 123-130.		0
206	Improving Dementia Care Through Physician Education: Some Challenges. Clinical Gerontologist, 2006, 29, 3-10.	1.2	8
207	Models of Physician Education for Alzheimer's Disease and Dementia: Practical Application in an Integrated Network. Clinical Gerontologist, 2006, 29, 11-23.	1.2	5
208	Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. Journal of Alzheimer's Disease, 2006, 10, 43-51.	1.2	40
209	Postmortem Indices Linking Risk Factors to Cognition. Alzheimer Disease and Associated Disorders, 2006, 20, S63-S68.	0.6	43
210	Predictors of Blood Mercury Levels in Older Urban Residents. Journal of Occupational and Environmental Medicine, 2006, 48, 715-722.	0.9	8
211	Advanced Dementia Research in the Nursing Home: The CASCADE Study. Alzheimer Disease and Associated Disorders, 2006, 20, 166-175.	0.6	97

#	Article	IF	CITATIONS
212	Lipid metabolism in Alzheimer's and Parkinson's disease. Future Lipidology, 2006, 1, 441-453.	0.5	14
213	Development of a Population-based Questionnaire to Explore Psychosocial Determinants of Screening for Memory Loss and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 182-191.	0.6	16
214	Facilitating Functional and Quality-of-Life Potential. Topics in Geriatric Rehabilitation, 2006, 22, 213-227.	0.2	12
216	Alzheimer Disease and Its Management. American Journal of Therapeutics, 2006, 13, 516-526.	0.5	38
217	Galantamine With Adjunctive Memantine: Combined Effects on Brain Nicotinic Acetylcholine Receptors and N-methyl-D-aspartate Receptors May Improve Alzheimer's Disease Symptomatology. Journal of Clinical Pharmacology, 2006, 46, 6S-7S.	1.0	1
218	Efficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date. Alzheimer Disease and Associated Disorders, 2006, 20, 23-29.	0.6	82
219	Caregiver Psychological Distress as a Barrier to Influenza Vaccination Among Community-Dwelling Elderly With Dementia. Medical Care, 2006, 44, 713-721.	1.1	32
220	The Neurology of Menopause. Neurologist, 2006, 12, 149-159.	0.4	24
221	ADCS Prevention Instrument Project: Behavioral Measures in Primary Prevention Trials. Alzheimer Disease and Associated Disorders, 2006, 20, S147-S151.	0.6	12
222	Combinatorial Mismatch Scan (CMS) for loci associated with dementia in the Amish. BMC Medical Genetics, 2006, 7, 19.	2.1	11
223	Translocation and potential neurological effects of fine and ultrafine particles a critical update. Particle and Fibre Toxicology, 2006, $3$ , $13$ .	2.8	454
224	Satisfaction with End-of-Life Care for Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society, 2006, 54, 1567-1572.	1.3	141
225	An evaluation of dementia screening in the primary care setting. Journal of the American Academy of Nurse Practitioners, 2006, 18, 351-360.	1.4	72
226	Improving Cognition and Function Through Exercise Intervention in Alzheimer's Disease. Journal of Nursing Scholarship, 2006, 38, 358-365.	1.1	93
227	Oral health status in individuals with dementia living in special facilities. International Journal of Dental Hygiene, 2006, 4, 67-71.	0.8	59
228	Long-term effects of antidepressants on cognition in patients with Alzheimer's disease. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 593-598.	0.7	24
229	Cardiovascular disease and Alzheimer's disease: common links. Journal of Internal Medicine, 2006, 260, 211-223.	2.7	260
230	A needle from the haystack. Nature, 2006, 440, 284-285.	13.7	21

#	ARTICLE	IF	CITATIONS
231	A pocketful of colour. Nature, 2006, 440, 285-285.	13.7	2
232	Public funding for Alzheimer disease research in the United States. Nature Medicine, 2006, 12, 770-773.	15.2	19
233	Covariate analysis of late-onset Alzheimer disease refines the chromosome 12 locus. Molecular Psychiatry, 2006, 11, 280-285.	4.1	20
234	The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. Journal of Infection, 2006, 53, 166-174.	1.7	179
235	NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 151-170.	9.6	346
236	Aneuploidy in the normal and diseased brain. Cellular and Molecular Life Sciences, 2006, 63, 2626-2641.	2.4	91
237	Genetic susceptibility testing for Alzheimer disease: Motivation to obtain information and control as precursors to coping with increased risk. Patient Education and Counseling, 2006, 64, 259-267.	1.0	54
238	Psychotropic medication use for behavioral symptoms of dementia. Current Neurology and Neuroscience Reports, 2006, 6, 490-495.	2.0	12
239	Interactions of Volatile Anesthetics with Neurodegenerative-Disease-Associated Proteins. Anesthesiology Clinics, 2006, 24, 381-405.	1.4	17
240	Altered states of consciousness: Processed EEG in mental disease. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2006, 20, 57-67.	1.7	16
241	Tools for Assessment of Pain in Nonverbal Older Adults with Dementia: A State-of-the-Science Review. Journal of Pain and Symptom Management, 2006, 31, 170-192.	0.6	379
242	Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease. Journal of Physiology (Paris), 2006, 99, 180-192.	2.1	58
243	The prevalence and special educational requirements of dyscompetent physicians. Journal of Continuing Education in the Health Professions, 2006, 26, 173-191.	0.4	59
244	The capacity to appoint a proxy and the possibility of concurrent proxy directives. Behavioral Sciences and the Law, 2006, 24, 469-478.	0.6	35
245	Lack of association between UBQLN1 and Alzheimer disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 208-213.	1.1	27
246	Endogenous sex hormones, cognitive decline, and future dementia in old men. Annals of Neurology, 2006, 60, 346-355.	2.8	65
247	The Value of Telephone Support Groups Among Ethnically Diverse Caregivers of Persons With Dementia. Gerontologist, The, 2006, 46, 134-138.	2.3	87
248	Can We Escape Stroke and Alzheimer Disease?. Stroke, 2006, 37, 279-280.	1.0	9

#	Article	IF	Citations
249	Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2006, 21, 2543-2548.	0.4	198
250	Cognitive leisure activities, but not watching TV, for future brain benefits. Neurology, 2006, 66, 794-795.	1.5	47
251	Using Focus Groups to Assess Preâ€" and Post-Placement Needs for Caregivers of Individuals with Alzheimer's Disease. Journal of Social Work in Long-Term Care, 2006, 3, 21-36.	0.1	7
252	Determination of the olfactory threshold using a piezoelectric microdispenser for neurodegenerative disease diagnostics. Measurement Science and Technology, 2006, 17, 3102-3109.	1.4	10
253	Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond. Current Pharmaceutical Design, 2006, 12, 4337-4355.	0.9	39
254	Making Sense of Mild Cognitive Impairment: A Qualitative Exploration of the Patient's Experience. Gerontologist, The, 2006, 46, 791-800.	2.3	100
255	Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease. Current Alzheimer Research, 2006, 3, 339-349.	0.7	111
256	The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy. Current Neuropharmacology, 2006, 4, 149-163.	1.4	42
257	Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies. Current Psychiatry Reviews, 2006, 2, 179-188.	0.9	3
258	New Learning Programs in Cognitive Vitality, Alzheimer's Disease, and Related Dementias. Gerontology and Geriatrics Education, 2006, 26, 47-61.	0.6	14
259	Exploring the association of glyceraldehyde-3-phosphate dehydrogenase gene and Alzheimer disease. Neurology, 2006, 67, 64-68.	1.5	24
260	Targeting Gonadotropins: An Alternative Option for Alzheimer Disease Treatment. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-8.	3.0	13
261	Recognition and treatment of Alzheimer's disease: A case-based review. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 119-125.	0.9	4
262	Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology, 2006, 66, 1399-1404.	1.5	115
263	Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease. Current Pharmaceutical Design, 2006, 12, 719-738.	0.9	29
264	Approaches to Palliative Therapies for Alzheimers Disease. Current Topics in Medicinal Chemistry, 2006, 6, 553-568.	1.0	27
265	Lipids and the pathogenesis of Alzheimer's disease: Is there a link?. International Review of Psychiatry, 2006, 18, 173-186.	1.4	54
266	Managing patients with Alzheimer's disease. Practical Neurology, 2006, 6, 78-89.	0.5	3

#	Article	IF	CITATIONS
267	Analysis of the LRRK2 G2019S Mutation in Alzheimer Disease. Archives of Neurology, 2006, 63, 156.	4.9	21
268	Information and Service Needs of Persons With Alzheimer's Disease and Their Family Caregivers Living in Rural Communities. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 226-233.	0.9	43
269	Delta-aminolevulinic acid dehydratase polymorphism and the relation between low level lead exposure and the Mini-Mental Status Examination in older men: the Normative Aging Study. Occupational and Environmental Medicine, 2006, 63, 746-753.	1.3	35
270	Multi-detector CT angiography in intracranial dural AV fistula at the foramen magnum. Neurology, 2006, 66, 1404-1404.	1.5	1
271	Cholinesterase Inhibitor Use and Age in the General Population. Archives of Neurology, 2006, 63, 154.	4.9	13
272	Behavior-Based Interventions to Enhance Cognitive Functioning and Independence in Older Adults. JAMA - Journal of the American Medical Association, 2006, 296, 2852.	3.8	13
273	Apolipoprotein E Genotype Modifies the Phenotype of Alzheimer Disease. Archives of Neurology, 2006, 63, 155.	4.9	65
274	3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain, 2006, 129, 2867-2873.	3.7	232
275	The Cost-Effectiveness of Noninstitutional Long-Term Care Services: Review and Synthesis of the Most Recent Evidence. Medical Care Research and Review, 2006, 63, 3-28.	1.0	139
276	Changing Relative Prevalence of Alzheimer Disease versus Non-Alzheimer Disease Dementias: Have We Underestimated the Looming Dementia Epidemic?. Dementia and Geriatric Cognitive Disorders, 2006, 22, 273-277.	0.7	8
277	Developing More Flexible Approaches to Respite for People Living with Dementia and Their Carers. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 234-241.	0.9	20
278	Hematologic Risk Factors of Vascular Disease and Their Relation to Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 21, 335-352.	0.7	21
279	DNA Oxidation in Alzheimer's Disease. Antioxidants and Redox Signaling, 2006, 8, 2039-2045.	2.5	133
280	More False Dichotomies: Play, Leisure, Environmental Enrichment, and Important Science Questions. Leisure Sciences, 2006, 28, 487-491.	2.2	2
281	Epitalk Advisor System in Smart Home Context. , 2006, , .		2
282	Health Care Policy Issues in End-of-Life Care. Journal of Palliative Medicine, 2006, 9, 731-748.	0.6	26
283	Pharmacology of Acetylcholinesterase Inhibitors and N-methyl-D-aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. Journal of Clinical Pharmacology, 2006, 46, 8S-16S.	1.0	69
285	Alzheimer's disease. Journal of the American Dental Association, 2006, 137, 1240-1251.	0.7	58

#	Article	IF	CITATIONS
286	Reductions in levels of the Alzheimer's amyloid $\hat{l}^2$ peptide after oral administration of ginsenosides. FASEB Journal, 2006, 20, 1269-1271.	0.2	153
287	The Double-Edged Flower: Roles of Complement Protein C1q in Neurodegenerative Diseases. , 2006, 586, 153-176.		32
289	Temporal Profile of Amyloid- $\hat{l}^2$ (A $\hat{l}^2$ ) Oligomerization in an in Vivo Model of Alzheimer Disease. Journal of Biological Chemistry, 2006, 281, 1599-1604.	1.6	342
291	Accelerating Amyloid- $\hat{l}^2$ Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models*. Journal of Biological Chemistry, 2007, 282, 23818-23828.	1.6	375
292	Conceptualizing Alzheimer's Disease as a Terminal Medical Illness. American Journal of Hospice and Palliative Medicine, 2007, 24, 77-82.	0.8	25
293	Presenilin-1 C410Y Alzheimer Disease Plaques Contain Synaptic Proteins. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 137-144.	0.9	8
294	Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. Current Medical Research and Opinion, 2007, 23, 3153-3165.	0.9	4
295	The application of facial expressions to the assessment of orofacial pain in cognitively impaired older adults. Journal of the American Dental Association, 2007, 138, 963-969.	0.7	27
296	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	1.4	41
299	An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes. Current Topics in Medicinal Chemistry, 2007, 7, 1600-1629.	1.0	124
300	Grief and Personal Growth Experience of Spouses and Adult-Child Caregivers of Individuals With Alzheimer's Disease and Related Dementias. Gerontologist, The, 2007, 47, 798-809.	2.3	122
301	Advances on the Understanding of the Origins of Synaptic Pathology in AD. Current Genomics, 2007, 8, 486-508.	0.7	32
302	Radioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status. Current Medicinal Chemistry, 2007, 14, 19-52.	1.2	126
303	Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 2007, 69, 459-469.	1.5	219
304	Current Therapeutic Options for Alzheimers Disease. Current Genomics, 2007, 8, 550-558.	0.7	63
305	G Protein-Coupled Receptor Signaling Complexity in Neuronal Tissue:Implications for Novel Therapeutics. Current Alzheimer Research, 2007, 4, 3-19.	0.7	53
306	How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The "LEARn" Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD. Current Alzheimer Research, 2007, 4, 219-228.	0.7	140
307	Advances in Dementia Care: A Themed Issue. Research and Theory for Nursing Practice, 2007, 21, 3-4.	0.2	O

#	Article	IF	Citations
308	Editorial Comment on †Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study' by Plassman et al Neuroepidemiology, 2007, 29, 133-135.	1.1	11
309	Assessing Statistical Applications in Publications on Alzheimer's Disease. Neuroepidemiology, 2007, 28, 235-245.	1.1	3
310	Patient's Rating of Cognitive Ability. Archives of Neurology, 2007, 64, 725.	4.9	182
311	The ICF and Dementia. Seminars in Speech and Language, 2007, 28, 273-282.	0.5	25
313	HOW COMMON ARE THE "COMMON―NEUROLOGIC DISORDERS?. Neurology, 2007, 69, 410-411.	1.5	368
314	Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. Archives of Neurology, 2007, 64, 108.	4.9	178
315	Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study. Neuroepidemiology, 2007, 29, 125-132.	1.1	1,622
316	New treatment options for vascular dementia. Aging Health, 2007, 3, 209-222.	0.3	3
317	Alzheimer's Disease. Seminars in Neurology, 2007, 27, 032-041.	0.5	97
318	Pragmatics and Adult Language Disorders: Past Achievements and Future Directions. Seminars in Speech and Language, 2007, 28, 096-110.	0.5	18
319	Prevention of Alzheimer's disease. International Review of Psychiatry, 2007, 19, 693-706.	1.4	30
320	Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2007, 8, 203-214.	0.9	49
321	Efficacy of Behavioral Interventions for Dementia Caregivers. Western Journal of Nursing Research, 2007, 29, 944-960.	0.6	43
322	Evaluated Need, Costs of Care, and Payer Perspective in Degenerative Dementia Patients Cared for in the United States. Alzheimer Disease and Associated Disorders, 2007, 21, 39-48.	0.6	36
324	A Digital Olfactometer for Smell Threshold Measurements in Neurodegenerative Disease Diagnostics. , 2007, , .		2
326	Would You Refer this Patient to Hospice? An Evaluation of Tools for Determining Life Expectancy in End-Stage Dementia. Journal of Palliative Medicine, 2007, 10, 1410-1419.	0.6	13
327	Cognitive-Behavioral Profiles of Neurodegenerative Dementias: Beyond Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 227-238.	1.2	76
329	Invited Commentary: Lipoproteins and DementiaIs It the Apolipoprotein A-I?. American Journal of Epidemiology, 2007, 165, 993-997.	1.6	14

#	Article	lF	Citations
330	Type 2 Diabetes and Alzheimer's Disease: From Common Pathologies to Potential New Therapeutics. Journal of Diabetes Science and Technology, 2007, 1, 590-594.	1.3	2
331	Deletion of tumor necrosis factor death receptor inhibits amyloid $\hat{l}^2$ generation and prevents learning and memory deficits in Alzheimer's mice. Journal of Cell Biology, 2007, 178, 829-841.	2.3	337
332	Survival of Ethnic Chinese With Alzheimer's Disease: A 5-Year Longitudinal Study in Taiwan. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 172-177.	1,2	10
333	A 93-Year-Old Man With Advanced Dementia and Eating Problems. JAMA - Journal of the American Medical Association, 2007, 298, 2527.	3.8	39
334	Estimated Prevalence of People With Cognitive Impairment: Results From Nationally Representative Community and Institutional Surveys. Gerontologist, The, 2007, 47, 350-354.	2.3	57
335	Dementia and Comorbidities: An Overview of Diagnosis and Management. Journal of Pharmacy Practice, 2007, 20, 296-317.	0.5	13
336	Long-Term Efficacy and Safety of Celecoxib in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2007, 23, 8-21.	0.7	119
337	An Estimate of the Prevalence of Dementia among Community-Dwelling Elderly in Israel. Dementia and Geriatric Cognitive Disorders, 2007, 24, 294-299.	0.7	22
338	Effectiveness of Advanced Illness Care Teams for Nursing Home Residents with Dementia. Social Work, 2007, 52, 321-329.	0.6	48
339	Intervention Approaches to Driving and Dementia. Health and Social Work, 2007, 32, 75-79.	0.5	10
340	Evaluation of Nootropic Effect of Argyreia speciosa in Mice. Journal of Health Science, 2007, 53, 382-388.	0.9	16
341	Alzheimer's Disease: <i>Progress in the Development of Anti-amyloid Disease-Modifying Therapies</i> CNS Spectrums, 2007, 12, 113-123.	0.7	26
342	Limits of evidence-based medicine in older adults. Aging Health, 2007, 3, 601-610.	0.3	0
343	Evidence-based psychological treatments for disruptive behaviors in individuals with dementia Psychology and Aging, 2007, 22, 28-36.	1.4	132
344	Positive aspects of caregiving as a moderator of treatment outcome over 12 months Psychology and Aging, 2007, 22, 361-371.	1.4	129
345	Cholesterol-Lowering Drugs And Alzheimer'S Disease. Future Lipidology, 2007, 2, 423-432.	0.5	18
346	Are We Ready to Meet Upcoming Behavioral Health Needs?. Nursing Administration Quarterly, 2007, 31, 192-194.	0.9	0
347	Influence of shunt surgery on healthcare expenditures of elderly fee-for-service Medicare beneficiaries with hydrocephalus. Journal of Neurosurgery, 2007, 107, 21-28.	0.9	49

#	Article	IF	Citations
348	Effects of Diagnosed Dementia on Medicare and Medicaid Program Costs. Inquiry (United States), 2007, 44, 481-494.	0.5	11
350	Physical Activity and Dementia. Exercise and Sport Sciences Reviews, 2007, 35, 24-29.	1.6	67
351	Rates of Depression in Individuals With Pathologic But Not Clinical Alzheimer Disease are Lower Than Those in Individuals Without the Disease: Findings From the Baltimore Longitudinal Study on Aging (BLSA). Alzheimer Disease and Associated Disorders, 2007, 21, 199-204.	0.6	11
352	Cumulative Lead Exposure and Cognitive Performance Among Elderly Men. Epidemiology, 2007, 18, 59-66.	1.2	128
353	Memory enhancing activity of Anwala churna (Emblica officinalis Gaertn.): An Ayurvedic preparation. Physiology and Behavior, 2007, 91, 46-54.	1.0	79
354	Prevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project. Physiology and Behavior, 2007, 92, 98-104.	1.0	121
355	Impact of amyloid imaging on drug development in Alzheimer's disease. Nuclear Medicine and Biology, 2007, 34, 809-822.	0.3	115
356	Racemization of the amyloidal $\hat{I}^2$ Asp1 residue blocks the acceleration of fibril formation caused by racemization of the Asp23 residue. Biochemical and Biophysical Research Communications, 2007, 364, 464-469.	1.0	25
357	Serum biomarkers for Alzheimer's disease: Proteomic discovery. Biomedicine and Pharmacotherapy, 2007, 61, 383-389.	2.5	53
358	Gonadotropins: A cohesive gender-based etiology of Alzheimer disease. Molecular and Cellular Endocrinology, 2007, 260-262, 271-275.	1.6	18
359	A simple method to rule out dementia with temporal orientation., 2007, 3, 28-32.		9
360	Brain health interventions: The need for further research. , 2007, 3, S80-S85.		6
361	Cognitive health: An emerging public health issue. , 2007, 3, S70-S73.		29
362	Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's and Dementia, 2007, 3, 385-397.	0.4	51
363	Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Research, 2007, 35, 7497-7504.	6.5	433
364	Longitudinal Trajectories of Cognitive Change in Preclinical Alzheimer's Disease: A Growth Mixture Modeling Analysis. Cortex, 2007, 43, 826-834.	1.1	79
365	Environmental and dietary risk factors in Alzheimer's disease. Expert Review of Neurotherapeutics, 2007, 7, 887-900.	1.4	93
366	Does This Patient Have Dementia?. JAMA - Journal of the American Medical Association, 2007, 297, 2391.	3.8	249

#	Article	IF	Citations
368	Polyfluorinated Bis-styrylbenzene $\hat{l}^2$ -Amyloid Plaque Binding Ligands. Journal of Medicinal Chemistry, 2007, 50, 4986-4992.	2.9	63
369	Sensory Gating in Patients With Alzheimer's Disease and Their Biological Children. American Journal of Alzheimer's Disease and Other Dementias, 2007, 21, 439-447.	0.9	21
370	NSAIDs for the Chemoprevention of Alzheimer's Disease. Sub-Cellular Biochemistry, 2007, 42, 229-248.	1.0	47
371	Telephone-Based Cognitive-Behavioral Intervention for Distressed Rural Dementia Caregivers. Clinical Gerontologist, 2007, 31, 21-41.	1.2	39
372	Dementia syndromes: evaluation and treatment. Expert Review of Neurotherapeutics, 2007, 7, 407-422.	1.4	82
373	Rivastigmine-induced dystonia. American Journal of Health-System Pharmacy, 2007, 64, 2468-2470.	0.5	9
374	Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opinion on Investigational Drugs, 2007, 16, 1183-1196.	1.9	20
375	Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Current Medical Research and Opinion, 2007, 23, 1187-1197.	0.9	46
376	Analytical Method for $\hat{l}^2$ -Amyloid Fibrils Using CE-Laser Induced Fluorescence and Its Application to Screening for Inhibitors of $\hat{l}^2$ -Amyloid Protein Aggregation. Analytical Chemistry, 2007, 79, 4887-4891.	3.2	41
377	The Application of Evidence-Based Principles of Care in Older Persons (Issue 5): Alzheimer's Disease. Journal of the American Medical Directors Association, 2007, 8, 183-193.	1.2	10
378	The Utility of PET Brain Imaging in the Initial Evaluation of Dementia. Journal of the American Medical Directors Association, 2007, 8, 150-157.	1.2	14
379	An Update on the Amyloid Hypothesis. Neurologic Clinics, 2007, 25, 669-682.	0.8	37
380	Normal Pressure Hydrocephalus. Neurologic Clinics, 2007, 25, 809-832.	0.8	44
381	E-Care: A Telecommunications Technology Intervention for Family Caregivers of Dementia Patients. American Journal of Geriatric Psychiatry, 2007, 15, 443-448.	0.6	129
382	Assessing the Capacity to Make Everyday Decisions: A Guide for Clinicians and an Agenda for Future Research. American Journal of Geriatric Psychiatry, 2007, 15, 101-111.	0.6	92
384	A Multi-Center Blinded Prospective Study of Urine Neural Thread Protein Measurements in Patients With Suspected Alzheimer's Disease. Journal of the American Medical Directors Association, 2007, 8, 21-30.	1.2	23
385	The Neuroprotective Role of Creatine. , 2007, 46, 205-243.		43
386	Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency. Journal of Medicinal Chemistry, 2007, 50, 5912-5925.	2.9	215

#	Article	IF	CITATIONS
387	The Pathogenesis of Alzheimer's Disease: General Overview. , 2007, , 3-29.		1
388	Converging Cell Therapy with Biomaterials. , 2007, , 591-609.		3
390	Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Frontiers in Bioscience - Landmark, 2007, 12, 4315.	3.0	28
391	Detecting Cognitive Impairment in Primary Care: Performance Assessment of Three Screening Instruments. Journal of Alzheimer's Disease, 2007, 11, 323-335.	1.2	64
392	Kalirin is Under-Expressed in Alzheimer's Disease Hippocampus. Journal of Alzheimer's Disease, 2007, $11$ , 385-397.	1.2	64
393	Differentiating Dementias in Long-Term Care Patients. The Consultant Pharmacist, 2007, 22, 14-28.	0.4	4
394	To Prescribe or Not to Prescribe? Atypical Antipsychotic Drugs in Patients with Dementia. Southern Medical Journal, 2007, 100, 961-963.	0.3	2
395	Introduction: Amyloid-Based Interventions in Alzheimer's Disease. CNS Spectrums, 2007, 12, 2-3.	0.7	11
396	Atypical Antipsychotics, Elderly Patients, and Mortality Risk. Southern Medical Journal, 2007, 100, 964-965.	0.3	8
397	Styrylâ€Based Compounds as Potential in vivo Imaging Agents for βâ€Amyloid Plaques. ChemBioChem, 2007, 8, 1679-1687.	1.3	78
398	TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Annals of Neurology, 2007, 61, 435-445.	2.8	753
399	Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease. Journal of Clinical Laboratory Analysis, 2007, 21, 24-33.	0.9	24
400	Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15). International Journal of Geriatric Psychiatry, 2007, 22, 1025-1030.	1.3	27
401	Oxidative damage in mild cognitive impairment and early Alzheimer's disease. Journal of Neuroscience Research, 2007, 85, 3036-3040.	1.3	212
402	Recent advances in the synthesis of nicotine and its derivatives. Tetrahedron, 2007, 63, 8065-8082.	1.0	56
403	A multigram chemical synthesis of the $\hat{I}^3$ -secretase inhibitor LY411575 and its diastereoisomers. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6392-6395.	1.0	64
404	Confounding in the estimation of mediation effects. Computational Statistics and Data Analysis, 2007, 51, 3173-3186.	0.7	18
405	A rapid method to measure beta-amyloid induced neurotoxicity in vitro. Journal of Neuroscience Methods, 2007, 161, 1-10.	1.3	16

#	Article	IF	CITATIONS
406	Amyloid β-peptide Aβ1–42 but not Aβ1–40 attenuates synaptic AMPA receptor function. Synapse, 2007, 61 367-374.	'0.6	67
407	Alzheimer's disease; taking the edge off with cannabinoids?. British Journal of Pharmacology, 2007, 152, 655-662.	2.7	108
408	Helpâ€seeking by older husbands caring for wives with dementia. Journal of Advanced Nursing, 2007, 59, 352-360.	1.5	53
409	Decisions to Forgo Hospitalization in Advanced Dementia: A Nationwide Study. Journal of the American Geriatrics Society, 2007, 55, 432-438.	1.3	90
410	Caring for Patients with Dementia: How Good Is the Quality of Care? Results from Three Health Systems. Journal of the American Geriatrics Society, 2007, 55, 1260-1268.	1.3	73
411	Quality Indicators for the Care of Dementia in Vulnerable Elders. Journal of the American Geriatrics Society, 2007, 55, S293-301.	1.3	34
412	Treatment of Dementia in Communityâ€Dwelling and Institutionalized Medicare Beneficiaries. Journal of the American Geriatrics Society, 2007, 55, 1508-1516.	1.3	64
413	Alterations in intrinsic neuronal excitability during normal aging. Aging Cell, 2007, 6, 327-336.	3.0	116
414	Family Caregivers' Patterns of Positive and Negative Affect. Family Relations, 2007, 56, 12-23.	1.1	57
415	Treatment Strategies for the Behavioral Symptoms of Alzheimer's Disease: Focus on Early Pharmacologic Intervention. Pharmacotherapy, 2007, 27, 399-411.	1.2	33
416	Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons. Brain Research, 2007, 1142, 223-236.	1.1	120
417	Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on $\hat{l}^2$ -amyloid peptide neurotoxicity. Brain Research, 2007, 1158, 123-134.	1.1	101
418	Attenuation of $\hat{l}^2$ -amyloid-induced toxicity by sialic-acid-conjugated dendrimers: Role of sialic acid attachment. Brain Research, 2007, 1161, 95-105.	1.1	70
419	Assessing Alzheimer's Disease and Dementia: Best Practices in Nursing Care. Geriatric Nursing, 2007, 28, 358-365.	0.9	6
420	Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. , 2007, 114, 34-55.		43
421	The role of amyloid $\hat{l}^2$ peptide 42 in Alzheimer's disease. , 2007, 116, 266-286.		279
422	Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiology of Disease, 2007, 28, 251-260.	2.1	71
423	Hospice Care for Patients with Dementia. Journal of Pain and Symptom Management, 2007, 34, 7-16.	0.6	104

#	Article	IF	Citations
424	Living Well until You Die. Annals of the New York Academy of Sciences, 2007, 1114, 194-203.	1.8	19
425	Approaches to neural tissue engineering using scaffolds for drug delivery. Advanced Drug Delivery Reviews, 2007, 59, 325-338.	6.6	325
426	How common are the "common" neurologic disorders?. Neurology, 2007, 68, 326-337.	1.5	1,246
427	Non-pharmacologic prevention of Alzheimer's disease: nutritional and life-style risk factors. Journal of Neural Transmission, 2007, 114, 1187-1197.	1.4	33
428	Metal-amyloid-β peptide interactions: a preliminary investigation of molecular mechanisms for Alzheimer's disease. Science in China Series B: Chemistry, 2007, 50, 453-467.	0.8	1
429	Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells. Plasmonics, 2007, 2, 55-64.	1.8	67
430	Production, purification and functional validation of human secreted amyloid precursor proteins for use as neuropharmacological reagents. Journal of Neuroscience Methods, 2007, 164, 68-74.	1.3	21
431	Behavior of neural stem cells in the Alzheimer brain. Cellular and Molecular Life Sciences, 2008, 65, 2372-2384.	2.4	91
432	Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 4-11.	3.3	17
433	The management of voiding dysfunction in persons with dementia. Current Bladder Dysfunction Reports, 2008, 3, 75-81.	0.2	0
434	Alzheimer's disease: epidemiology, genetics, and beyond. Neuroscience Bulletin, 2008, 24, 105-109.	1.5	62
435	The Environment, Epigenetics and Amyloidogenesis. Journal of Molecular Neuroscience, 2008, 34, 1-7.	1.1	90
436	Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn―model. Biogerontology, 2008, 9, 375-379.	2.0	58
437	Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathologica, 2008, 115, 509-532.	3.9	140
438	Epidemiology of Parkinson's disease. Journal of Neurology, 2008, 255, 18-32.	1.8	314
439	Publication trends in behavioral gerontology in the past 25 years: are the elderly still an understudied population in behavioral research?. Behavioral Interventions, 2008, 23, 65-74.	0.8	18
440	Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. Neurotherapeutics, 2008, 5, 381-390.	2.1	23
441	Association of Alzheimer's disease and Chlamydophila pneumoniae. Journal of Infection, 2008, 56, 423-431.	1.7	8

#	ARTICLE	IF	CITATIONS
442	Synthesis and evaluation of xanomeline analogsâ€"Probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor. Bioorganic and Medicinal Chemistry, 2008, 16, 1376-1392.	1.4	33
443	Use of Home-Based Formal Services by Adult Day Care Clients with Alzheimer's Disease. Home Health Care Services Quarterly, 2008, 27, 217-239.	0.3	12
444	Conditionally inducible tau mice $\hat{a}\in$ designing a better mouse model of neurodegenerative diseases. Genes, Brain and Behavior, 2008, 7, 12-27.	1.1	14
445	Financial Conflicts Facing Late‣ife Remarried Alzheimer's Disease Caregivers*. Family Relations, 2008, 57, 492-503.	1.1	10
446	Sociodemographic and Clinical Correlates of Utility Scores in Alzheimer's Disease. Value in Health, 2008, 11, 1120-1130.	0.1	7
447	The Costâ€Effectiveness of a Behavior Intervention with Caregivers of Patients with Alzheimer's Disease. Journal of the American Geriatrics Society, 2008, 56, 413-420.	1.3	99
448	Magnetic Resonance Imaging Characterization of Brain Structure and Function in Mild Cognitive Impairment: A Review. Journal of the American Geriatrics Society, 2008, 56, 920-934.	1.3	130
449	Ethnic Differences in Singapore's Dementia Prevalence: The Stroke, Parkinson's Disease, Epilepsy, and Dementia in Singapore Study. Journal of the American Geriatrics Society, 2008, 56, 2061-2068.	1.3	45
450	Prognostic Significance of Potential Frailty Criteria. Journal of the American Geriatrics Society, 2008, 56, 2211-2216.	1.3	374
451	Linkage and Association Study of Lateâ€Onset Alzheimer Disease Families Linked to 9p21.3. Annals of Human Genetics, 2008, 72, 725-731.	0.3	49
452	The assessment of depression in Parkinson's disease. European Journal of Neurology, 2008, 15, 487-492.	1.7	25
453	A literature review of spirituality in coping with earlyâ€stage Alzheimer's disease. Journal of Clinical Nursing, 2008, 17, 88-97.	1.4	39
454	Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer's disease mutants. BMC Neuroscience, 2008, 9, 17.	0.8	73
455	Immune defects in Alzheimer's disease: new medications development. BMC Neuroscience, 2008, 9, S13.	0.8	30
456	NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neuroscience, 2008, 9, S8.	0.8	153
457	Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Services Research, 2008, 8, 108.	0.9	165
458	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine, 2008, 45, 219-230.	1.3	95
459	Promoting Cognitive Health and Vitality: A Review of Clinical Implications. Geriatric Nursing, 2008, 29, 302-310.	0.9	16

#	Article	IF	CITATIONS
460	Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Research, 2008, 1200, 159-168.	1.1	322
461	Androgen regulation of $\hat{l}^2$ -amyloid protein and the risk of Alzheimer's disease. Brain Research Reviews, 2008, 57, 444-453.	9.1	84
462	Regenerative potential of allopregnanolone. Brain Research Reviews, 2008, 57, 398-409.	9.1	95
463	Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cellular Signalling, 2008, 20, 1-9.	1.7	100
464	Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurology, The, 2008, 7, 161-172.	4.9	128
465	Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology, The, 2008, 7, 436-450.	4.9	146
466	Patients Dying with Dementia: Experience at the End of Life and Impact of Hospice Care. Journal of Pain and Symptom Management, 2008, 35, 499-507.	0.6	125
467	Enumeration in Alzheimer's disease and other late life psychiatric syndromes. Neuropsychologia, 2008, 46, 2696-2708.	0.7	12
468	Using risperidone for Alzheimer's dementia-associated psychosis. Expert Opinion on Pharmacotherapy, 2008, 9, 2537-2543.	0.9	8
469	Nanofluidic Biosensing for $\hat{I}^2$ -Amyloid Detection Using Surface Enhanced Raman Spectroscopy. Nano Letters, 2008, 8, 1729-1735.	4.5	188
470	Transdermal Delivery of Treatment for Alzheimer's Disease. Drugs and Aging, 2008, 25, 761-775.	1.3	27
471	Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3154-3170.	2.9	56
472	Early diagnosis and treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2008, 8, 769-780.	1.4	24
473	Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiology of Aging, 2008, 29, 253-266.	1.5	46
474	EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiology of Aging, 2008, 29, 819-827.	1.5	125
475	Aging of the brain, neurotrophin signaling, and Alzheimer's disease: Is IGF1-R the common culprit?. Neurobiology of Aging, 2008, 29, 795-811.	1.5	<b>7</b> 5
476	Drug therapy in Alzheimer disease: an update for the oral health care provider. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2008, 106, 467-476.	1.6	16
477	Exercise and Fitness. , 2008, , 393-418.		0

#	Article	IF	Citations
478	Current approaches in the treatment of Alzheimer's disease. Biomedicine and Pharmacotherapy, 2008, 62, 199-207.	2.5	139
479	Psychosocial determinants of intention to screen for Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 353-360.	0.4	39
480	Practicality of a computerized system for cognitive assessment in the elderly. Alzheimer's and Dementia, 2008, 4, 14-21.	0.4	51
481	Diseaseâ€modifying therapies in Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 65-79.	0.4	132
482	Oneâ∈week dose titration of extended release galantamine in patients with Alzheimer's disease. Alzheimer's and Dementia, 2008, 4, 30-37.	0.4	11
483	Eyes on the prize: Federal Alzheimer's research effort aims to facilitate interventions. Alzheimer's and Dementia, 2008, 4, S37-47.	0.4	8
484	Trends in the prevalence and mortality of cognitive impairment in the United States: Is there evidence of a compression of cognitive morbidity?. Alzheimer's and Dementia, 2008, 4, 134-144.	0.4	330
485	Decision analytic models for Alzheimer's disease: State of the art and future directions. Alzheimer's and Dementia, 2008, 4, 212-222.	0.4	41
486	2008 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2008, 4, 110-133.	0.4	185
487	Health service utilization among Alzheimer's disease patients: Evidence from managed care. Alzheimer's and Dementia, 2008, 4, 361-367.	0.4	42
488	Contributions of non-human primates to neuroscience research. Lancet, The, 2008, 371, 1126-1135.	6.3	183
489	Dementia: psychosocial interventions for family caregivers. Lancet, The, 2008, 372, 182-183.	6.3	23
490	Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, The, 2008, 372, 207-215.	6.3	440
491	Application of 18Fâ€PET Imaging for the Study of Alzheimer's Disease. , 2008, , 67-84.		1
492	Dementia of the Alzheimer Type. Epidemiologic Reviews, 2008, 30, 15-34.	1.3	126
493	Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. Neurolmage, 2008, 42, 19-27.	2.1	134
494	Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2008, 16, 883-892.	0.6	108
495	Health Care Proxy Grief Symptoms Before the Death of Nursing Home Residents With Advanced Dementia. American Journal of Geriatric Psychiatry, 2008, 16, 664-673.	0.6	76

#	Article	IF	CITATIONS
496	Psychiatric Emergency Services for the U.S. Elderly: 2008 and Beyond. American Journal of Geriatric Psychiatry, 2008, 16, 706-717.	0.6	32
497	Practical utility of urinary assay in the diagnosis of Alzheimer's disease: AlzheimAlert™. Expert Review of Molecular Diagnostics, 2008, 8, 21-28.	1.5	8
498	Donepezil: potential neuroprotective and disease-modifying effects. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1363-1369.	1.5	53
499	Cu(II) Binding to Monomeric, Oligomeric, and Fibrillar Forms of the Alzheimer's Disease Amyloid-β Peptide. Biochemistry, 2008, 47, 5006-5016.	1.2	111
500	Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood. Molecular Diagnosis and Therapy, 2008, 12, 307-320.	1.6	31
501	African Americans with Memory Loss: Findings from a Community Clinic in Lexington, Kentucky. Nursing Clinics of North America, 2008, 43, 437-447.	0.7	11
502	Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Archives of Neurology, 2008, 65, 1509.	4.9	923
503	lconic Sign Comprehension in Older Adults: The Role of Cognitive Impairment and Text Enhancement. Canadian Journal on Aging, 2008, 27, 253-265.	0.6	39
504	Telephone-delivered psychosocial intervention reduces burden in dementia caregivers. Dementia, 2008, 7, 503-520.	1.0	96
506	Performance Evaluation and Fusion of Methods for Early Detection of Alzheimer Disease., 2008,,.		4
507	Role of the Neuropathology of Alzheimer Disease in Dementia in the Oldest-Old. Archives of Neurology, 2008, 65, 1211-7.	4.9	142
508	PENN Neurodegenerative Disease Research – In the Spirit of Benjamin Franklin. NeuroSignals, 2008, 16, 5-10.	0.5	8
509	PENN Biomarker Core of the Alzheimer's Disease Neuroimaging Initiative. NeuroSignals, 2008, 16, 19-23.	0.5	46
510	Chapter 8; Alzheimer's Disease and Related Dementias. Journal of Gerontological Social Work, 2008, 50, 191-214.	0.6	8
511	Clinical Predictors of Older Driver Performance on a Standardized Road Test. Traffic Injury Prevention, 2008, 9, 456-462.	0.6	50
512	Treatment Options in Alzheimer's Disease: Maximizing Benefit, Managing Expectations. Dementia and Geriatric Cognitive Disorders, 2008, 25, 408-422.	0.7	109
513	Biomarkers for Early Detection of Alzheimer Pathology. NeuroSignals, 2008, 16, 11-18.	0.5	83
514	Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment. Current Psychiatry Reviews, 2008, 4, 58-62.	0.9	0

#	ARTICLE	IF	CITATIONS
515	History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology, 2008, 70, 1258-1264.	1.5	207
517	Help-Seeking Patterns of Older Spousal Caregivers of Older Adults with Dementia. Issues in Mental Health Nursing, 2008, 29, 839-852.	0.6	40
518	Ethical issues in the care of the patient with dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 121-136.	1.0	0
519	Transitioning Dementia Residents from Assisted Living to Memory Care Units: A Pilot Study. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 355-362.	0.9	4
521	Young Adult Attitudes About Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 267-273.	0.9	29
522	In vitro detection of beta amyloid exploiting surface enhanced Raman scattering (SERS) using a nanofluidic biosensor. Proceedings of SPIE, 2008, , .	0.8	4
523	An Educational Intervention to Support Caregivers of Elders With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 233-241.	0.9	22
524	Non-cholinergic drug development for Alzheimer's disease. Expert Opinion on Drug Discovery, 2008, 3, 745-760.	2.5	4
525	Beyond Cholesterol: Statin Benefits in Alzheimer's Disease., 2007,, 53-80.		1
526	Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genetics in Medicine, 2008, 10, 207-214.	1.1	36
527	Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiological Genomics, 2008, 33, 240-256.	1.0	264
528	Treatment decisions regarding hospitalization and surgery for nursing home residents with advanced dementia: the CareAD Study. International Psychogeriatrics, 2008, 20, 406-18.	0.6	40
529	Menopause, Estrogen, and Gonadotropins in Alzheimer's Disease. Advances in Clinical Chemistry, 2008, 45, 139-153.	1.8	10
530	Nonestrogen-based hormonal therapies for Alzheimer's disease. Future Neurology, 2008, 3, 399-407.	0.9	0
532	The Canine (Dog) Model of Human Aging and Disease: Dietary, Environmental and Immunotherapy Approaches. Journal of Alzheimer's Disease, 2008, 15, 685-707.	1.2	167
533	Prevalence of Cognitive Impairment without Dementia in the United States. Annals of Internal Medicine, 2008, 148, 427.	2.0	758
534	Chapter 5.4 Memory and cognitive performance in preclinical Alzheimer's disease and preclinical vascular disease. Handbook of Behavioral Neuroscience, 2008, 18, 537-551.	0.7	1
535	The Worldwide Challenge of the Dementias: A Role for B Vitamins and Homocysteine?. Food and Nutrition Bulletin, 2008, 29, S143-S172.	0.5	200

#	ARTICLE	IF	CITATIONS
536	Implications of Comorbidity on Costs for Patients With Alzheimer Disease. Medical Care, 2008, 46, 839-846.	1.1	76
537	Cranial Electrical Stimulation. Family and Community Health, 2008, 31, 240-246.	0.5	7
538	Community-Based Service Use by Elders With Dementia and Their Caregivers. Nursing Research, 2008, 57, 312-321.	0.8	54
539	One in Eight Baby Boomers Expected to Develop AD. Neurology Today: an Official Publication of the American Academy of Neurology, 2008, 8, 20.	0.0	0
540	Hidden Workplace Violence. Health Care Manager, 2008, 27, 357-363.	1.4	12
541	Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2008, 22, 209-221.	0.6	203
542	Serum Zinc in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 443-450.	1.2	47
543	Errorless learning and spaced retrieval techniques to relearn instrumental activities of daily living in mild Alzheimer's disease: A case report study. Neuropsychiatric Disease and Treatment, 2008, 4, 987.	1.0	43
544	Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program. Patient Preference and Adherence, 2008, 2, 79.	0.8	12
545	Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. Journal of Inflammation Research, 2008, 1, 29.	1.6	49
546	Present and prospective clinical therapeutic regimens for Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2008, 4, 765.	1.0	19
547	Nutritional Biomarkers in Alzheimer's Disease: The Association between Carotenoids, n-3 Fatty Acids, and Dementia Severity. Journal of Alzheimer's Disease, 2008, 13, 31-38.	1.2	103
548	Functional Rescue of Degenerating Photoreceptors in Mice Homozygous for a Hypomorphic cGMP Phosphodiesterase 6 b Allele ( <i>Pde6b</i> <sup><i>H620Q</i></sup> )., 2008, 49, 5067.		57
549	Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.		

#	Article	IF	Citations
555	Nucleic acid induced protein aggregation and its role in biology and pathology. Frontiers in Bioscience - Landmark, 2009, 14, 5084.	3.0	14
556	Statins in Neurological Disorders: Mechanisms and Therapeutic Value. Scientific World Journal, The, 2009, 9, 1242-1259.	0.8	32
557	Neuropathology of dementia., 0,, 142-160.		2
558	Review: Donepezil in Severe Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2009, 24, 185-192.	0.9	29
559	The Adaptive Brain: Aging and Neurocognitive Scaffolding. Annual Review of Psychology, 2009, 60, 173-196.	9.9	2,045
560	Amino Acid Position-specific Contributions to Amyloid $\hat{l}^2$ -Protein Oligomerization. Journal of Biological Chemistry, 2009, 284, 23580-23591.	1.6	79
561	Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1194-1201.	0.9	128
562	Establishment of a Predominantly African-American Cohort for the Study of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2009, 27, 329-336.	0.7	13
563	100 Years After Alzheimer: Contemporary Neurology Practice Assessment of Referrals for Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2009, 23, 516-527.	0.9	4
564	Surrogate consent for dementia research. Neurology, 2009, 72, 149-155.	1.5	60
565	Homotaurine: A failed drug for Alzheimer's disease and now a nutraceutical for memory protection. American Journal of Health-System Pharmacy, 2009, 66, 1950-1953.	0.5	9
566	The Association of Transient Ischemic Attack Symptoms With Memory Impairment Among Elderly Participants of the Third US National Health and Nutrition Examination Survey. Journal of Geriatric Psychiatry and Neurology, 2009, 22, 46-51.	1.2	10
567	Older Adults' Attitudes Toward Enrollment of Non-competent Subjects Participating in Alzheimer's Research. American Journal of Psychiatry, 2009, 166, 182-188.	4.0	63
568	Differences in Brain Volume, Hippocampal Volume, Cerebrovascular Risk Factors, and Apolipoprotein E4 Among Mild Cognitive Impairment Subtypes. Archives of Neurology, 2009, 66, 1393-9.	4.9	83
569	Predicting dementia: role of dementia risk indices. Future Neurology, 2009, 4, 555-560.	0.9	24
570	Pharmacology of the Intracellular Pathways Activated by Amyloid Beta Protein. Mini-Reviews in Medicinal Chemistry, 2009, 9, 724-740.	1.1	17
572	Increased Tau Phosphorylation and Cleavage in Mouse Models of Type 1 and Type 2 Diabetes. Endocrinology, 2009, 150, 5294-5301.	1.4	220
573	Memory-enhancing activity of <i>Rose alba </i> in mice. International Journal of Green Pharmacy, 2009, 3, 239.	0.1	4

#	Article	IF	CITATIONS
575	DNA Damage and Repair in Alzheimers Disease. Current Alzheimer Research, 2009, 6, 36-47.	0.7	130
576	AIP-1 ameliorates β-amyloid peptide toxicity in a Caenorhabditis elegans Alzheimer's disease model. Human Molecular Genetics, 2009, 18, 2739-2747.	1.4	56
577	Effects of a Cyclooxygenase-2 Preferential Inhibitor in Young Healthy Dogs Exposed to Air Pollution: A Pilot Study. Toxicologic Pathology, 2009, 37, 644-660.	0.9	23
578	Validity of Estimated Dietary Eicosapentaenoic Acid and Docosahexaenoic Acid Intakes Determined by Interviewer-Administered Food Frequency Questionnaire Among Older Adults With Mild-to-Moderate Cognitive Impairment or Dementia. American Journal of Epidemiology, 2009, 170, 95-103.	1.6	30
579	Problems Meeting Basic Needs Predict Cognitive Decline in Community-Dwelling Hispanic Older Adults. Journal of Aging and Health, 2009, 21, 848-863.	0.9	12
580	Progranulin and $\hat{I}^2$ -Amyloid Distribution: A Case Report of the Brain From Preclinical PS-1 Mutation Carrier. American Journal of Alzheimer's Disease and Other Dementias, 2009, 24, 456-460.	0.9	23
581	Nitric Oxide Activity and Isoenzyme Expression in the Senescence-Accelerated Mouse P8 Model of Alzheimer's Disease: Effects of Anti-Amyloid Antibody and Antisense Treatments. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1025-1030.	1.7	25
582	Treatment of Alzheimer's disease in the long-term-care setting. American Journal of Health-System Pharmacy, 2009, 66, 899-907.	0.5	31
583	Vitamin D Is Associated With Cognitive Function in Elders Receiving Home Health Services. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 888-895.	1.7	159
585	Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 667, 82-97.	0.4	239
586	Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 34, 525-534.	2.1	117
587	Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiology of Disease, 2009, 36, 303-311.	2.1	42
588	TNF-α and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects. Journal of Neuroimmunology, 2009, 216, 92-97.	1.1	222
589	Functional characterization of three singleâ€nucleotide polymorphisms present in the human <i>APOE</i> promoter sequence: Differential effects in neuronal cells and on DNA–protein interactions. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 185-201.	1.1	32
590	A $\hat{I}^3 \hat{a} \in \mathbf{s}$ ecretase inhibitor decreases amyloid $\hat{a} \in \hat{I}^2$ production in the central nervous system. Annals of Neurology, 2009, 66, 48-54.	2.8	314
591	What do Korean American immigrants know about Alzheimer's disease (AD)? The impact of acculturation and exposure to the disease on AD knowledge. International Journal of Geriatric Psychiatry, 2010, 25, 66-73.	1.3	58
592	Association between altered systemic inflammatory interleukinâ $\in$ 1 $\hat{1}^2$ and natural killer cell activity and subsequently agitation in patients with alzheimer disease. International Journal of Geriatric Psychiatry, 2010, 25, 604-611.	1.3	20
593	Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 780-788.	1.3	64

#	Article	IF	Citations
594	In vitro and inâ€vivo Staining Characteristics of Small, Fluorescent, Aβ42â€Binding <scp>D</scp> â€Enantiomeric Peptides in Transgenic AD Mouse Models. ChemMedChem, 2009, 4, 276-282.	1.6	60
595	5â€HT <sub>6</sub> antagonists as potential treatment for cognitive dysfunction. Drug Development Research, 2009, 70, 145-168.	1.4	77
596	Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathologica, 2009, 118, 381-389.	3.9	35
597	Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives. Bioorganic and Medicinal Chemistry, 2009, 17, 6937-6941.	1.4	21
598	Improved Behavioral Response as a Valid Biomarker for Drug Screening Program in Transgenic Rodent Models of Tauopathies. Cellular and Molecular Neurobiology, 2009, 29, 937-944.	1.7	1
599	Fatigue in Parkinson's disease patients. Current Treatment Options in Neurology, 2009, 11, 186-190.	0.7	21
600	Psychological distress and risk for dementia. Current Psychiatry Reports, 2009, 11, 41-47.	2.1	50
601	CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease?. Journal of NeuroImmune Pharmacology, 2009, 4, 462-475.	2.1	174
602	Effects of motor practice on cognitive disorders in older adults. European Review of Aging and Physical Activity, 2009, 6, 67-74.	1.3	20
603	Cell Cycle Activation and CNS Injury. Neurotoxicity Research, 2009, 16, 221-237.	1.3	55
604	Antiamnesic potential of <i> Murraya koenigii</i> leaves. Phytotherapy Research, 2009, 23, 308-316.	2.8	42
605	Amyloid $\hat{l}^2$ and impairment in multiple memory systems in older transgenic APP TgCRND8 mice. Genes, Brain and Behavior, 2009, 8, 676-684.	1.1	20
606	Olfaction in Aging and Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1170, 647-657.	1.8	36
607	Alzheimer Disease in Women: A Clinical and Genetics Perspective. Nursing for Women's Health, 2009, 13, 312-324.	0.3	1
608	Healthcare Proxies of Nursing Home Residents with Advanced Dementia: Decisions They Confront and Their Satisfaction with Decisionâ€Making. Journal of the American Geriatrics Society, 2009, 57, 1149-1155.	1.3	101
609	Risk Perception and Preference for Prevention of Alzheimer's Disease. Value in Health, 2009, 12, 450-458.	0.1	25
610	Proinflammatory cytokine interferonâ $\in$ γ increases induction of indoleamine 2,3â $\in$ dioxygenase in monocytic cells primed with amyloid β peptide 1â $\in$ "42: implications for the pathogenesis of Alzheimerâ $\in$ ™s disease. Journal of Neurochemistry, 2009, 110, 791-800.	2.1	53
611	Family decisionâ€making in advanced dementia: narrative and ethics. Scandinavian Journal of Caring Sciences, 2009, 23, 251-258.	1.0	74

#	ARTICLE	IF	CITATIONS
612	Synthesis and evaluation of a new class of tertiary alcohol based BACE-1 inhibitors. Tetrahedron, 2009, 65, 10047-10059.	1.0	14
613	A one-pot synthesis of unsymmetrical bis-styrylbenzenes. Tetrahedron Letters, 2009, 50, 6228-6230.	0.7	14
614	Ambient intelligence: Technologies, applications, and opportunities. Pervasive and Mobile Computing, 2009, 5, 277-298.	2.1	800
615	Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. Journal of Neuroscience Methods, 2009, 177, 427-433.	1.3	54
616	Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. Journal of Nutritional Biochemistry, 2009, 20, 1-10.	1.9	92
617	Factors associated with cognition in adults: The Seattle Longitudinal Study. Research in Nursing and Health, 2009, 32, 540-550.	0.8	24
618	Modeling of Alzheimer's disease using viral vectors. Neurochemical Journal, 2009, 3, 253-259.	0.2	0
619	The Inflammatory Reflex and the Role of Complementary and Alternative Medical Therapies. Annals of the New York Academy of Sciences, 2009, 1172, 172-180.	1.8	109
620	Intrinsic Disorder in Proteins Associated with Neurodegenerative Diseases. Focus on Structural Biology, 2009, , 21-75.	0.1	8
621	Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection. Pharmacological Reviews, 2009, 61, 39-61.	7.1	256
623	The Clinical Course of Advanced Dementia. New England Journal of Medicine, 2009, 361, 1529-1538.	13.9	1,336
624	Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18563-18568.	3.3	76
625	Current Hypotheses and Research Milestones in Alzheimer's Disease. , 2009, , .		4
626	Chapter 7 Application of Pet Imaging to Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment1. International Review of Neurobiology, 2009, 84, 133-149.	0.9	26
627	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme. Diabetes Research and Clinical Practice, 2009, 83, 387-393.	1.1	26
628	Prevention of age-associated dementia. Brain Research Bulletin, 2009, 80, 315-325.	1.4	26
629	Signaling of the neurotrophin receptor p75 in relation to Alzheimer's disease. Biochemical and Biophysical Research Communications, 2009, 390, 352-356.	1.0	39
630	Implications of age and diet on canine cerebral cortex transcription. Neurobiology of Aging, 2009, 30, 1314-1326.	1.5	37

#	Article	IF	CITATIONS
631	The pathological interaction between diabetes and presymptomatic Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1910-1917.	1.5	48
632	Egr-1 and Hipk2 are required for the TrkA to p75NTR switch that occurs downstream of IGF1-R. Neurobiology of Aging, 2009, 30, 2010-2020.	1.5	9
633	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 2009, 30, 1026-1036.	1.5	558
635	The role of the anaphylatoxins in health and disease. Molecular Immunology, 2009, 46, 2753-2766.	1.0	582
636	Resolving the relationship between ApolipoproteinE and depression. Neuroscience Letters, 2009, 455, 116-119.	1.0	25
637	Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Research Reviews, 2009, 8, 285-305.	5.0	211
638	Enteral tube feeding for older people with advanced dementia. The Cochrane Library, 2009, , CD007209.	1.5	253
639	Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Current Medical Research and Opinion, 2009, 25, 2577-2587.	0.9	55
640	Cognitive impairment and preferences for current health. Health and Quality of Life Outcomes, 2009, 7, 1.	1.0	117
641	Development and preliminary evaluation of a quality of life measure targeted at dementia caregivers. Health and Quality of Life Outcomes, 2009, 7, 56.	1.0	28
643	Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 600-607.	0.9	210
644	The Biochemistry of Disease: Desperately Seeking Syzygy. Annual Review of Biochemistry, 2009, 78, 55-63.	<b>5.</b> 0	2
645	Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US. Drugs and Aging, 2009, 26, 483-492.	1.3	97
646	Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer $\hat{E}\frac{1}{4}$ s Disease. Drugs and Aging, 2009, 26, 231-239.	1.3	27
647	Genomics of Brain Aging: Apolipoprotein E. , 2009, , 685-693.		0
648	Bioavailability of Gallic Acid and Catechins from Grape Seed Polyphenol Extract is Improved by Repeated Dosing in Rats: Implications for Treatment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 113-124.	1.2	223
649	Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opinion on Drug Delivery, 2009, 6, 211-225.	2.4	112
650	Examination of a Psychoeducational Intervention and a Respite Grant in Relieving Psychosocial Stressors Associated with Being an Alzheimer's Caregiver. Journal of Gerontological Social Work, 2009, 52, 89-104.	0.6	29

#	Article	IF	CITATIONS
651	Can peripheral leukocytes be used as Alzheimer's disease biomarkers?. Expert Review of Neurotherapeutics, 2009, 9, 1623-1633.	1.4	34
652	Race differences in emotional adaptation of family caregivers. Aging and Mental Health, 2009, 13, 715-724.	1.5	42
653	Functional imaging studies of episodic memory in Alzheimer's disease: a quantitative meta-analysis. Neurolmage, 2009, 45, 181-190.	2.1	151
654	Advancing Alzheimer's disease drug review as a national priority. , 2009, 5, 180-181.		2
655	2009 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2009, 5, 234-270.	0.4	339
656	Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 463-469.	0.4	115
657	Dementia and Life Expectancy: What Do We Know?. Journal of the American Medical Directors Association, 2009, 10, 466-471.	1.2	72
658	Willingness to Participate in Alzheimer Disease Research and Attitudes Towards Proxy-Informed Consent: Results From the Health and Retirement Study. American Journal of Geriatric Psychiatry, 2009, 17, 65-74.	0.6	18
659	Intelligent Assistive Technology Applications to Dementia Care: Current Capabilities, Limitations, and Future Challenges. American Journal of Geriatric Psychiatry, 2009, 17, 88-104.	0.6	286
660	Ethnic Differences in Beliefs Regarding Alzheimer Disease Among Dementia Family Caregivers. American Journal of Geriatric Psychiatry, 2009, 17, 925-933.	0.6	105
661	Research Ethics Issues in Geriatric Psychiatry. Psychiatric Clinics of North America, 2009, 32, 395-411.	0.7	21
662	Family Oversight and the Quality of Nursing Home Care for Residents With Advanced Dementia. Medical Care, 2009, 47, 568-574.	1.1	23
664	Ethical Perspectives on Emerging Assistive Technologies: Insights from Focus Groups with Stakeholders in Long-Term Care Facilities. Journal of Empirical Research on Human Research Ethics, 2009, 4, 25-36.	0.6	45
665	Epidemiology and risk factors. , 0, , 120-130.		0
666	In the balance: silver tsunami or longevity dividend?. Quality in Ageing and Older Adults, 2009, 10, 15-22.	0.4	9
667	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	0.9	492
668	Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With Hypertension. Archives of Internal Medicine, 2009, 169, 1195.	4.3	199
669	The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women. Archives of Neurology, 2009, 66, 324-8.	4.9	168

#	Article	IF	CITATIONS
670	Trichotomous processes in early memory development, aging, and neurocognitive impairment: A unified theory Psychological Review, 2009, 116, 783-832.	2.7	63
671	Integrative cognitive–behavioral and spiritual counseling for rural dementia caregivers with depression Rehabilitation Psychology, 2009, 54, 449-461.	0.7	19
672	$11\ \text{The Early Detection of Alzheimer's Disease with Positron Emission Tomography.},2009,,151\text{-}168.$		0
673	Food Antioxidants and Alzheimer's Disease. Oxidative Stress and Disease, 2009, , .	0.3	O
674	A Potential Role for Alterations of Zinc and Zinc Transport Proteins in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 471-483.	1.2	80
675	Racial Differences in Knowledge and Beliefs About Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2009, 23, 110-116.	0.6	100
676	A New Scale Measuring Psychologic Impact of Genetic Susceptibility Testing for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2009, 23, 50-56.	0.6	28
677	A Model of Consequences of Dementia Caregivers' Stress Process: Influence on Behavioral Symptoms of Dementia and Caregivers' Behavior-Related Reactions. Research and Theory for Nursing Practice, 2009, 23, 181-202.	0.2	18
678	Bayesian Interval Estimation for Predictive Values from Case-Control Studies. Communications in Statistics Part B: Simulation and Computation, 2009, 39, 101-110.	0.6	4
679	Patterns of Cognitive Impairment in Neurological Disease. Current Psychiatry Reviews, 2010, 6, 244-251.	0.9	0
680	Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence. CNS and Neurological Disorders - Drug Targets, 2010, 9, 132-139.	0.8	98
681	The role of positron emission tomography imaging of $\hat{l}^2$ -amyloid in patients with Alzheimer's disease. Nuclear Medicine Communications, 2010, 31, 4-11.	0.5	18
682	Transgenic Alzheimer Mice Have a Larger Minimum Alveolar Anesthetic Concentration of Isoflurane than Their Nontransgenic Littermates. Anesthesia and Analgesia, 2010, 110, 438-441.	1.1	18
683	Surrogate consent for research involving adults with impaired decision making: Survey of Institutional Review Board practices. Critical Care Medicine, 2010, 38, 2146-2154.	0.4	40
684	Deciding to Institutionalize. Journal of Neuroscience Nursing, 2010, 42, 95-103.	0.7	46
685	Meditation Effects on Cognitive Function and Cerebral Blood Flow In Subjects with Memory Loss: A Preliminary Study. Journal of Alzheimer's Disease, 2010, 20, 517-526.	1.2	131
686	Genetic Polymorphisms in Apolipoprotein E and Glutathione Peroxidase 1 Genes in the Ecuadorian Population Affected With Alzheimer's Disease. American Journal of the Medical Sciences, 2010, 340, 373-377.	0.4	29
688	Characterization of changes in global gene expression in the brain of neuron-specific enolase/human Tau23 transgenic mice in response to overexpression of Tau protein. International Journal of Molecular Medicine, 2010, 25, 667-75.	1.8	20

#	Article	IF	CITATIONS
689	Neuroprotective Herbs and Foods from Different Traditional Medicines and Diets. Molecules, 2010, 15, 3517-3555.	1.7	123
690	Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis. Journal of Alzheimer's Disease, 2010, 21, 843-851.	1.2	32
693	Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging. Journal of Alzheimer's Disease, 2010, 20, 843-854.	1.2	230
694	Physical Activity and Cognition in Older Adults: The Potential of Tai Chi Chuan. Journal of Aging and Physical Activity, 2010, 18, 451-472.	0.5	94
695	Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage, and Late Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 325-339.	1.2	36
696	Targets for the Prevention of Dementia. Journal of Alzheimer's Disease, 2010, 20, 915-924.	1.2	73
697	Pathways linking $\hat{A^2}$ and tau pathologies. Biochemical Society Transactions, 2010, 38, 993-995.	1.6	76
698	Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Review of Proteomics, 2010, 7, 919-929.	1.3	20
699	Alzheimer's Disease. New England Journal of Medicine, 2010, 362, 329-344.	13.9	4,116
700	Alzheimer Disease. Disease-a-Month, 2010, 56, 484-546.	0.4	391
700	Alzheimer Disease. Disease-a-Month, 2010, 56, 484-546.  Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1575-1593.	3.3	391 27
	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.		
701	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1575-1593.  Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine:	3.3	27
701	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1575-1593.  Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 144-152.  Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model	3.3	27
701 702 703	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1575-1593.  Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 144-152.  Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system. Brain Structure and Function, 2010, 214, 263-283.  Potential therapeutic agents against Alzheimer's disease from natural sources. Archives of Pharmacal	3.3 1.7 1.2	27 201 56
701 702 703 704	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1575-1593.  Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 144-152.  Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system. Brain Structure and Function, 2010, 214, 263-283.  Potential therapeutic agents against Alzheimer's disease from natural sources. Archives of Pharmacal Research, 2010, 33, 1589-1609.  Synthesis and biological evaluation of 3,6-diaryl-7H-thiazolo[3,2-b] [1,2,4]triazin-7-one derivatives as	3.3 1.7 1.2 2.7	27 201 56 64
701 702 703 704 705	Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1575-1593.  Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 144-152.  Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system. Brain Structure and Function, 2010, 214, 263-283.  Potential therapeutic agents against Alzheimer's disease from natural sources. Archives of Pharmacal Research, 2010, 33, 1589-1609.  Synthesis and biological evaluation of 3,6-diaryl-7H-thiazolo[3,2-b] [1,2,4]triazin-7-one derivatives as acetylcholinesterase inhibitors. Archives of Pharmacal Research, 2010, 33, 1641-1649.  Progression of Atrophy in Alzheimer's Disease and Related Disorders. Neurotoxicity Research, 2010, 18,	3.3 1.7 1.2 2.7	27 201 56 64 17

#	ARTICLE	IF	CITATIONS
709	Amyloid-plaque imaging in early and differential diagnosis of dementia. Annals of Nuclear Medicine, 2010, 24, 55-66.	1.2	38
710	Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example. Journal of Computer-Aided Molecular Design, 2010, 24, 803-817.	1.3	11
711	Is the Presence of Mild to Moderate Cognitive Impairment Associated With Self-Report of Non-cancer Pain? A Cross-Sectional Analysis of a Large Population-Based Study. Journal of Pain and Symptom Management, 2010, 39, 734-742.	0.6	23
712	Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model. BMC Medical Informatics and Decision Making, 2010, 10, 24.	1.5	11
713	The effect of alcohol and tobacco consumption, and apolipoprotein E genotype, on the age of onset in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 511-518.	1.3	87
714	<i>APOE</i> predicts amyloidâ€beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 2010, 67, 122-131.	2.8	727
715	A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Annals of Neurology, 2010, 68, 521-534.	2.8	685
716	The SeniorWISE Study: Improving Everyday Memory in Older Adults. Archives of Psychiatric Nursing, 2010, 24, 291-306.	0.7	59
717	Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD). Archives of Gerontology and Geriatrics, 2010, 51, 245-249.	1.4	39
718	An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. Journal of Neuroscience Methods, 2010, 190, 171-179.	1.3	76
719	A synthesis of the $\hat{I}^3$ -secretase inhibitor BMS-708163. Tetrahedron Letters, 2010, 51, 6542-6544.	0.7	6
720	Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core. European Journal of Medicinal Chemistry, 2010, 45, 870-882.	2.6	22
721	Withanamides in <i>Withania somnifera</i> fruit protect PCâ€12 cells from βâ€amyloid responsible for Alzheimer's disease. Phytotherapy Research, 2010, 24, 859-863.	2.8	112
722	Are All Commonly Prescribed Antipsychotics Associated with Greater Mortality in Elderly Male Veterans with Dementia?. Journal of the American Geriatrics Society, 2010, 58, 1027-1034.	1.3	55
723	Hospitalization in Communityâ€Dwelling Persons with Alzheimer's Disease: Frequency and Causes. Journal of the American Geriatrics Society, 2010, 58, 1542-1548.	1.3	162
724	Confronting Alzheimer's Disease and Other Dementias. Journal of the American Geriatrics Society, 2010, 58, 1587-1590.	1.3	3
725	Hospice Use and Outcomes in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society, 2010, 58, 2284-2291.	1.3	95
726	A novel effect of rivastigmine on preâ€synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. Journal of Neurochemistry, 2010, 112, 843-853.	2.1	52

#	Article	IF	Citations
727	Rural-Urban Differences in Preventable Hospitalizations Among Community-Dwelling Veterans With Dementia. Journal of Rural Health, 2010, 26, 146-155.	1.6	43
728	Costâ€ofâ€illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatrica Scandinavica, 2010, 121, 243-259.	2.2	121
729	Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. International Journal of Clinical Practice, 2010, 64, 651-660.	0.8	29
730	Neural mechanisms of ageing and cognitive decline. Nature, 2010, 464, 529-535.	13.7	1,079
731	Preparation and characterization of toxic $\hat{Al^2}$ aggregates for structural and functional studies in Alzheimer's disease research. Nature Protocols, 2010, 5, 1186-1209.	5.5	225
732	Metabolic analysis of <sup>13</sup> Câ€labeled pyruvate for noninvasive assessment of mitochondrial function. Annals of the New York Academy of Sciences, 2010, 1201, 111-120.	1.8	12
733	Alterations of Zinc Transporter Proteins ZnTâ€1, ZnTâ€4 and ZnTâ€6 in Preclinical Alzheimer's Disease Brain. Brain Pathology, 2010, 20, 343-350.	2.1	84
734	Dementia and Dementia Care: The Contributions of a Psychosocial Perspective. Sociology Compass, 2010, 4, 249-262.	1.4	4
735	Research Article: Correlating heart rate and perceived exertion during aerobic exercise in Alzheimer's disease. Australian Journal of Cancer Nursing, 2010, 12, 375-380.	0.8	15
736	Ageâ€related driving disorders: Screening in hospitals and outpatients settings. Geriatrics and Gerontology International, 2010, 10, 288-294.	0.7	5
737	Liberating the wanderers: using technology to unlock doors for those living with dementia. Sociology of Health and Illness, 2010, 32, 288-303.	1.1	71
740	Structural imaging of Alzheimer's disease. , 0, , 313-331.		0
742	DNA Repair in Premature Aging Disorders and Neurodegeneration. Current Aging Science, 2010, 3, 3-19.	0.4	82
743	Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 573-589.	1.2	112
744	CSF Biomarkers for Alzheimer's Disease Diagnosis. International Journal of Alzheimer's Disease, 2010, 2010, 1-12.	1.1	92
745	Dementia Revealed: Novel Chromosome 6 Locus for Late-Onset Alzheimer Disease Provides Genetic Evidence for Folate-Pathway Abnormalities. PLoS Genetics, 2010, 6, e1001130.	1.5	130
746	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	1.1	347
747	Cardiac Output as a Potential Risk Factor for Abnormal Brain Aging. Journal of Alzheimer's Disease, 2010, 20, 813-821.	1.2	86

#	Article	IF	CITATIONS
748	Biopsy Pathology of Neurodegenerative Disorders in Adults. , 2010, , 551-571.		0
749	Pharmacological evidences for antiamnesic potentials of Phyllanthus amarus in mice. African Journal Biomedical Research, 2010, $10$ , .	0.2	9
750	Alzheimer's Disease and Glaucoma: Imaging the Biomarkers of Neurodegenerative Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-9.	1.1	39
751	In Vivo Systems: Animal Models of Neurodegeneration*. , 2010, , 399-413.		0
752	Driving decision-making in older adults with dementia. Dementia, 2010, 9, 45-60.	1.0	58
753	Associations of Special Care Units and Outcomes of Residents With Dementia: 2004 National Nursing Home Survey. Gerontologist, The, 2010, 50, 509-518.	2.3	30
754	Levetiracetam: A Practical Option for Seizure Management in Elderly Patients With Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 149-154.	0.9	37
755	Caregiver Burden, Health Utilities, and Institutional Service Costs Among Community-dwelling Patients With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 380-389.	0.6	11
756	"Dementia-friendly Hospitals. Alzheimer Disease and Associated Disorders, 2010, 24, 372-379.	0.6	92
757	Cognition and Function in Alzheimer's Disease: Identifying the Transitions from Moderate to Severe Disease. Dementia and Geriatric Cognitive Disorders, 2010, 29, 309-316.	0.7	14
758	Spine Surgery under General Anesthesia May Not Increase the Risk of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2010, 29, 233-239.	0.7	31
759	Evaluation of Academic Detailing for Primary Care Physician Dementia Education. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 333-339.	0.9	19
760	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease and Associated Disorders, 2010, 24, 220-226.	0.6	57
761	The S100B/RAGE Axis in Alzheimer's Disease. Cardiovascular Psychiatry and Neurology, 2010, 2010, 1-11.	0.8	69
762	Survival and Comfort After Treatment of Pneumonia in Advanced Dementia. Archives of Internal Medicine, 2010, 170, 1102-7.	4.3	144
763	Diet and Prevention of Alzheimer DiseaseDiet and Prevention of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 303, 2519.	3.8	9
764	B-type natriuretic peptide as a predictor of declining cognitive function and dementia—a cohort study of an elderly general population with a 5-year follow-up. Annals of Medicine, 2010, 42, 207-215.	1.5	61
765	Apply the Feature of Entropy Convergence of ACO to Short the Runtime of Gene Order. , 2010, , .		2

#	Article	IF	Citations
766	Social Workers' Knowledge, Beliefs, and Practices Regarding Driving and Dementia. Social Work in Health Care, 2010, 49, 551-564.	0.8	5
767	Caregiver Perspectives on Transitions to Assisted Living and Memory Care. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 255-264.	0.9	17
768	Dementia and Transitioning From Assisted Living to Memory Care Units: Perspectives of Administrators in Three Facility Types. Gerontologist, The, 2010, 50, 192-203.	2.3	7
769	Deletion of M <sub>1</sub> Muscarinic Acetylcholine Receptors Increases Amyloid Pathology <i>In Vitro</i> and <i>In Vivo</i> . Journal of Neuroscience, 2010, 30, 4190-4196.	1.7	109
770	Recognizing Dementia as a Terminal Illness in Nursing Home Residents. Archives of Internal Medicine, 2010, 170, 1107-9.	4.3	11
771	Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer's disease. Brain, 2010, 133, 2714-2726.	3.7	118
772	Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments. Current Alzheimer Research, 2010, 7, 214-222.	0.7	10
773	Aging Matters: Humanistic and Transpersonal Approaches to Psychotherapy With Elders With Dementia. Journal of Humanistic Psychology, 2010, 50, 142-174.	1.4	4
774	The Association Between Noncancer Pain, Cognitive Impairment, and Functional Disability: An Analysis of the Canadian Study of Health and Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2010, 65A, 880-886.	1.7	34
775	Primary Care Physicians' Dementia Care Practices: Evidence of Geographic Variation. Gerontologist, The, 2010, 50, 179-191.	2.3	33
776	Oral Health in Alzheimers Disease: A Review. Current Alzheimer Research, 2010, 7, 368-373.	0.7	28
777	Cognitive decline in incident Alzheimer disease in a community population. Neurology, 2010, 74, 951-955.	1.5	55
778	Relative Capability of MR Imaging and FDG PET to Depict Changes Associated with Prodromal and Early Alzheimer Disease. Radiology, 2010, 256, 932-942.	3.6	107
779	Prediction of 6-Month Survival of Nursing Home Residents With Advanced Dementia Using ADEPT vs Hospice Eligibility Guidelines. JAMA - Journal of the American Medical Association, 2010, 304, 1929.	3.8	193
780	Hypometabolism in Alzheimer-Affected Brain Regions in Cognitively Healthy Latino Individuals Carrying the Apolipoprotein E ε4 Allele. Archives of Neurology, 2010, 67, 462-8.	4.9	89
781	Menopause and Mitochondria. Progress in Brain Research, 2010, 182, 77-96.	0.9	65
782	Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer's Disease. Journal of the American Medical Directors Association, 2010, 11, 636-644.e1.	1.2	13
783	A Memory and Organizational Aid Improves Alzheimer Disease Research Consent Capacity: Results of a Randomized, Controlled Trial. American Journal of Geriatric Psychiatry, 2010, 18, 1124-1132.	0.6	41

#	Article	IF	CITATIONS
784	Caring for the Elderly Female Psychiatric Patient. Psychiatric Clinics of North America, 2010, 33, 475-485.	0.7	2
786	Dialysis in old patients: Need for closer cooperation between nephrologists and geriatricians. European Geriatric Medicine, 2010, 1, 26-28.	1.2	0
787	Alzheimer's disease: Visual system review. Optometry - Journal of the American Optometric Association, 2010, 81, 12-21.	0.6	50
788	The heterogeneity of mild cognitive impairment: A neuropsychological analysis. Journal of the International Neuropsychological Society, 2010, 16, 84-93.	1.2	108
789	Aging Research: Translating Scientific Discovery into Clinical Intervention. World Medical and Health Policy, 2010, 2, 6-15.	0.9	3
790	Serum levels of S100B and NSE proteins in Alzheimer's disease patients. Journal of Neuroinflammation, 2010, 7, 6.	3.1	158
791	Engineered Proteolytic Nanobodies Reduce Al $^2$ Burden and Ameliorate Al $^2$ -Induced Cytotoxicity. Biochemistry, 2010, 49, 4501-4508.	1.2	23
792	The Future of Financing for Long-Term Care: The <i>Own Your Future</i> Campaign. Journal of Aging and Social Policy, 2010, 22, 379-393.	0.9	11
793	Back to the Plaque. Annual Reports in Medicinal Chemistry, 2010, 45, 314-328.	0.5	0
794	DNA Methylation and Alzheimer's Disease. , 2010, , 315-326.		6
795	Phenolic Bis-styrylbenzenes as $\hat{l}^2$ -Amyloid Binding Ligands and Free Radical Scavengers. Journal of Medicinal Chemistry, 2010, 53, 7992-7999.	2.9	37
796	A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochemistry International, 2010, 56, 937-947.	1.9	131
797	Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 754-761.	1.2	66
798	Effect of Music on Pain for Home-Dwelling Persons with Dementia. Pain Management Nursing, 2010, 11, 141-147.	0.4	34
799	Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiology of Aging, 2010, 31, 1077-1088.	1.5	261
800	Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiology of Aging, 2010, 31, 1419-1428.	1.5	64
801	Low energy laser light (632.8 nm) suppresses amyloid- $\hat{l}^2$ peptide-induced oxidative and inflammatory responses in astrocytes. Neuroscience, 2010, 171, 859-868.	1.1	54
802	Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Research Reviews, 2010, 9, 218-225.	5.0	172

#	Article	IF	CITATIONS
803	Screening Instruments and Brief Batteries for Dementia., 2010,, 503-530.		18
804	Oligomers of $\hat{l}^2$ -amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Experimental Neurology, 2010, 223, 394-400.	2.0	35
805	An examination of Alzheimer's disease case definitions using Medicare claims and survey data. Alzheimer's and Dementia, 2010, 6, 334-341.	0.4	68
806	Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimer's and Dementia, 2010, 6, 482-493.	0.4	61
807	2010 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2010, 6, 158-194.	0.4	471
808	Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neurolmage, 2010, 49, 169-176.	2.1	61
809	Atrophy patterns in Alzheimer's disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neurolmage, 2010, 49, 2264-2274.	2.1	97
810	Oligemic Hypoperfusion Differentially Affects Tau and Amyloid- $\hat{l}^2$ . American Journal of Pathology, 2010, 177, 300-310.	1.9	113
811	Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25–35. Experimental Neurology, 2010, 221, 26-37.	2.0	156
812	Advances in Computational Biology. Advances in Experimental Medicine and Biology, 2010, , .	0.8	2
813	Epigenetics of Aging. , 2010, , .		10
814	Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimer's Research and Therapy, 2010, 2, 34.	3.0	144
815	Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Review of Neurotherapeutics, 2010, 10, 729-745.	1.4	175
816	Early detection of Alzheimer's based on intrinsic measurements. , 2011, , .		1
817	Can functional magnetic resonance imaging improve success rates in central nervous system drug discovery?. Expert Opinion on Drug Discovery, 2011, 6, 597-617.	2.5	56
818	Mental Health and Aging in the 21st Century. Journal of Aging and Social Policy, 2011, 23, 228-243.	0.9	13
819	Can aerobic exercise protect against dementia?. Alzheimer's Research and Therapy, 2011, 3, 6.	3.0	16
820	Use of Biomarkers in Clinical Trials of Alzheimer Disease. Molecular Diagnosis and Therapy, 2011, 15, 313-325.	1.6	20

#	Article	IF	CITATIONS
821	Physical Restraint Use and Falls in Nursing Homes: A Comparison Between Residents With and Without Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2011, 26, 44-50.	0.9	38
822	The Effect of Labeling on Employee Perceptions of Residents Living onÂAlzheimer's Disease Specialized CareÂUnits. Journal of the American Medical Directors Association, 2011, 12, 547-550.	1.2	2
823	Low Energy Laser Light (632.8 nm) Suppresses Amyloid-Beta Peptide-Induced Oxidative and Inflammatory Responses in Astrocytes. Biophysical Journal, 2011, 100, 624a.	0.2	3
824	Selenium and Alzheimer's Disease: A Systematic Review. Journal of Alzheimer's Disease, 2011, 26, 81-104.	1.2	158
825	Adult Hypertension Is Associated With Blood Pressure Variability in Childhood in Blacks and Whites: The Bogalusa Heart Study. American Journal of Hypertension, 2011, 24, 77-82.	1.0	53
826	Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease. Annals of Pharmacotherapy, 2011, 45, 1416-1424.	0.9	104
827	Deep Brain Stimulation for Psychiatric Disorders. Annual Review of Neuroscience, 2011, 34, 289-307.	5.0	239
828	Role of Serotonin in Alzheimer's Disease. CNS Drugs, 2011, 25, 765-781.	2.7	89
831	Combination Therapy for Alzheimer's Disease. Drugs and Aging, 2011, 28, 539-546.	1.3	75
832	An epidemiological study of Alzheimer's disease in elderly Mongolian and Han populations living in rural areas of Inner Mongolia. Aging Clinical and Experimental Research, 2011, 23, 470-475.	1.4	4
833	Small molecule inhibitors of amyloid $\hat{l}^2$ peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacologica Sinica, 2011, 32, 545-551.	2.8	206
834	Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 22.	3.0	20
836	The Alzheimer's amyloid $\hat{l}^2$ -peptide (A $\hat{l}^2$ ) binds a specific DNA A $\hat{l}^2$ -interacting domain (A $\hat{l}^2$ ID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif. Gene, 2011, 488, 1-12.	1.0	106
837	Functional activity of the novel Alzheimer's amyloid $\hat{l}^2$ -peptide interacting domain (A $\hat{l}^2$ ID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene, 2011, 488, 13-22.	1.0	70
838	The role of Cdk5 in cognition and neuropsychiatric and neurological pathology. Brain Research Bulletin, 2011, 85, 9-13.	1.4	48
839	Brain aging, Alzheimer's disease, and mitochondria. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1630-1639.	1.8	251
840	Interfering effect and mechanism of neuregulin on experimental dementia model in rats. Behavioural Brain Research, 2011, 222, 321-325.	1.2	7
841	Measurement of cerebral microvascular compliance in a model of atherosclerosis with optical coherence tomography. Biomedical Optics Express, 2011, 2, 3079.	1.5	19

#	Article	IF	Citations
842	Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease. Journal of Chemical Neuroanatomy, 2011, 42, 111-117.	1.0	31
843	In vitro Pb exposure disturbs the balance between ${\rm A}\hat{\rm I}^2$ production and elimination: The role of ${\rm A}\hat{\rm I}^2$ PP and neprilysin. NeuroToxicology, 2011, 32, 300-306.	1.4	54
844	The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology, 2011, 150, 123-129.	0.8	34
845	Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment. Neurobiology of Aging, 2011, 32, 778-790.	1.5	69
846	Age-related brain pathology in Octodon degu: Blood vessel, white matter and Alzheimer-like pathology. Neurobiology of Aging, 2011, 32, 1651-1661.	1.5	58
847	Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiology of Aging, 2011, 32, 2113-2122.	1.5	93
848	A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2011, 32, 2322.e5-2322.e18.	1.5	281
849	The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiology of Learning and Memory, 2011, 96, 529-543.	1.0	386
850	Epidemiology of Cognitive Aging and Alzheimer's Disease: Contributions of the Cache County Utah Study of Memory, Health and Aging. Current Topics in Behavioral Neurosciences, 2011, 10, 3-31.	0.8	18
851	Prevention of Dementia. Psychiatric Clinics of North America, 2011, 34, 127-145.	0.7	39
852	Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases. Metallomics, 2011, 3, 271.	1.0	38
853	Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention., 2011, 7, e118-e123.		22
854	Alzheimer's Disease Management Guideline: Update 2008. Alzheimer's and Dementia, 2011, 7, e51-9.	0.4	35
855	Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimer's and Dementia, 2011, 7, 80-93.	0.4	399
856	Counting dementia: There is no one "best―way. , 2011, 7, 10-14.		29
857	Sources of variability in estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's and Dementia, 2011, 7, 74-79.	0.4	67
858	National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimer's and Dementia, 2011, 7, 61-73.	0.4	305
859	2011 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2011, 7, 208-244.	0.4	558

#	Article	IF	Citations
860	The Capacity to Vote of Persons with Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	O
861	Staining of Amyloid Beta (Abeta) Using (Immuno) Histochemical Techniques and Abeta42 Specific Peptides. , 0, , .		O
862	Hypotension in Subcortical Vascular Dementia, a New Risk Factor – Wasn't It Hypertension?. , 0, , .		0
863	Mitochondria, Amyloid $\hat{l}^2$ , and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	1.1	44
864	A New Approach to the Treatment of Alzheimer's Disease: the Need for a Controlled Study. Journal of Alzheimer's Disease, 2011, 25, 209-212.	1.2	16
865	Lead, Manganese, and Methylmercury as Risk Factors for Neurobehavioral Impairment in Advanced Age. International Journal of Alzheimer's Disease, 2011, 2011, 1-11.	1.1	18
866	Dysfunctional Incidental Olfaction in Mild Cognitive Impairment (MCI): An Electroencephalography (EEG) Study. Brain Sciences, 2011, 1, 3-15.	1.1	4
867	Cognitive, functional and behavioral assessment: Alzheimer's disease. Dementia E Neuropsychologia, 2011, 5, 153-166.	0.3	22
868	Clinical Research Participation among Aging Adults Enrolled in an Alzheimer's Disease Center Research Registry. Journal of Alzheimer's Disease, 2011, 23, 443-452.	1.2	49
869	Why age (and timing) really matters in developing drugs for neurodegenerative disease. Therapy: Open Access in Clinical Medicine, 2011, 8, 459-461.	0.2	0
870	Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. International Psychogeriatrics, 2011, 23, 44-53.	0.6	24
871	Shunting for idiopathic normal-pressure hydrocephalus: can we predict response?. Future Neurology, 2011, 6, 223-236.	0.9	0
872	Breakfast and Adult and Child Behaviors. , 2011, , 67-84.		0
874	Sleep Disturbances and Nocturnal Agitation Behaviors in Older Adults with Dementia. Sleep, 2011, 34, 779-86.	0.6	54
875	Memory Function in a Mouse Genetic Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 433-444.	1.2	8
876	Infant Exposure to Lead (Pb) and Epigenetic Modifications in the Aging Primate Brain: Implications for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 819-833.	1.2	140
877	Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. British Journal of Clinical Pharmacology, 2011, 71, 365-376.	1.1	284
878	Targets for AD treatment: conflicting messages from $\hat{I}^3$ -secretase inhibitors. Journal of Neurochemistry, 2011, 117, 359-374.	2.1	59

#	Article	IF	Citations
879	Screening for Cognitive Impairment in an Elderly Veteran Population: Acceptability and Results Using Different Versions of the Mini-Cog. Journal of the American Geriatrics Society, 2011, 59, 309-313.	1.3	85
880	Value of Neuropsychological Tests, Neuroimaging, and Biomarkers for Diagnosing Alzheimer's Disease in Younger and Older Age Cohorts. Journal of the American Geriatrics Society, 2011, 59, 1705-1710.	1.3	51
881	Improving Decision-Making for Feeding Options in Advanced Dementia: A Randomized, Controlled Trial. Journal of the American Geriatrics Society, 2011, 59, 2009-2016.	1.3	175
882	Concomitant Use of Cholinesterase Inhibitors and Anticholinergics: Prevalence and Outcomes. Journal of the American Geriatrics Society, 2011, 59, 2069-2076.	1.3	34
883	Psychotropic Medication Burden and Factors Associated with Antipsychotic Use: An Analysis of a Population-Based Sample of Community-Dwelling Older Persons with Dementia. Journal of the American Geriatrics Society, 2011, 59, 2100-2107.	1.3	36
884	Incidence of Serious Upper and Lower Gastrointestinal Events in Older Adults with and without Alzheimer's Disease. Journal of the American Geriatrics Society, 2011, 59, 2053-2061.	1.3	18
885	A Structureâ€based QSAR and Docking Study on Imidazo[1,5â€a][1,2,4]â€triazolo[1,5â€d][1,4,]benzodiazepines Selective GABA <sub>A</sub> α5 Inverse Agonists. Chemical Biology and Drug Design, 2011, 78, 612-621.	3 as 1.5	7
886	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	9.4	1,676
887	Obesity, leptin, and Alzheimer's disease. Annals of the New York Academy of Sciences, 2011, 1243, 15-29.	1.8	104
888	Mental Health and Exposure to Patient Distress Among Families of Nursing Home Residents with Advanced Dementia. Journal of Pain and Symptom Management, 2011, 42, 183-191.	0.6	4
889	Road safe seniors: Screening for age-related driving disorders in inpatient and outpatient settings. Journal of Safety Research, 2011, 42, 165-169.	1.7	5
890	Alzheimer's disease and age-related memory decline (preclinical). Pharmacology Biochemistry and Behavior, 2011, 99, 190-210.	1.3	72
891	Parallel findings in age-related macular degeneration and Alzheimer's disease. Progress in Retinal and Eye Research, 2011, 30, 217-238.	7.3	236
892	Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurology, 2011, 11, 21.	0.8	51
893	PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice. European Journal of Pharmacology, 2011, 662, 22-30.	1.7	82
894	The Role of Behavior Analysis in the Rehabilitation of Persons With Dementia. Behavior Therapy, 2011, 42, 9-21.	1.3	33
895	Command Use and Compliance in Staff Communication With Elderly Residents of Long-Term Care Facilities. Behavior Therapy, 2011, 42, 47-58.	1.3	31
896	Ligand polarizability contributes to tau fibril binding affinity. Bioorganic and Medicinal Chemistry, 2011, 19, 5147-5154.	1.4	13

#	Article	IF	CITATIONS
897	Lead (Pb) and the Risk of Alzheimer's disease or cognitive decline: A systematic review. Toxin Reviews, 2011, 30, 103-114.	1.5	15
898	Galantamine: an update. Neurodegenerative Disease Management, 2011, 1, 227-234.	1.2	2
899	Residual vectors for Alzheimer disease diagnosis and prognostication. Brain and Behavior, 2011, 1, 142-152.	1.0	7
900	Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. Journal of Neural Transmission, 2011, 118, 463-471.	1.4	188
901	A Population-based study of dementia in the oldest old: the Monzino 80-plus Study. BMC Neurology, 2011, 11, 54.	0.8	24
902	Alzheimer's disease: synapses gone cold. Molecular Neurodegeneration, 2011, 6, 63.	4.4	250
903	Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARMâ€Elderly Project. Pharmacoepidemiology and Drug Safety, 2011, 20, 497-505.	0.9	20
904	Proteomic analysis of brain proteins in APP/PSâ€1 human double mutant knockâ€in mice with increasing amyloid βâ€peptide deposition: Insights into the effects of in vivo treatment with ⟨i⟩N⟨ i⟩â€acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.  Proteomics, 2011, 11, 4243-4256.	1.3	39
905	Conditioned media from cell lines: A complementary model to clinical specimens for the discovery of diseaseâ€specific biomarkers. Proteomics, 2011, 11, 794-804.	1.3	123
906	Reversal of memory deficits by Coriandrum sativum leaves in mice. Journal of the Science of Food and Agriculture, 2011, 91, 186-192.	1.7	44
907	Decreased brain stiffness in Alzheimer's disease determined by magnetic resonance elastography. Journal of Magnetic Resonance Imaging, 2011, 34, 494-498.	1.9	277
908	Catalytic Asymmetric Hydrogenation of Ethyl 2â€(Benzo[ <i>b</i> )]thiophenâ€5â€yl)â€2â€oxoacetate with Ruâ€SunPhos in the Formal Synthesis of Tâ€588. Chinese Journal of Chemistry, 2011, 29, 2581-2583.	2.6	3
909	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25. Bioorganic and Medicinal Chemistry, 2011, 19, 359-373.	1.4	20
910	Triazole-linked reduced amide isosteres: An approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3992-3996.	1.0	43
911	Hemoglobin level in older persons and incident Alzheimer disease. Neurology, 2011, 77, 219-226.	1.5	114
912	Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species. Current Medicinal Chemistry, 2011, 18, 3314-3321.	1.2	28
913	Savion., 2011,,.		4
914	Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology, 2011, 77, 713-721.	1.5	28

#	Article	IF	CITATIONS
915	Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease. Current Neuropharmacology, 2011, 9, 693-705.	1.4	26
916	Cognitive Reserve in Aging. Current Alzheimer Research, 2011, 8, 354-360.	0.7	426
917	Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?. Current Alzheimer Research, 2011, 8, 652-658.	0.7	5
918	Finding meaning as a mediator of burden on the health of caregivers of spouses with dementia. Aging and Mental Health, 2011, 15, 522-530.	1.5	42
919	A Randomized Controlled Trial of an Activity Specific Exercise Program for Individuals With Alzheimer Disease in Long-term Care Settings. Journal of Geriatric Physical Therapy, 2011, 34, 50-56.	0.6	72
920	Low-Density Lipoprotein Receptor–Related Protein Is Decreased in Optic Neuropathy of Alzheimer Disease. Journal of Neuro-Ophthalmology, 2011, 31, 139-146.	0.4	8
921	Impact of the Life Review Program on Elders With Dementia. The Journal of Nursing Research: JNR, 2011, 19, 199-209.	0.7	10
922	What Spouse Caregivers Know About Communication in Alzheimer's Disease: Development of the AD Communication Knowledge Test. Issues in Mental Health Nursing, 2011, 32, 28-34.	0.6	14
923	Cognitive Stimulation for Apathy in Probable Early-Stage Alzheimer's. Journal of Aging Research, 2011, 2011, 1-6.	0.4	27
924	Internet-Based Dementia Resources. Journal of Applied Gerontology, 2011, 30, 513-523.	1.0	7
925	Changes in the Prevalence of Cognitive Impairment Among Older Americans, 1993-2004: Overall Trends and Differences by Race/Ethnicity. American Journal of Epidemiology, 2011, 174, 274-283.	1.6	41
926	Reliability and Validity of Food Frequency Questionnaire and Nutrient Biomarkers in Elders With and Without Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2011, 25, 49-57.	0.6	43
927	PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2011, 25, 206-212.	0.6	134
928	Neocortical and hippocampal amyloid- $\hat{l}^2$ and tau measures associate with dementia in the oldest-old. Brain, 2011, 134, 3708-3715.	3.7	82
929	Labor Prices and the Treatment of Nursing Home Residents with Dementia. International Journal of the Economics of Business, 2011, 18, 273-292.	1.0	14
930	Abnormalities of the optic disc. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 102, 117-157.	1.0	22
931	The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases. Toxicological Sciences, 2011, 124, 225-250.	1.4	334
932	A Systematic Review of Single Chinese Herbs for Alzheimer's Disease Treatment. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-8.	0.5	32

#	Article	IF	CITATIONS
933	Maximizing the Impact of a Symposium to Facilitate Change in Student Attitudes about Interdisciplinary Teamwork. Clinical Gerontologist, 2011, 34, 399-412.	1.2	12
934	The Effects of Familism and Cultural Justification on the Mental and Physical Health of Family Caregivers. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2011, 66B, 3-14.	2.4	88
935	Association of Metabolic Dysregulation With Volumetric Brain Magnetic Resonance Imaging and Cognitive Markers of Subclinical Brain Aging in Middle-Aged Adults. Diabetes Care, 2011, 34, 1766-1770.	4.3	117
936	How Do Top Cable News Websites Portray Cognition as an Aging Issue?. Gerontologist, The, 2012, 52, 367-382.	2.3	17
937	Multimodal MRI in Neurodegenerative Disorders. Neurology Research International, 2012, 2012, 1-2.	0.5	8
938	Cognitive function in the community setting: the neighbourhood as a source of  cognitive reserve'?. Journal of Epidemiology and Community Health, 2012, 66, 730-736.	2.0	131
939	Overview and Findings from the Rush Memory and Aging Project. Current Alzheimer Research, 2012, 9, 646-663.	0.7	733
940	Telephone-based, cognitive-behavioral therapy for African American dementia caregivers with depression: Initial findings Rehabilitation Psychology, 2012, 57, 124-139.	0.7	68
941	Air Pollution, Oxidative Stress, and Alzheimer's Disease. Journal of Environmental and Public Health, 2012, 2012, 1-9.	0.4	162
942	Treatment with $A\hat{l}^2$ 42 Binding d-Amino Acid Peptides Reduce Amyloid Deposition and Inflammation in APP/PS1 Double Transgenic Mice. Advances in Protein Chemistry and Structural Biology, 2012, 88, 133-152.	1.0	21
943	Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease. Archives of Neurology, 2012, 69, 59.	4.9	193
944	Road to the Nursing Home. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 90-99.	0.9	7
945	Adapting the Family Management Style Framework for Families Caring for Older Adults With Dementia. Journal of Family Nursing, 2012, 18, 123-145.	1.0	22
946	Exposure to Particulate Air Pollution and Cognitive Decline in Older Women. Archives of Internal Medicine, 2012, 172, 219.	4.3	399
947	Sources of Stress for Family Members of Nursing Home Residents With Advanced Dementia. Alzheimer Disease and Associated Disorders, 2012, 26, 254-259.	0.6	71
948	Using Mental Imagery to Improve Memory in Patients With Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2012, 26, 124-134.	0.6	40
949	Hippocampal Atrophy and Ventricular Enlargement in Normal Aging, Mild Cognitive Impairment (MCI), and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2012, 26, 17-27.	0.6	254
952	Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders. Current Alzheimer Research, 2012, 9, 5-17.	0.7	261

#	Article	IF	CITATIONS
953	Clinically Asymptomatic Vascular Brain Injury: A Potent Cause of Cognitive Impairment Among Older Individuals. Journal of Alzheimer's Disease, 2012, 33, S417-S426.	1.2	38
954	The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006148-a006148.	2.9	292
955	Effects of an 8-Week Meditation Program on Mood and Anxiety in Patients with Memory Loss. Journal of Alternative and Complementary Medicine, 2012, 18, 48-53.	2.1	55
956	Value of Diagnostic tests to Predict Conversion to Alzheimer's Disease in Young and Old Patients with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 29, 641-648.	1.2	37
957	Glaucoma, Alzheimer Disease and Other Dementia: A Longitudinal Analysis. Ophthalmic Epidemiology, 2012, 19, 285-292.	0.8	78
958	Older Adults With Intellectual Disabilities: Targets for Increasing Victimization, A Call for a Preemptive Screening Policy. Journal of Mental Health Research in Intellectual Disabilities, 2012, 5, 157-167.	1.3	3
959	Improving Recall in a Person With Dementia. Clinical Case Studies, 2012, 11, 393-405.	0.5	2
960	A Bio-Psycho-Social model enhances young adults' understanding of and beliefs about people with Alzheimer's disease: A case study. Dementia, 2012, 11, 95-112.	1.0	11
961	Caring for a Loved One With Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 579-583.	0.9	4
962	Multimodal MRI Neuroimaging Biomarkers for Cognitive Normal Adults, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease. Neurology Research International, 2012, 2012, 1-17.	0.5	26
963	Functional Connectivity Variations in Mild Cognitive Impairment: Associations with Cognitive Function. Journal of the International Neuropsychological Society, 2012, 18, 39-48.	1.2	48
964	Perceived Discrimination and Cognition in Older African Americans. Journal of the International Neuropsychological Society, 2012, 18, 856-865.	1.2	130
965	Alzheimer's Disease, Cerebrovascular Disease, and the $\hat{l}^2$ -amyloid Cascade. Canadian Journal of Neurological Sciences, 2012, 39, 712-728.	0.3	141
966	Does ionizing radiation influence Alzheimer's disease risk?. Journal of Radiation Research, 2012, 53, 815-822.	0.8	45
967	Scales for the Evaluation of End-of-Life Care in Advanced Dementia. Alzheimer Disease and Associated Disorders, 2012, 26, 358-363.	0.6	23
968	Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurology, 2012, 7, 749-771.	0.9	96
969	Trends in Percutaneous Endoscopic Gastrostomy Placement in the Elderly From 1993 to 2003. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 609-613.	0.9	46
970	Recent Advances in Imaging Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S313-S327.	1.2	21

#	Article	IF	CITATIONS
971	Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease. Current Alzheimer Research, 2012, 9, 110-119.	0.7	30
972	Transgenic Mouse Models of Alzheimer Disease: Developing a Better Model as a Tool for Therapeutic Interventions. Current Pharmaceutical Design, 2012, 18, 1131-1147.	0.9	146
973	Novel Disease-Modifying Therapies for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 475-492.	1.2	78
975	Terpenoids as Potential Anti-Alzheimer's Disease Therapeutics. Molecules, 2012, 17, 3524-3538.	1.7	110
976	Depressive Symptoms, Antidepressant Use, and Brain Volumes on MRI in a Population-Based Cohort of Old Persons without Dementia. Journal of Alzheimer's Disease, 2012, 30, 75-82.	1.2	45
977	Mitochondrial DNA Sequence Variation Associated with Dementia and Cognitive Function in the Elderly. Journal of Alzheimer's Disease, 2012, 32, 357-372.	1.2	37
978	Protective effect of 7-difluoromethoxy-5,4'-Di-hydroxyl isoflavone against the damage induced by glutamate in PC12 cells. International Journal of Molecular Medicine, 2012, 30, 1159-1165.	1.8	1
979	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
980	Establishing Diganostic Criteria: The Role of Clinical Pragmatics. Lodz Papers in Pragmatics, 2012, 8, .	0.3	23
981	Nutritional determinants of cognitive aging and dementia. Proceedings of the Nutrition Society, 2012, 71, 1-13.	0.4	137
982	Older people dying with dementia: a nationwide study. International Psychogeriatrics, 2012, 24, 1581-1591.	0.6	39
983	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectrums, 2012, 17, 176-206.	0.7	28
984	Amyloid and Alzheimer's Disease: Inside and Out. Canadian Journal of Neurological Sciences, 2012, 39, 286-298.	0.3	56
985	Advanced Dementia: State of the Art and Priorities for the Next Decade. Annals of Internal Medicine, 2012, 156, 45.	2.0	119
986	Ingestion and Alzheimer's Disease: Evidence of Early Changes. Perspectives on Swallowing and Swallowing Disorders (Dysphagia), 2012, 21, 91-95.	0.2	1
987	Living alone is associated with depression among the elderly in a rural community in Japan. Psychogeriatrics, 2012, 12, 179-185.	0.6	87
988	Making a Difference: Resident-Focused Models for Memory Care Facilities. Journal of Interior Design, 2012, 37, v-xii.	0.4	1
989	Cognitive function in patients with chronic pain treated with opioids: characteristics and associated factors. Acta Anaesthesiologica Scandinavica, 2012, 56, 1257-1266.	0.7	29

#	Article	IF	CITATIONS
990	AAC to Support Conversation in Persons with Moderate Alzheimer's Disease. AAC: Augmentative and Alternative Communication, 2012, 28, 219-231.	0.8	36
991	TDP-43: A new player on the AD field?. Experimental Neurology, 2012, 237, 90-95.	2.0	25
992	Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies., 2012, 8, 407-416.		10
993	Global gray matter changes in posterior cortical atrophy: A serial imaging study. Alzheimer's and Dementia, 2012, 8, 502-512.	0.4	45
994	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimer's and Dementia, 2012, 8, 496-501.	0.4	116
995	2012 Alzheimer's disease facts and figures Alzheimer's Association <sup>â^—</sup> . Alzheimer's and Dementia, 2012, 8, 131-168.	0.4	829
996	Common Alzheimer's Disease Research Ontology: National Institute onÂAging and Alzheimer's Association Collaborative Project. , 2012, 8, 372-375.		38
997	Does This Dementia Patient Meet the Prognosis Eligibility Requirements for Hospice Enrollment?. Journal of Pain and Symptom Management, 2012, 44, 750-756.	0.6	16
998	Music-based memory enhancement in Alzheimer's Disease: Promise and limitations. Neuropsychologia, 2012, 50, 3295-3303.	0.7	71
999	Unmet Home Care Service Needs of Rural Older Adults With Alzheimer's Disease: A Perspective of Informal Caregivers. Journal of Gerontological Social Work, 2012, 55, 409-425.	0.6	26
1000	Misperceptions of Medicaid Ineligibility Persist among African American Caregivers of Alzheimer's Dementia Care Recipients. Population Health Management, 2012, 15, 174-180.	0.8	3
1001	Detecting wandering behavior based on GPS traces for elders with dementia. , 2012, , .		53
1002	Remarriage as Context for Dementia Caregiving: Implications of Positive Support and Negative Interactions for Caregiver Well-Being. Research in Human Development, 2012, 9, 165-182.	0.8	8
1003	Unmet Service Needs: A Comparison Between Dementia and Non-Dementia Caregivers. Home Health Care Services Quarterly, 2012, 31, 41-59.	0.3	18
1004	With Love From Me to Me: Using Songwriting to Teach Coping Skills to Caregivers of Those With Alzheimer's and Other Dementias. Journal of Creativity in Mental Health, 2012, 7, 153-164.	0.6	22
1005	Gender differences in sexual behaviors of AD patients and their relationship to spousal caregiver well-being. Aging and Mental Health, 2012, 16, 89-101.	1.5	34
1006	Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiology of Aging, 2012, 33, 856-866.	1.5	55
1007	Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1057-1066.	1.5	90

#	Article	IF	CITATIONS
1008	Coexistence of narcolepsy and Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1318-1319.	1.5	31
1009	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiology of Aging, 2012, 33, 627.e1-627.e12.	1.5	74
1010	$3xTgAD$ mice exhibit altered behavior and elevated $A\hat{l}^2$ after chronic mild social stress. Neurobiology of Aging, 2012, 33, 830.e1-830.e12.	1.5	73
1011	A review of the structural alterations in the cerebral hemispheres of the aging rhesus monkey. Neurobiology of Aging, 2012, 33, 2357-2372.	1.5	103
1012	Whole brain N-acetylaspartate concentration is conserved throughout normal aging. Neurobiology of Aging, 2012, 33, 2440-2447.	1.5	25
1013	Fluorine-18 labeling of three novel d-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. Nuclear Medicine and Biology, 2012, 39, 315-323.	0.3	16
1014	Increased $\hat{l}^2$ -amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure. Toxicology Letters, 2012, 213, 211-219.	0.4	55
1015	A Longitudinal Analysis of the Lifetime Cost of Dementia. Health Services Research, 2012, 47, 1660-1678.	1.0	51
1016	Microbiosensor for Alzheimer's disease diagnostics: detection of amyloid beta biomarkers. Journal of Neurochemistry, 2012, 122, 374-381.	2.1	58
1017	Discovery of Novel Inhibitors of Amyloid β-Peptide 1–42 Aggregation. Journal of Medicinal Chemistry, 2012, 55, 9521-9530.	2.9	39
1018	Mitochondria, Diabetes, and Alzheimer's Disease. Diabetes, 2012, 61, 991-992.	0.3	17
1019	Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease. RSC Advances, 2012, 2, 5008.	1.7	48
1020	White matter integrity and vulnerability to Alzheimer's disease: Preliminary findings and future directions. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 416-422.	1.8	132
1021	PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 370-379.	1.8	132
1022	Alzheimer's disease multiple intervention trial (ADMIT): study protocol for a randomized controlled clinical trial. Trials, 2012, 13, 92.	0.7	15
1023	Immunosenescence, inflammation and Alzheimer's disease. Longevity & Healthspan, 2012, 1, 8.	6.7	58
1024	Brain iron accumulation in aging and neurodegenerative disorders. Expert Review of Neurotherapeutics, 2012, 12, 1467-1480.	1.4	83
1025	Screening and treatment for Alzheimer's disease: Predicting population-level outcomes., 2012, 8, 31-38.		4

#	Article	IF	CITATIONS
1026	Tools to Detect Delirium Superimposed on Dementia: A Systematic Review. Journal of the American Geriatrics Society, 2012, 60, 2005-2013.	1.3	124
1027	Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. The Cochrane Library, 2012, , CD006378.	1.5	166
1028	Neurotrophic Factors and Neurodegenerative Diseases. International Review of Neurobiology, 2012, 102, 207-247.	0.9	26
1029	Neuronuclear Imaging in the Evaluation of Dementia and Mild Decline in Cognition. Seminars in Nuclear Medicine, 2012, 42, 415-422.	2.5	27
1030	Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice. Behavioural Brain Research, 2012, 235, 1-6.	1.2	47
1031	SCN1A Affects Brain Structure and the Neural Activity of the Aging Brain. Biological Psychiatry, 2012, 72, 677-683.	0.7	7
1032	Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environmental Toxicology and Pharmacology, 2012, 34, 272-279.	2.0	100
1033	Late-Life Body Mass Index and Dementia: An Integrative Literature Review. Journal for Nurse Practitioners, 2012, 8, 725-728.	0.4	0
1034	Age-related decrease in cerebrovascular-derived neuroprotective proteins: Effect of acetaminophen. Microvascular Research, 2012, 84, 278-285.	1.1	18
1035	Computational Evidence to Inhibition of Human Acetyl Cholinesterase by Withanolide A for Alzheimer Treatment. Journal of Biomolecular Structure and Dynamics, 2012, 29, 651-662.	2.0	48
1037	Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. Brain Imaging and Behavior, 2012, 6, 610-620.	1.1	59
1038	Effect of Selective Serotonin Reuptake Inhibitors in Alzheimer's Disease with Comorbid Depression. Drugs and Aging, 2012, 29, 793-806.	1.3	79
1039	Role of testosterone in memory impairment of Alzheimer disease induced by Streptozotocin in male rats. DARU, Journal of Pharmaceutical Sciences, 2012, 20, 98.	0.9	11
1040	Reversal of memory deficits by ethanolic extract of Mimusops elengi Linn. in mice. Pharmacognosy Journal, 2012, 4, 30-39.	0.3	2
1041	The General Public's Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer's Disease Medication. Pharmacoeconomics, 2012, 30, 1085-1095.	1.7	5
1042	Evaluation of visual recognition memory for the early diagnosis of Alzheimer's disease in patients over 75 years. Revue Neurologique, 2012, 168, 483-487.	0.6	6
1043	Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1297-304.	1.4	8
1044	3xTg-AD Mice Exhibit an Activated Central Stress Axis During Early-Stage Pathology. Journal of Alzheimer's Disease, 2012, 33, 407-422.	1.2	62

#	Article	IF	CITATIONS
1045	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimer's Research and Therapy, 2012, 4, 34.	3.0	103
1046	Polyunsaturated fatty acids in the prevention of Alzheimer's disease: A literature review. Advances in Gerontology, 2012, 2, 340-344.	0.1	0
1047	Neuronal LR11 Expression Does Not Differentiate between Clinically-Defined Alzheimer's Disease and Control Brains. PLoS ONE, 2012, 7, e40527.	1.1	10
1048	Ageing Increases Vulnerability to AÎ <sup>2</sup> 42 Toxicity in Drosophila. PLoS ONE, 2012, 7, e40569.	1.1	35
1049	Astrocyte Senescence as a Component of Alzheimer's Disease. PLoS ONE, 2012, 7, e45069.	1.1	393
1050	Older Men Who Use Computers Have Lower Risk of Dementia. PLoS ONE, 2012, 7, e44239.	1.1	55
1051	Promising Genetic Biomarkers of Preclinical Alzheimer's Disease: The Influence of <i>APOE </i> and <i>TOMM40 </i> on Brain Integrity. International Journal of Alzheimer's Disease, 2012, 2012, 1-15.	1.1	25
1052	A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines. Scientific World Journal, The, 2012, 2012, 1-15.	0.8	626
1053	Evidence-based pharmacotherapy of Alzheimer's disease., 0,, 262-277.		0
1054	Calpain Dysregulation in Alzheimer's Disease. , 2012, 2012, 1-12.		48
1055	Promoting Brain Health for African Americans: Evaluating the Healthy Brain Initiative, a Community-Level Demonstration Project. Journal of Health Care for the Poor and Underserved, 2012, 23, 99-113.	0.4	5
1056	Bispecific Tandem Single Chain Antibody Simultaneously Inhibits $\hat{l}^2$ -Secretase and Promotes $\hat{l}_\pm$ -Secretase Processing of A $\hat{l}^2$ PP. Journal of Alzheimer's Disease, 2012, 28, 961-969.	1.2	14
1057	A Clinical Approach to Early-Onset Inheritable Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 154-161.	0.9	16
			(0)
1058	The Fear of Alzheimer's Disease Scale: a new measure designed to assess anticipatory dementia in older adults. International Journal of Geriatric Psychiatry, 2012, 27, 521-528.	1.3	60
1058		2.6	29
	adults. International Journal of Geriatric Psychiatry, 2012, 27, 521-528.  A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. BioFactors, 2012, 38,		
1059	adults. International Journal of Geriatric Psychiatry, 2012, 27, 521-528.  A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. BioFactors, 2012, 38, 98-106.  Heart failure with preserved ejection fraction in the elderly: scope of the problem. Heart Failure	2.6	29

#	Article	IF	CITATIONS
1063	Assessment and management of patients with cognitive impairment and dementia in primary care. Journal of Nutrition, Health and Aging, 2012, 16, 462-467.	1.5	22
1064	Calorimetric investigation of copper(II) binding to $\hat{Al^2}$ peptides: thermodynamics of coordination plasticity. Journal of Biological Inorganic Chemistry, 2012, 17, 531-541.	1.1	39
1065	Family Perceptions of Endâ€ofâ€Life Care for Longâ€Term Care Residents with Dementia: Differences Between the United States and the Netherlands. Journal of the American Geriatrics Society, 2012, 60, 316-322.	1.3	35
1066	Finding Dementia in Primary Care: The Results of a Clinical Demonstration Project. Journal of the American Geriatrics Society, 2012, 60, 210-217.	1.3	48
1067	Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. Journal of Pineal Research, 2012, 52, 167-202.	3.4	255
1068	Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid- $\hat{l}^2$ cascade. Free Radical Biology and Medicine, 2012, 52, 593-600.	1.3	41
1069	The Development of Direct-Care Staff Social Interaction Coding Schemas for Nursing Home Residents with Dementia. Geriatric Nursing, 2012, 33, 113-117.	0.9	7
1070	Centre Stage Diagramming: Late-stage Parkinson's disease and Alzheimer's disease. Journal of Aging Studies, 2012, 26, 204-213.	0.7	1
1071	Preoperative Cognitive Dysfunction Is Related to Adverse Postoperative Outcomes in the Elderly. Journal of the American College of Surgeons, 2012, 215, 12-17.	0.2	196
1072	The Relationship of Pain and Cognitive Impairment with Social Vulnerability—An Analysis of the Canadian Study of Health and Aging. Pain Medicine, 2012, 13, 190-197.	0.9	15
1073	Transitions in Care for Older Adults with and without Dementia. Journal of the American Geriatrics Society, 2012, 60, 813-820.	1.3	195
1074	Magnetic resonance elastography of the brain in a mouse model of Alzheimer's disease: initial results. Magnetic Resonance Imaging, 2012, 30, 535-539.	1.0	77
1075	Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Neurobiology of Disease, 2012, 45, 381-387.	2.1	72
1076	Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors., 2012, 134, 8-25.		180
1077	Isolation of synaptic terminals from Alzheimer's disease cortex. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 248-254.	1.1	31
1078	Association between caregiver quality of life and the care provided to persons with Alzheimer's disease: protocol for a systematic review. Systematic Reviews, 2013, 2, 17.	2.5	21
1079	A1C., 2013,, 1-1.		0
1080	A revised limbic system model for memory, emotion and behaviour. Neuroscience and Biobehavioral Reviews, 2013, 37, 1724-1737.	2.9	529

#	Article	IF	CITATIONS
1081	A review of multidomain interventions to support healthy cognitive ageing. Journal of Nutrition, Health and Aging, 2013, 17, 252-257.	1.5	73
1082	The impact of Medicare prescription drug coverage on the use of antidementia drugs. BMC Geriatrics, 2013, 13, 37.	1.1	15
1083	Amyloid <i>sî²</i> -Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. Antioxidants and Redox Signaling, 2013, 19, 823-835.	2.5	439
1084	Genetics of Alzheimer Disease. , 2013, , 1-20.		0
1085	Protective effect of Cnestis ferruginea and its active constituent on scopolamine-induced memory impairment in mice: A behavioral and biochemical study. Pharmaceutical Biology, 2013, 51, 825-835.	1.3	40
1086	A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. International Journal of Pharmaceutics, 2013, 453, 395-399.	2.6	52
1087	Distinct patterns of medial temporal impairment in degenerative dementia: a brain SPECT perfusion study in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 932-942.	3.3	5
1088	Interaction between baicalein and amyloid- $\hat{l}^2$ fibrils studied by fluorescence spectroscopy. Chemical Research in Chinese Universities, 2013, 29, 20-25.	1.3	5
1089	The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion on Therapeutic Targets, 2013, 17, 1203-1220.	1.5	42
1090	Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications. Diabetes/Metabolism Research and Reviews, 2013, , n/a-n/a.	1.7	20
1091	Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicity. Drug Discovery Today: Technologies, 2013, 10, e115-e119.	4.0	95
1092	Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Drugs and Aging, 2013, 30, 783-792.	1.3	50
1093	Drug resistance confounding prion therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4160-9.	3.3	120
1094	Monetary Costs of Dementia in the United States. New England Journal of Medicine, 2013, 368, 1326-1334.	13.9	1,164
1095	2013 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2013, 9, 208-245.	0.4	1,151
1096	Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Advances in Predictive, Preventive and Personalised Medicine, 2013, , .	0.6	3
1097	Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radical Biology and Medicine, 2013, 65, 595-606.	1.3	56
1098	ABCA7 expression is associated with Alzheimer's disease polymorphism and disease status. Neuroscience Letters, 2013, 556, 58-62.	1.0	86

#	ARTICLE	IF	CITATIONS
1099	Poor Oral Health as a Chronic, Potentially Modifiable Dementia Risk Factor: Review of the Literature. Current Neurology and Neuroscience Reports, 2013, 13, 384.	2.0	99
1100	Brains from non-Alzheimer's individuals containing amyloid deposits accelerate Aβ deposition in vivo. Acta Neuropathologica Communications, 2013, 1, 76.	2.4	30
1101	Willingness-to-pay to prevent Alzheimer's disease: a contingent valuation approach. International Journal of Health Care Finance and Economics, 2013, 13, 233-245.	1.2	28
1102	Antioxidant. , 2013, , 105-106.		0
1103	Hippocampal correlates of depression in healthy elderly adults. Hippocampus, 2013, 23, 1137-1142.	0.9	17
1104	Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology, 2013, 80, 1778-1783.	1.5	2,122
1105	Functional requirements and design issues for a socially assistive robot for elderly people with mild cognitive impairments. , $2013$ , , .		11
1106	An Intelligent Monitoring System for Cognitive Impaired People. , 2013, , .		O
1107	Rhein lysinate decreases the generation of $\hat{l}^2$ -amyloid in the brain tissues of Alzheimer's disease model mice by inhibiting inflammatory response and oxidative stress. Journal of Asian Natural Products Research, 2013, 15, 756-763.	0.7	16
1108	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of Aging, 2013, 34, 73-82.	1.5	41
1109	Tauroursodeoxycholic acid suppresses amyloid $\hat{l}^2$ -induced synaptic toxicity in vitro and in APP/PS1 mice. Neurobiology of Aging, 2013, 34, 551-561.	1.5	44
1110	Hyperglycemia-Induced Tau Cleavage in vitro and in vivo: A Possible Link Between Diabetes and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 727-739.	1.2	64
1111	Effects of positive cognitions and resourcefulness on caregiver burden among caregivers of persons with dementia. International Journal of Mental Health Nursing, 2013, 22, 340-346.	2.1	35
1112	Gut microbiota, immune development and function. Pharmacological Research, 2013, 69, 87-113.	3.1	200
1113	Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. NeuroImage: Clinical, 2013, 3, 180-195.	1.4	277
1114	A semi-quantitative method for correlating brain disease groups with normal controls using SPECT: Alzheimer's disease versus vascular dementia. Computerized Medical Imaging and Graphics, 2013, 37, 40-47.	3.5	23
1115	Maternal genotype influences behavioral development of 3×Tg-AD mouse pups. Behavioural Brain Research, 2013, 252, 40-48.	1.2	21
1116	Structural and Functional Magnetic Resonance Imaging. PET Clinics, 2013, 8, 407-430.	1.5	1

#	Article	IF	CITATIONS
1117	Association of GWASâ€linked loci with lateâ€onset Alzheimer's disease inÂa northern Han Chinese population. Alzheimer's and Dementia, 2013, 9, 546-553.	0.4	127
1118	Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. Alzheimer's and Dementia, 2013, 9, 30-38.	0.4	112
1119	Simultaneous separation, identification and activity evaluation of three butyrylcholinesterase inhibitors from Plumula nelumbinis using on-line HPLC-UV coupled with ESI-IT-TOF-MS and BChE biochemical detection. Talanta, 2013, 110, 180-189.	2.9	32
1120	Worming Our Way to Alzheimer's Disease Drug Discovery. Biological Psychiatry, 2013, 73, 396-398.	0.7	2
1121	Impact of a Decision Aid on Surrogate Decision-Makers' Perceptions of Feeding Options for Patients With Dementia. Journal of the American Medical Directors Association, 2013, 14, 114-118.	1.2	54
1122	Deep Brain Stimulation for the Treatment of Alzheimer Disease and Dementias. World Neurosurgery, 2013, 80, S28.e1-S28.e8.	0.7	89
1123	Information use environments of African-American dementia caregivers over the course of cognitive–behavioral therapy for depression. Library and Information Science Research, 2013, 35, 191-199.	1.2	9
1124	Vestibular loss as a contributor to Alzheimer's disease. Medical Hypotheses, 2013, 80, 360-367.	0.8	65
1125	Decreased activity of daily living produced by the combination of Alzheimer's disease and lower limb fracture in elderly requiring nursing care. Environmental Health and Preventive Medicine, 2013, 18, 16-23.	1.4	7
1126	A commentary on studies presenting projections of the future prevalence of dementia. BMC Public Health, 2013, 13, 1.	1.2	1,151
1127	Challenges in Assessing Nursing Home Residents with Advanced Dementia for Suspected Urinary Tract Infections. Journal of the American Geriatrics Society, 2013, 61, 62-66.	1.3	143
1128	Senescent Cells: A Novel Therapeutic Target for Aging and Age-Related Diseases. Clinical Pharmacology and Therapeutics, 2013, 93, 105-116.	2.3	225
1129	Design, synthesis and structure–activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1720-1726.	1.0	18
1130	Alpha-Amylase., 2013,, 69-71.		0
1131	Brain aging and mitochondria-targeted plastoquinone antioxidants of SkQ-type. Biochemistry (Moscow), 2013, 78, 295-300.	0.7	12
1132	Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers. Journal of Medicinal Chemistry, 2013, 56, 3121-3147.	2.9	121
1133	2â€Phenylethynylâ€butyltellurium attenuates amyloidâ€Î² peptide(25–35)â€induced learning and memory impairments in mice. Journal of Neuroscience Research, 2013, 91, 848-853.	1.3	12
1134	Highâ€Dose Donepezil (23Âmg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines. CNS Neuroscience and Therapeutics, 2013, 19, 294-301.	1.9	53

#	Article	IF	CITATIONS
1136	What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders. Molecular Psychiatry, 2013, 18, 425-434.	4.1	60
1137	Bapineuzumab and solanezumab for Alzheimer's disease: is the â€~amyloid cascade hypothesis' still alive?. Expert Opinion on Biological Therapy, 2013, 13, 1075-1084.	1.4	100
1138	Reduced Prevalence of Cognitive Impairment in Families With Exceptional Longevity. JAMA Neurology, 2013, 70, 867.	4.5	21
1139	Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA. Neurotherapeutics, 2013, 10, 486-497.	2.1	133
1140	Advances in electrochemical detection for study of neurodegenerative disorders. Analytical and Bioanalytical Chemistry, 2013, 405, 5725-5741.	1.9	35
1142	Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research and Therapy, 2013, 5, 12.	3.0	11
1143	Autoimmune Diabetes., 2013,, 163-163.		0
1144	Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease. Psychopharmacology, 2013, 230, 279-289.	1.5	28
1145	Acetylcholine., 2013,, 14-16.		0
1146	The impact of alcohol on Alzheimer's disease: A systematic review. Aging and Mental Health, 2013, 17, 133-146.	1.5	79
1147	Predicting Cognitive Decline in Subjects at Risk for Alzheimer Disease by Using Combined Cerebrospinal Fluid, MR Imaging, and PET Biomarkers. Radiology, 2013, 266, 583-591.	3.6	212
1148	Cross-cultural differences in dementia: the Sociocultural Health Belief Model. International Psychogeriatrics, 2013, 25, 517-530.	0.6	90
1149	Overlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes. Molecular Neurobiology, 2013, 47, 399-424.	1.9	71
1150	Targeting the Chameleon: a Focused Look at α-Synuclein and Its Roles in Neurodegeneration. Molecular Neurobiology, 2013, 47, 446-459.	1.9	22
1151	The Role of Antipsychotic Drugs in the Treatment of Neuropsychiatric Symptoms of Dementia. Focus (American Psychiatric Publishing), 2013, 11, 32-38.	0.4	5
1152	The coming crisis. Neurology, 2013, 80, 1989-1996.	1.5	144
1153	Age Trajectory of High Cognitive Functioning Among the Oldest Old. Annual Review of Gerontology and Geriatrics, 2013, 33, 35-48.	0.5	5
1154	Current mechanisms in stroke. Acta Pharmacologica Sinica, 2013, 34, 1-2.	2.8	38

#	Article	IF	CITATIONS
1155	Cholinergic Modulation by Opioid Receptor Ligands: Potential Application to Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2013, 13, 456-466.	1.1	7
1156	SPION-Enhanced Magnetic Resonance Imaging of Alzheimer's Disease Plaques in AÎ <sup>2</sup> PP/PS-1 Transgenic Mouse Brain. Journal of Alzheimer's Disease, 2013, 34, 349-365.	1.2	86
1157	Depressive Symptoms and Memory Performance Among Older Adults. Journal of Aging and Health, 2013, 25, 209S-229S.	0.9	36
1158	Age and apolipoprotein E Îμ4 effects on neural correlates of odor memory Behavioral Neuroscience, 2013, 127, 339-349.	0.6	11
1159	Sleep, memory, and aging: The link between slow-wave sleep and episodic memory changes from younger to older adults Psychology and Aging, 2013, 28, 105-114.	1.4	134
1160	Assessment of capacity in an aging society American Psychologist, 2013, 68, 158-171.	3.8	123
1161	Abnormal Gephyrin Immunoreactivity Associated With Alzheimer Disease Pathologic Changes. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1009-1015.	0.9	29
1162	Effects of isoflurane-induced anaesthesia on cognitive performance in a mouse model of Alzheimer's disease. European Journal of Anaesthesiology, 2013, 30, 605-611.	0.7	10
1163	Health Care Utilization and Costs Among Patients With AD With and Without Dysphagia. Alzheimer Disease and Associated Disorders, 2013, 27, 138-144.	0.6	17
1164	The Impact of a Gerontology Course and a Service-Learning Program on College Students' Attitudes Toward People With Dementia. Journal of Applied Gerontology, 2013, 32, 139-163.	1.0	36
1165	How do older people describe others with cognitive impairment? A multiethnic study in the United States. Ageing and Society, 2013, 33, 369-392.	1.2	25
1166	Reliability, Validity, and Interpretation of the Dependence Scale in Mild to Moderately Severe Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 738-749.	0.9	14
1167	Health Disparities in Cost of Care in Patients With Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 84-92.	0.9	43
1168	Method to detect the variants of the erythrocyte in a rat model of Aβ25–35-induced neurotoxicity based on micro-Raman spectroscopy. Journal of Biomedical Optics, 2013, 18, 118003.	1.4	4
1170	The Case for Screening for Cognitive Impairment in Older Adults. Journal of the American Geriatrics Society, 2013, 61, 1203-1205.	1.3	9
1171	Cholinergic Depletion in Alzheimer's Disease Shown by [18F]FEOBV Autoradiography. International Journal of Molecular Imaging, 2013, 2013, 1-6.	1.3	33
1172	Receptor for Advanced Glycation End Products and Its Involvement in Inflammatory Diseases. International Journal of Inflammation, 2013, 2013, 1-15.	0.9	181
1173	Amyloid Beta Peptides Differentially Affect Hippocampal Theta Rhythms <i>In Vitro</i> International Journal of Peptides, 2013, 2013, 1-11.	0.7	19

#	Article	IF	CITATIONS
1174	An Evidence-Based Systematic Review on Cognitive Interventions for Individuals With Dementia. American Journal of Speech-Language Pathology, 2013, 22, 126-145.	0.9	64
1175	Speech-Language Pathology in the Long-Term Care Setting: It Isn't Your Grandmother's Nursing Home Anymore. Seminars in Speech and Language, 2013, 34, 029-036.	0.5	1
1176	Skilled Nursing Facility Admissions of Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society, 2013, 61, 1645-1650.	1.3	21
1177	Genome scan in familial lateâ€onset Alzheimer's disease: A locus on chromosome 6 contributes to ageâ€onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 201-212.	1.1	5
1178	Inâ€Hospital Mortality and Coronary Procedure Use for Individuals with Dementia with Acute Myocardial Infarction in the United States. Journal of the American Geriatrics Society, 2013, 61, 1932-1936.	1.3	18
1179	Dementia Caregiving in the Context of Lateâ€Life Remarriage: Support Networks, Relationship Quality, and Wellâ€being. Journal of Marriage and Family, 2013, 75, 1149-1163.	1.6	34
1180	Oral health in older adults with dementia living in different environments: a propensity analysis. Special Care in Dentistry, 2013, 33, 239-247.	0.4	14
1181	Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study. Current Medical Research and Opinion, 2013, 29, 989-1000.	0.9	15
1182	Effects of electronic maps on wayfinding abilities of patients with mild Alzheimer disease. Journal of Industrial and Production Engineering, 2013, 30, 397-404.	2.1	2
1183	Molecular Docking Studies of (1 <i>5<i>E</i>)-1,6-Bis(substituted phenyl)hexa-1,3,5-triene and 1,4-Bis(substituted <i>trans</i>-styryl)benzene Analogs as Novel Tyrosinase Inhibitors.  Biological and Pharmaceutical Bulletin, 2013, 36, 55-65.</i>	0.6	8
1185	Grief Experiences of 3 Caregiving Wives of Veterans With Dementia. American Journal of Hospice and Palliative Medicine, 2013, 30, 137-145.	0.8	8
1187	Amyloid- $\hat{l}^2$ peptide active site: theoretical Cu K-edge XANES study. Journal of Physics: Conference Series, 2013, 430, 012042.	0.3	1
1188	Critical window hypothesis of hormone therapy and cognition. Menopause, 2013, 20, 695-709.	0.8	171
1189	The Role of Oxidative Stress in Alzheimer ' s Disease. , 2013, 03, .		20
1191	The role of APP in Alzheimer's disease. Advances in Alzheimer's Disease, 2013, 02, 60-65.	0.3	2
1192	Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clinical Interventions in Aging, 2013, 8, 1007.	1.3	123
1193	Disturbed Sleep in Preclinical Cognitive Impairment: Cause and Effect?. Sleep, 2013, 36, 1275-1276.	0.6	12
1194	The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases. American Journal of Alzheimer's Disease (Columbia, Mo ), 2013, 1, .	0.3	32

#	Article	IF	CITATIONS
1195	Beliefs and Communication Practices Regarding Cognitive Functioning Among Consumers and Primary Care Providers in the United States, 2009. Preventing Chronic Disease, 2013, 10, E58; quiz 8-13.	1.7	18
1196	Fluorine-18 Radiolabeled Heterocycles as PET Tracers for Imaging β - Amyloid Plaques in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2013, 13, 909-919.	1.0	33
1197	A Plan to Address Alzheimer's Disease. Public Health Reports, 2013, 128, 76-77.	1.3	1
1198	Mutation in E1, the Ubiquitin Activating Enzyme, Reduces Drosophila Lifespan and Results in Motor Impairment. PLoS ONE, 2013, 8, e32835.	1.1	31
1199	GPR3 Stimulates $A\hat{l}^2$ Production via Interactions with APP and $\hat{l}^2$ -Arrestin2. PLoS ONE, 2013, 8, e74680.	1.1	32
1200	Dementia: An Evidence-Based Review of Common Presentations and Family-Based Interventions. Journal of Osteopathic Medicine, 2013, 113, 768-775.	0.4	12
1202	A review of cardiorespiratory fitness-related neuroplasticity in the aging brain. Frontiers in Aging Neuroscience, 2013, 5, 31.	1.7	110
1203	Association of Metabolic Syndrome and Inflammation with Cognitive Decline in Adults Aged 60 Years and Older: Findings from a National Health Survey in the United States. Neuroscience Journal, 2013, 2013, 1-7.	2.3	7
1204	Role of Copper and Cholesterol Association in the Neurodegenerative Process. International Journal of Alzheimer's Disease, 2013, 2013, 1-15.	1.1	16
1205	Bioethical Issues in Disclosing APOE Genetic Information in Research Programmes. Asian Bioethics Review, 2013, 5, 85-92.	0.9	0
1206	Genetic Variants in the SORL1 Gene Are Associated with Age at Onset of Alzheimer Disease: A Survival Analysis. International Journal of Medical Genetics, 2014, 2014, 1-6.	0.6	1
1207	Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clinical Epidemiology, 2014, 6, 37.	1.5	703
1208	Neuronal Networks and Therapeutics in Neurodegenerative Disorders. , 2014, , 335-348.		1
1209	ncPred: ncRNA-Disease Association Prediction through Tripartite Network-Based Inference. Frontiers in Bioengineering and Biotechnology, 2014, 2, 71.	2.0	56
1210	Meta-Review of CSF Core Biomarkers in Alzheimer $\tilde{A}$ ¢ $\hat{a}$ , $\neg \hat{a}$ ,,¢s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Frontiers in Aging Neuroscience, 2014, 6, 47.	1.7	105
1211	Decreased Default Mode Network connectivity correlates with age-associated structural and cognitive changes. Frontiers in Aging Neuroscience, 2014, 6, 256.	1.7	86
1212	Detection of bacterial antigens and Alzheimer $\tilde{A}$ ¢ $\hat{a}$ , ¬ $\hat{a}$ , ¢s disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae. Frontiers in Aging Neuroscience, 2014, 6, 304.	1.7	65
1213	Skewed X-Chromosome Inactivation in Women Affected by Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1251-1259.	1.2	17

#	Article	IF	CITATIONS
1214	Treating the elderly diabetic patient: special considerations. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 391.	1.1	10
1215	Systematic Review of the Effects of Exercise on Activities of Daily Living in People With Alzheimer's Disease. American Journal of Occupational Therapy, 2014, 68, 50-56.	0.1	88
1216	Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer's disease. Patient Preference and Adherence, 2014, 8, 1223.	0.8	8
1217	Educational bias in the assessment of severe dementia: Brazilian cutoffs for severe Mini-Mental State Examination. Arquivos De Neuro-Psiquiatria, 2014, 72, 273-277.	0.3	25
1218	The triple power of $D\hat{A}^3$ : Protein intrinsic disorder in degenerative diseases. Frontiers in Bioscience - Landmark, 2014, 19, 181.	3.0	78
1220	Perceived Stigma in Caregivers of Persons with Dementia and its Impact on Depressive Symptoms. Journal of Depression & Anxiety, 2014, 03, .	0.1	4
1221	Potent Acetylcholinesterase Inhibitory Compounds from <i>Myristica fragrans</i> . Natural Product Communications, 2014, 9, 1934578X1400900.	0.2	13
1222	I Am Sure to Grow Old. , 2014, , 239-265.		4
1223	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. The Cochrane Library, 2014, , CD010771.	1.5	37
1224	Epidemiological and Economic Burden of Alzheimer's Disease: A Systematic Literature Review of Data across Europe and the United States of America. Journal of Alzheimer's Disease, 2014, 43, 1271-1284.	1.2	168
1225	Gaps in Alzheimer's Knowledge Among College Students. Educational Gerontology, 2014, 40, 655-665.	0.7	9
1226	Protein-Based Biomarkers in Cerebrospinal Fluid and Blood for Alzheimer's Disease. Journal of Molecular Neuroscience, 2014, 54, 739-747.	1.1	15
1227	Comorbidity and Chronic Conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2014, 69, S154-S165.	2.4	86
1228	Neurocognitive Disorders in Aging: A Primer on DSM-5 Changes and Framework for Application to Practice. Clinical Gerontologist, 2014, 37, 317-346.	1.2	6
1229	Depression, Diabetes and Dementia. Key Issues in Mental Health, 2015, , 42-53.	0.6	1
1230	Antioxidant and Anti-Inflammatory Role of Melatonin in Alzheimer's Neurodegeneration. , 2014, , 177-193.		8
1231	Digital memory notebook. , 2014, , .		2
1232	Dual-retrieval models and neurocognitive impairment Journal of Experimental Psychology: Learning Memory and Cognition, 2014, 40, 41-65.	0.7	17

#	Article	IF	CITATIONS
1233	Cognitive Aging and Rate of Hospitalization in an Urban Population of Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 447-454.	1.7	17
1234	Chronic stress as a risk factor for Alzheimer's disease. Reviews in the Neurosciences, 2014, 25, 785-804.	1.4	132
1235	High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. European Heart Journal, 2014, 35, 1817-1824.	1.0	37
1236	Amperometric acetylcholine biosensor based on graphene-PEDOT:PSS modified electrode. , 2014, , .		0
1237	Suppression of Alzheimer-Associated Inflammation by Microglial Prostaglandin-E <sub>2</sub> EP4 Receptor Signaling. Journal of Neuroscience, 2014, 34, 5882-5894.	1.7	90
1238	P44, the †longevityâ€assurance' isoform of P53, regulates tau phosphorylation and is activated in an ageâ€dependent fashion. Aging Cell, 2014, 13, 449-456.	3.0	41
1239	Association between Cancer and Alzheimer's Disease: Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 42, 565-573.	1.2	57
1240	Stress, race, and APOE: understanding the interplay of risk factors for changes in cognitive functioning. Aging and Mental Health, 2014, 18, 784-791.	1.5	11
1241	Detection of $\hat{Al^2}$ plaques in mouse brain by using a disaggregation-induced fluorescence-enhancing probe. Chemical Communications, 2014, 50, 5741.	2.2	18
1242	Palliative Care as a Primary Therapeutic Approach in Advanced Dementia: A Narrative Review. Clinical Therapeutics, 2014, 36, 1512-1517.	1.1	9
1243	Diagnostic methods and biomarkers for Alzheimer's disease. Toxicology and Environmental Health Sciences, 2014, 6, 133-147.	1.1	12
1244	Saccade deficits in amnestic mild cognitive impairment resemble mild Alzheimer's disease. European Journal of Neuroscience, 2014, 39, 2000-2013.	1.2	64
1245	Patients Surviving Six Months in Hospice Care: Who Are They?. Journal of Palliative Medicine, 2014, 17, 899-905.	0.6	14
1246	Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?. Pediatric Blood and Cancer, 2014, 61, 1739-1742.	0.8	4
1247	Endogenous Sex Hormones and Cognitive Function in Older Adults. Western Journal of Nursing Research, 2014, 36, 388-426.	0.6	45
1248	Lysophosphatidylcholine and Amide as Metabolites for Detecting Alzheimer Disease Using Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry–Based Metabonomics. Journal of Neuropathology and Experimental Neurology, 2014, 73, 954-963.	0.9	76
1249	Pulse Wave Velocity and Cognitive Function in Older Adults. Alzheimer Disease and Associated Disorders, 2014, 28, 44-49.	0.6	58
1250	Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. Journal of Neuropathology and Experimental Neurology, 2014, 73, 244-252.	0.9	65

#	Article	IF	CITATIONS
1251	Functional Decline Predicts Emergency Department Use in Veterans With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 362-371.	0.9	8
1252	Damaging effects of a high-fat diet to the brain and cognition: A review of proposed mechanisms. Nutritional Neuroscience, 2014, 17, 241-251.	1.5	243
1253	Surrogate Decision Making. Medical Decision Making, 2014, 34, 258-269.	1.2	22
1254	An Antidepressant Decreases CSF $\hat{Al^2}$ Production in Healthy Individuals and in Transgenic AD Mice. Science Translational Medicine, 2014, 6, 236re4.	5.8	142
1256	Type Of Attending Physician Influenced Feeding Tube Insertions For Hospitalized Elderly People With Severe Dementia. Health Affairs, 2014, 33, 675-682.	2.5	25
1257	Insulin resistance, neuroinflammation, and Alzheimer's disease. Reviews in the Neurosciences, 2014, 25, 509-25.	1.4	51
1258	Neuropathology staging and treatment strategies of Alzheimer′s disease: An update. International Journal of Nutrition, Pharmacology, Neurological Diseases, 2014, 4, 28.	0.6	2
1259	Comparison Between Clinical Diagnosis and CSF Biomarkers of Alzheimer Disease in Elderly Patients with Late Onset Psychosis: Helsinki Old Age Psychosis StudyÂ(HOPS). American Journal of Geriatric Psychiatry, 2014, 22, 908-916.	0.6	12
1260	Association of dementia with early rehospitalization among Medicare beneficiaries. Archives of Gerontology and Geriatrics, 2014, 59, 162-168.	1.4	64
1261	A novel approach for integrative studies on neurodegenerative diseases in human brains. Journal of Neuroscience Methods, 2014, 226, 171-183.	1.3	17
1262	Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer's Disease. Cell Reports, 2014, 7, 261-268.	2.9	154
1263	Qualification and application of a liquid chromatography–tandem mass spectrometric method for the determination of human Aβ1-40 and Aβ1-42 peptides in transgenic mouse plasma using micro-elution solid phase extraction. Archives of Pharmacal Research, 2014, 37, 636-644.	2.7	4
1264	Investigational drugs in Alzheimer's disease: current progress. Expert Opinion on Investigational Drugs, 2014, 23, 837-846.	1.9	48
1265	Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer's disease. Neuropathology, 2014, 34, 370-377.	0.7	80
1266	A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. Journal of Neuroinflammation, 2014, 11, 30.	3.1	42
1267	Alzheimerâ∈™s Disease and Type 2 Diabetes: Multiple Mechanisms Contribute to Interactions. Current Diabetes Reports, 2014, 14, 476.	1.7	137
1268	1,8-Cineole (Eucalyptol) Mitigates Inflammation in Amyloid Beta Toxicated PC12 Cells: Relevance to Alzheimer's Disease. Neurochemical Research, 2014, 39, 344-352.	1.6	80
1269	Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1248-1257.	1.8	158

#	ARTICLE	IF	CITATIONS
1270	2014 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2014, 10, e47-92.	0.4	750
1271	Mitochondrial DNA sequence associations with dementia and amyloid- $\hat{l}^2$ in elderly African Americans. Neurobiology of Aging, 2014, 35, 442.e1-442.e8.	1.5	27
1272	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. Journal of Alzheimer's Disease, 2014, 42, S177-S187.	1.2	64
1274	Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): A paradigm worth exploring. Biochemical Pharmacology, 2014, 88, 573-583.	2.0	13
1275	The influence of cannabinoids on generic traits of neurodegeneration. British Journal of Pharmacology, 2014, 171, 1347-1360.	2.7	57
1276	Type 2 Diabetes and Cognitive Impairment. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 47-55.	1.2	60
1277	Dementia in the USA: state variation in prevalence. Journal of Public Health, 2014, 37, fdu080.	1.0	35
1278	Intrinsic Brain Activity of Cognitively Normal Older Persons Resembles More That of Patients Both with and at Risk for Alzheimer's Disease Than That of Healthy Younger Persons. Brain Connectivity, 2014, 4, 323-336.	0.8	2
1279	Predictors of Grief in Bereaved Family Caregivers of Person's With Alzheimer's Disease: A Prospective Study. Death Studies, 2014, 38, 395-403.	1.8	44
1280	Monoclonal Antibodies against A $\hat{1}^2$ 42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain. Journal of Biological Chemistry, 2014, 289, 32131-32143.	1.6	103
1281	The Impact of Atrial Fibrillation and Its Treatment on Dementia. Current Cardiology Reports, 2014, 16, 519.	1.3	20
1282	Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10. Molecular Therapy, 2014, 22, 1299-1309.	3.7	179
1283	Targeting the low-hanging fruit of neurodegeneration. Neurology, 2014, 83, 1470-1473.	1.5	19
1284	TFP5, a Peptide Derived from p35, a Cdk5 Neuronal Activator, Rescues Cortical Neurons from Glucose Toxicity. Journal of Alzheimer's Disease, 2014, 39, 899-909.	1.2	35
1285	Diabetes and neurodegeneration in the brain. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 489-511.	1.0	34
1286	Developing neural stem cell-based treatments for neurodegenerative diseases. Stem Cell Research and Therapy, 2014, 5, 72.	2.4	16
1287	Total body 100-mGy X-irradiation does not induce Alzheimer's disease-like pathogenesis or memory impairment in mice. Journal of Radiation Research, 2014, 55, 84-96.	0.8	25
1288	The mitochondrial O-linked N-acetylglucosamine transferase (mOGT) in the diabetic patient could be the initial trigger to develop Alzheimer disease. Experimental Gerontology, 2014, 58, 198-202.	1.2	20

#	Article	IF	CITATIONS
1289	Hyperplasticity in Autism Spectrum Disorder confers protection from Alzheimer's disease. Medical Hypotheses, 2014, 83, 337-342.	0.8	40
1290	Infantile postnatal exposure to lead (Pb) enhances tau expression in the cerebral cortex of aged mice: Relevance to AD. NeuroToxicology, 2014, 44, 114-120.	1.4	65
1291	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. , 2014, , .		20
1292	Ghrelin: A link between ageing, metabolism and neurodegenerative disorders. Neurobiology of Disease, 2014, 72, 72-83.	2.1	65
1293	The Indiana University Cognitive Health Outcomes Investigation of the Comparative Effectiveness of dementia screening (CHOICE) study: study protocol for a randomized controlled trial. Trials, 2014, 15, 209.	0.7	15
1294	Association between Stroke and Alzheimer's Disease: Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 43, 479-489.	1.2	114
1295	Cognitive Impairment in Older Adults and Oral Health Considerations. Dental Clinics of North America, 2014, 58, 815-828.	0.8	41
1296	Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Molecular Brain, 2014, 7, 40.	1.3	107
1298	Feasibility and Efficacy of Intensive Cognitive Training in Early-Stage Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 150-158.	0.9	18
1299	Implications of early treatment among Medicaid patients with Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 214-224.	0.4	39
1300	Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass. Neuroscience Bulletin, 2014, 30, 243-252.	1.5	95
1301	Emergency department visits and hospitalizations by tube-fed nursing home residents with varying degrees of cognitive impairment: a national study. BMC Geriatrics, 2014, 14, 35.	1.1	11
1302	RIG-1 receptor expression in the pathology of Alzheimer's disease. Journal of Neuroinflammation, 2014, 11, 67.	3.1	25
1303	Neural HO-1/sterol interactions in vivo: Implications for Alzheimer's disease. Neuroscience, 2014, 280, 40-49.	1.1	17
1304	A Program to Improve Detection of Undiagnosed Dementia in Primary Care and Its Association with Healthcare Utilization. American Journal of Geriatric Psychiatry, 2014, 22, 1282-1291.	0.6	18
1305	Treatment effects in a transgenic mouse model of Alzheimer's disease: A magnetic resonance spectroscopy study after passive immunization. Neuroscience, 2014, 259, 94-100.	1.1	17
1306	Developing Physician Consensus on the Reporting of Patients with Mild Cognitive Impairment and Mild Dementia to Transportation Authorities in a Region with Mandatory Reporting Legislation. American Journal of Geriatric Psychiatry, 2014, 22, 1530-1543.	0.6	20
1307	Household Members of Persons with <scp>A</scp> lzheimer's Disease: Health Conditions, Healthcare Resource Use, and Healthcare Costs. Journal of the American Geriatrics Society, 2014, 62, 435-441.	1.3	31

#	Article	IF	CITATIONS
1308	Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nature Medicine, 2014, 20, 659-663.	15.2	858
1309	Age-Related Macular Degeneration: Genetics and Biology Coming Together. Annual Review of Genomics and Human Genetics, 2014, 15, 151-171.	2.5	394
1310	A Bayesian network decision model for supporting the diagnosis of dementia, Alzheimer×3s disease and mild cognitive impairment. Computers in Biology and Medicine, 2014, 51, 140-158.	3.9	154
1311	Variants in <i>PPP3R1</i> and <i>MAPT</i> are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. Alzheimer's and Dementia, 2014, 10, 366-371.	0.4	36
1312	Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. Journal of Alzheimer's Disease, 2014, 43, 1059-1072.	1.2	71
1313	Alzheimer's disease: is a vaccine possible?. Brazilian Journal of Medical and Biological Research, 2014, 47, 438-444.	0.7	11
1314	Optical and SPION-Enhanced MR Imaging Shows that trans-Stilbene Inhibitors of NF-κB Concomitantly Lower Alzheimer's Disease Plaque Formation and Microglial Activation in AβPP/PS-1 Transgenic Mouse Brain. Journal of Alzheimer's Disease, 2014, 40, 191-212.	1.2	51
1316	Morphologyâ€based mammalian stem cell tests reveal potential developmental toxicity of donepezil. Molecular Reproduction and Development, 2014, 81, 994-1008.	1.0	24
1317	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. The Cochrane Library, 2014, , CD010079.	1.5	76
1318	Associations between Verbal Learning Slope and Neuroimaging Markers across the Cognitive Aging Spectrum. Journal of the International Neuropsychological Society, 2015, 21, 455-467.	1.2	31
1319	Preventing Cognitive Decline. Hearing Journal, 2015, 68, 22.	0.1	4
1320	A combination of dual-tree discrete wavelet transform and minimum redundancy maximum relevance method for diagnosis of Alzheimer's disease. International Journal of Bioinformatics Research and Applications, $2015,11,433.$	0.1	4
1321	Centella asiatica Attenuates Amyloid- $\hat{l}^2$ -Induced Oxidative Stress and Mitochondrial Dysfunction. Journal of Alzheimer's Disease, 2015, 45, 933-946.	1.2	67
1322	Dysregulation and Diagnostic Potential ofÂmicroRNA in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 1-12.	1.2	33
1323	Proteomic Analysis of Protein Expression Throughout Disease Progression in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 915-926.	1.2	15
1324	Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. Journal of Clinical Investigation, 2015, 125, 350-364.	3.9	117
1326	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 75-80.	1.2	4
1327	Caregiver perceptions regarding the measurement of level and quality of care in Alzheimer's disease. BMC Nursing, 2015, 14, 54.	0.9	12

#	Article	IF	Citations
1328	Familyâ€based genome scan for age at onset of lateâ€onset Alzheimer's disease in whole exome sequencing data. Genes, Brain and Behavior, 2015, 14, 607-617.	1.1	13
1329	Stability of Diagnoses of Cognitive Impairment, Not Dementia in a Veterans Affairs Primary Care Population. Journal of the American Geriatrics Society, 2015, 63, 1105-1111.	1.3	7
1330	Circadian Disruption Reveals a Correlation of an Oxidative GSH/GSSG Redox Shift with Learning and Impaired Memory in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease, 2015, 49, 301-316.	1.2	13
1331	Diagnostic Pathways to Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2015, 29, 330-337.	0.6	13
1333	Visual-spatial perception: a comparison between instruments frequently used in the primary care setting and a computerized cognitive assessment battery. Clinical Interventions in Aging, 2015, 10, 1881.	1.3	1
1334	Inflammatory Cyclooxygenase Activity and PGE <sub>2</sub> Signaling in Models of Alzheimer's Disease. Current Immunology Reviews, 2015, 11, 125-131.	1.2	22
1335	Role of Environmental Contaminants in the Etiology of Alzheimer's Disease: A Review. Current Alzheimer Research, 2015, 12, 116-146.	0.7	217
1336	Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults. Frontiers in Aging Neuroscience, 2015, 7, 219.	1.7	48
1337	High Fat Diet and Inflammation – Modulation of Haptoglobin Level in Rat Brain. Frontiers in Cellular Neuroscience, 2015, 9, 479.	1.8	35
1338	Strategies for Research Recruitment and Retention of Older Adults of Racial and Ethnic Minorities. Journal of Gerontological Nursing, 2015, 41, 14-23.	0.3	50
1339	Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. Neuropsychiatric Disease and Treatment, 2015, 11, 565.	1.0	13
1340	Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatric Disease and Treatment, 2015, 11, 1723.	1.0	133
1341	Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds. BioMed Research International, 2015, 2015, 1-9.	0.9	53
1342	Epitope Fingerprinting for Recognition of the Polyclonal Serum Autoantibodies of Alzheimer's Disease. BioMed Research International, 2015, 2015, 1-8.	0.9	8
1344	A Chronic Grief Intervention for Dementia Family Caregivers in Long-Term Care. Western Journal of Nursing Research, 2015, 37, 6-27.	0.6	39
1345	Geriatrics Models of Care. , 2015, , .		12
1346	A Companion to Biological Anthropology. Anthropological Review, 2015, 78, 107-108.	0.2	5
1347	Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. The Cochrane Library, 2015, , CD010860.	1.5	37

#	Article	IF	CITATIONS
1348	A Survey on Dementia Training Needs Among Staff at Community-Based Outpatient Clinics. Educational Gerontology, 2015, 41, 903-915.	0.7	24
1349	Identifying the components of clinical vignettes describing Alzheimer's disease or other dementias: a scoping review. BMC Medical Informatics and Decision Making, 2015, 15, 54.	1.5	14
1350	Education Research: Changing medical student perceptions of dementia. Neurology, 2015, 85, 739-741.	1.5	24
1351	Translational synthetic biology. Systems and Synthetic Biology, 2015, 9, 191-195.	1.0	3
1352	A path based approach to quantifying the progression of Alzheimer's disease., 2015,,.		0
1353	Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer's Disease: Optimization, Biological Efficacy, and Potential Toxicity. Journal of Pharmaceutical Sciences, 2015, 104, 3544-3556.	1.6	236
1354	Greater cortical thinning in normal older adults predicts later cognitive impairment. Neurobiology of Aging, 2015, 36, 903-908.	1.5	71
1355	Endocannabinoids and Alzheimer's disease. , 2015, , 15-33.		1
1356	Clinical and Neuroimaging Characterization of Chinese Dementia Patients with <b><i>PSEN1</i></b> and <b><i>PSEN2</i></b> Mutations. Dementia and Geriatric Cognitive Disorders, 2015, 39, 32-40.	0.7	29
1357	Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain. European Journal of Health Economics, 2015, 16, 895-905.	1.4	32
1358	Determination of LC50 and sub-chronic neurotoxicity of diesel exhaust nanoparticles. Environmental Toxicology and Pharmacology, 2015, 40, 615-625.	2.0	38
1359	A cautionary note on using secondary phenotypes in neuroimaging genetic studies. NeuroImage, 2015, 121, 136-145.	2.1	7
1360	Inflammation in Alzheimer's Disease and Molecular Genetics: Recent Update. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 333-344.	1.0	67
1361	Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics. Archives of Toxicology, 2015, 89, 1669-1680.	1.9	155
1362	Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides, 2015, 52, 1-18.	0.9	405
1363	Hypothalamicââ,¬â€œPituitaryââ,¬â€œGonadal Axis Involvement in Learning and Memory and Alzheimerââ,¬ Disease: More than ââ,¬Å"Justââ,¬Â•Estrogen. Frontiers in Endocrinology, 2015, 6, 45.	â,¢s 1.5	38
1364	Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1-12.	1.9	9
1365	Experimental Rat Model of Diabetic Nephropathy : Rage Detection and Effect of Spironolactone Monotherapy. The Egyptian Journal of Hospital Medicine, 2015, 58, 120-128.	0.0	O

#	Article	IF	CITATIONS
1366	Clearance systems in the brain—implications for Alzheimer disease. Nature Reviews Neurology, 2015, 11, 457-470.	4.9	1,127
1367	Development of the Cognitive Test for Severe Dementia. Dementia and Geriatric Cognitive Disorders, 2015, 40, 94-106.	0.7	13
1368	Connectivity analysis of normal and mild cognitive impairment patients based on FDG and PiB-PET images. Neuroscience Research, 2015, 98, 50-58.	1.0	19
1369	3d discrete wavelet transform for computer aided diagnosis of <scp>A</scp>  zheimer's disease using t1â€weighted brain <scp>MRI</scp> . International Journal of Imaging Systems and Technology, 2015, 25, 179-190.	2.7	12
1370	Conditions for Exercising Residents' Voting Rights in Long-Term Care Residences: A Prospective Multicenter Study. Journal of Aging and Social Policy, 2015, 27, 47-62.	0.9	4
1371	Roundoc Rx: Mild Cognitive Impairment and Memory Loss. Alternative and Complementary Therapies, 2015, 21, 51-56.	0.1	0
1372	Activity Engagement: Perspectives from Nursing Home Residents with Dementia. Educational Gerontology, 2015, 41, 182-192.	0.7	91
1373	Prevalence of dementia in the oldest old: The Monzino 80â€plus population based study. Alzheimer's and Dementia, 2015, 11, 258.	0.4	56
1374	Brain aerobic glycolysis functions and Alzheimer's disease. Clinical and Translational Imaging, 2015, 3, 27-37.	1.1	71
1375	From cellular senescence to Alzheimer's disease: The role of telomere shortening. Ageing Research Reviews, 2015, 22, 1-8.	5.0	99
1376	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. The Cochrane Library, 2015, , CD010772.	1.5	71
1377	2015 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2015, 11, 332-384.	0.4	1,501
1378	Mild cognitive impairment: a history and the state of current diagnostic criteria. International Psychogeriatrics, 2015, 27, 199-211.	0.6	17
1379	A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. Drugs and Aging, 2015, 32, 453-467.	1.3	115
1380	Infection, systemic inflammation, and Alzheimer's disease. Microbes and Infection, 2015, 17, 549-556.	1.0	81
1381	The promise of stem cells in the therapy of Alzheimer's disease. Translational Neurodegeneration, 2015, 4, 8.	3.6	21
1382	Normative Data for 8 Neuropsychological Tests in Older Blacks and Whites From the Atherosclerosis Risk in Communities (ARIC) Study. Alzheimer Disease and Associated Disorders, 2015, 29, 32-44.	0.6	55
1383	Combination of Pharmacophore Matching, 2D Similarity Search, and ⟨i⟩In Vitro⟨/i⟩ Biological Assays in the Selection of Potential 5â€HT⟨sub⟩6⟨/sub⟩ Antagonists from Large Commercial Repositories. Chemical Biology and Drug Design, 2015, 86, 864-880.	1.5	6

#	Article	IF	CITATIONS
1385	Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's. Biomedicine and Pharmacotherapy, 2015, 71, 146-152.	2.5	33
1386	Dementia and the Home Healthcare Clinician. Home Healthcare Now, 2015, 33, 150-154.	0.1	0
1387	Heparin nanoparticles for $\hat{l}^2$ amyloid binding and mitigation of $\hat{l}^2$ amyloid associated cytotoxicity. Carbohydrate Research, 2015, 405, 110-114.	1.1	15
1388	An Adapted Mindfulness-Based Stress Reduction Program for Elders in a Continuing Care Retirement Community. Journal of Applied Gerontology, 2015, 34, 518-538.	1.0	47
1389	Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease. Trends in Neurosciences, 2015, 38, 621-636.	4.2	134
1390	Synthesis and characterization of water soluble choline labeled cadmium selenide/zinc selenide/zinc sulfide luminescent quantum dots. Inorganic Chemistry Communication, 2015, 60, 87-90.	1.8	1
1391	A Multipronged, Adaptive Approach for theÂRecruitment of Diverse Community-Residing Elders with Memory Impairment: The MIND at Home Experience. American Journal of Geriatric Psychiatry, 2015, 23, 698-708.	0.6	17
1392	Raman spectroscopy for detecting supported planar lipid bilayers composed of ganglioside-GM1/sphingomyelin/cholesterol in the presence of amyloid- $\hat{l}^2$ . Physical Chemistry Chemical Physics, 2015, 17, 22711-22720.	1.3	25
1393	The Vulnerable Patient. Journal of the American College of Cardiology, 2015, 66, 1077-1078.	1.2	5
1394	Associations Between Sleepâ€Disordered Breathing, Nocturnal Hypoxemia, and Subsequent Cognitive Decline in Older Communityâ€Dwelling Men: The Osteoporotic Fractures in Men Sleep Study. Journal of the American Geriatrics Society, 2015, 63, 453-461.	1.3	106
1395	Decision Factors Nurses Use to Assess Pain in Nursing Home Residents With Dementia. Archives of Psychiatric Nursing, 2015, 29, 316-320.	0.7	37
1396	Fuzzy-trace theory and lifespan cognitive development. Developmental Review, 2015, 38, 89-121.	2.6	44
1397	Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker. Translational Psychiatry, 2015, 5, e650-e650.	2.4	32
1398	Alzheimer's disease: rare variants with large effect sizes. Current Opinion in Genetics and Development, 2015, 33, 49-55.	1.5	33
1399	Luteinizing hormone: Evidence for direct action in the CNS. Hormones and Behavior, 2015, 76, 57-62.	1.0	42
1400	The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. Neurobiology of Disease, 2015, 81, 49-65.	2.1	115
1401	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
1402	Effects of selenium on lead-induced alterations in $A\hat{l}^2$ production and Bcl-2 family proteins. Environmental Toxicology and Pharmacology, 2015, 39, 221-228.	2.0	18

#	ARTICLE	IF	CITATIONS
1403	Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 561-578.	0.4	213
1404	Handbook of Clinical Nutrition and Aging. , 2015, , .		15
1405	Lack of orthostatic symptoms in dementia patients with orthostatic hypotension. Clinical Autonomic Research, 2015, 25, 87-94.	1.4	32
1406	Epigenomics of Alzheimer's disease. Translational Research, 2015, 165, 200-220.	2.2	97
1407	Inadequate supply of vitamins and DHA in the elderly: Implications for brain aging and Alzheimer-type dementia. Nutrition, 2015, 31, 261-275.	1.1	96
1408	Neurodegeneration through oxidative stress: Monitoring hydrogen peroxide induced apoptosis in primary cells from the subventricular zone of BALB/c mice using field-effect transistors. Biosensors and Bioelectronics, 2015, 67, 490-496.	5.3	24
1409	Lutein, Brain, and Neurological Functions., 2015,, 41-47.		0
1410	The Role of Cysteine Protease in Alzheimer Disease. Materia Socio-medica, 2016, 28, 235.	0.3	25
1411	Overview of Alzheimer $\hat{a} \in \mathbb{R}^M$ s Disease and Some Therapeutic Approaches Targeting A <i><math>\hat{l}^2</math></i> by Using Several Synthetic and Herbal Compounds. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-22.	1.9	126
1412	Role of ADH1B rs1229984 and ALDH2 rs671 gene polymorphisms in the development of Alzheimer's disease. Genetics and Molecular Research, 2016, 15, .	0.3	27
1413	Comparing Cognitive Profiles of Licensed Drivers with Mild Alzheimer's Disease and Mild Dementia with Lewy Bodies. International Journal of Alzheimer's Disease, 2016, 2016, 1-11.	1.1	5
1414	The association between caregiver well-being and care provided to persons with Alzheimer's disease and related disorders. BMC Research Notes, 2016, 9, 344.	0.6	6
1415	The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. PLoS ONE, 2016, 11, e0167201.	1.1	90
1416	Preparation and evaluation of novel galantamine hydrobromide sustained-release capsule. Bangladesh Journal of Pharmacology, 2016, 11, S82-S91.	0.1	3
1417	Benefits of Deep Transcranial Magnetic Stimulation in Alzheimer Disease. Journal of ECT, 2016, 32, 127-133.	0.3	15
1418	Peripheral Inflammation and Alzheimer's Disease: Periodontal Disease. , 2016, , 93-106.		0
1419	Permeability of blood–brain barrier in macaque model of 1â€methylâ€4â€phenylâ€1,2,3,6â€ŧetrahydropyridineâ€induced Parkinson disease. Synapse, 2016, 70, 231-239.	0.6	11
1420	Predicting the role of assistive technologies in the lives of people with dementia using objective care recipient factors. BMC Geriatrics, 2016, 16, 143.	1.1	21

#	Article	IF	CITATIONS
1421	The Global Demography of Aging. Handbook of the Economics of Population Aging, 2016, 1, 3-56.	0.5	84
1422	Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Molecular Neurodegeneration, 2016, 11, 50.	4.4	82
1423	Direct Electrical Stimulation of the Human Entorhinal Region and Hippocampus Impairs Memory. Neuron, 2016, 92, 983-990.	3.8	181
1424	Fidelity to a behavioral intervention to improve goals of care decisions for nursing home residents with advanced dementia. Clinical Trials, 2016, 13, 599-604.	0.7	27
1425	$\hat{A^2}PP/PS1$ Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging. Journal of Alzheimer's Disease, 2016, 54, 645-656.	1.2	40
1426	Privacy challenges in Ambient Intelligence systems. Journal of Ambient Intelligence and Smart Environments, 2016, 8, 619-644.	0.8	13
1427	Predictors of perceived benefits and drawbacks of using paid service among daughter and daughter-in-law caregivers of people with dementia. Journal of Women and Aging, 2016, 28, 161-169.	0.5	2
1428	Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE <sub>2</sub> Signaling in Alzheimer's Disease. ACS Chemical Neuroscience, 2016, 7, 454-463.	1.7	45
1429	Regional brain stiffness changes across the Alzheimer's disease spectrum. Neurolmage: Clinical, 2016, 10, 283-290.	1.4	152
1431	Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. Brain, 2016, 139, 2063-2081.	3.7	86
1434	2016 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2016, 12, 459-509.	0.4	2,219
1435	Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease. Experimental Biology and Medicine, 2016, 241, 1351-1363.	1.1	64
1436	Differences between the behavioral and psychological symptoms of Alzheimer's disease and Parkinson's disease. Journal of the Neurological Sciences, 2016, 369, 278-282.	0.3	13
1437	Morphometricity as a measure of the neuroanatomical signature of a trait. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5749-56.	3.3	53
1438	Chemotherapy for Cancer and the Aging Brain: Blessing or Burden?. Archives of Physical Medicine and Rehabilitation, 2016, 97, e135.	0.5	0
1439	Financial exploitation, financial capacity, and Alzheimer's disease American Psychologist, 2016, 71, 312-320.	3.8	45
1440	Gain of BDNF Function in Engrafted Neural Stem Cells Promotes the Therapeutic Potential for Alzheimer's Disease. Scientific Reports, 2016, 6, 27358.	1.6	65
1441	The Vanderbilt Memory & Design and Baseline Cohort Overview. Journal of Alzheimer's Disease, 2016, 52, 539-559.	1.2	44

#	Article	IF	Citations
1442	Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2016, 59, 5823-5846.	2.9	89
1443	The Lichtenberg Financial Decision Screening Scale (LFDSS): A new tool for assessing financial decision making and preventing financial exploitation. Journal of Elder Abuse and Neglect, 2016, 28, 134-151.	0.5	34
1444	HDL-cholesterol and apolipoproteins in relation to dementia. Current Opinion in Lipidology, 2016, 27, 76-87.	1.2	35
1445	Obesity and sex interact in the regulation of Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2016, 67, 102-118.	2.9	65
1446	Cognitive-enhancing activities of the polyprenol preparation Ropren® in gonadectomized β-amyloid (25–35) rat model of Alzheimer's disease. Physiology and Behavior, 2016, 157, 55-62.	1.0	21
1447	Car drivers with dementia: Different complications due to different etiologies?. Traffic Injury Prevention, 2016, 17, 9-23.	0.6	23
1448	$\hat{a}$ ∈ I wish they would remember that I forget: $\hat{a}$ ∈ The effects of memory loss on the lives of individuals with mild-to-moderate dementia. Dementia, 2016, 15, 1053-1067.	1.0	9
1449	Meta-analysis of the Association between Alzheimer Disease and Variants in GAB2, PICALM, and SORL1. Molecular Neurobiology, 2016, 53, 6501-6510.	1.9	35
1450	Molecular Pathways in Alzheimer's Disease and Cognitive Function. , 2016, , 135-167.		1
1451	Deficit of RACK1 contributes to the spatial memory impairment via upregulating BECLIN1 to induce autophagy. Life Sciences, 2016, 151, 115-121.	2.0	26
1452	Nanoparticle transport across the blood brain barrier. Tissue Barriers, 2016, 4, e1153568.	1.6	121
1453	Diabetes and Alzheimer's disease crosstalk. Neuroscience and Biobehavioral Reviews, 2016, 64, 272-287.	2.9	161
1454	Difference in white matter microstructure in differential diagnosis of normal pressure hydrocephalus and Alzheimer's disease. Clinical Neurology and Neurosurgery, 2016, 140, 52-59.	0.6	16
1455	Development of the Knowledge of Dementia Competencies Self-Assessment Tool. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 18-26.	0.9	2
1456	The effects of normal aging on amyloidâ€Î² deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B. Alzheimer's and Dementia, 2016, 12, 380-390.	0.4	65
1457	Transcriptional signatures of brain aging and Alzheimer's disease: What are our rodent models telling us?. Behavioural Brain Research, 2017, 322, 311-328.	1.2	79
1458	Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models. Brain, Behavior, and Immunity, 2017, 61, 1-11.	2.0	266
1459	Case–control association mapping by proxy using family history of disease. Nature Genetics, 2017, 49, 325-331.	9.4	192

#	Article	IF	CITATIONS
1460	Geriatric Care Issues. Primary Care - Clinics in Office Practice, 2017, 44, e15-e36.	0.7	7
1461	MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. Journal of Alzheimer's Disease, 2017, 57, 483-491.	1.2	126
1462	Financial Capacity and Financial Exploitation of Older Adults: Research Findings, Policy Recommendations and Clinical Implications. Clinical Gerontologist, 2017, 40, 3-13.	1.2	45
1463	Sleep EEG Detects Epileptiform Activity in Alzheimer's Disease with High Sensitivity. Journal of Alzheimer's Disease, 2017, 56, 1175-1183.	1.2	50
1464	Assessment of brain core temperature using MR DWI-thermometry in Alzheimer disease patients compared to healthy subjects. Japanese Journal of Radiology, 2017, 35, 168-171.	1.0	11
1465	Molecular mechanisms of brain-derived neurotrophic factor in neuro-protection: Recent developments. Brain Research, 2017, 1665, 1-21.	1.1	93
1466	Pharmaceutical Use and Spending Trend in Medicare Beneficiaries With Dementia, From 2006 to 2012. Gerontology and Geriatric Medicine, 2017, 3, 233372141770494.	0.8	4
1467	Assessment of cerebral microbleeds by susceptibility-weighted imaging in Alzheimer's disease patients: A neuroimaging biomarker of the disease. Neuroradiology Journal, 2017, 30, 330-335.	0.6	21
1468	The Numbers Count. Thought, 2017, 6, 129-134.	0.3	2
1470	Impact of the <scp>REACH II</scp> and <scp>REACH VA</scp> Dementia Caregiver Interventions on Healthcare Costs. Journal of the American Geriatrics Society, 2017, 65, 931-936.	1.3	31
1471	Immunological memory to hyperphosphorylated tau in asymptomatic individuals. Acta Neuropathologica, 2017, 133, 767-783.	3.9	43
1472	Development of a decision-making tool for reporting drivers with mild dementia and mild cognitive impairment to transportation administrators. International Psychogeriatrics, 2017, 29, 1551-1563.	0.6	13
1473	2017 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2017, 13, 325-373.	0.4	969
1474	Alzheimer's disease: The next frontierâ€"Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.4	88
1475	Centella asiatica attenuates $\hat{A^2}$ -induced neurodegenerative spine loss and dendritic simplification. Neuroscience Letters, 2017, 646, 24-29.	1.0	34
1476	Goals of Care or Goals of Trust? How Family Members Perceive Goals for Dying Nursing Home Residents. Journal of Palliative Medicine, 2017, 20, 360-365.	0.6	31
1477	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 153-174.	1.1	607
1478	Genomic variants, genes, and pathways of Alzheimer's disease: An overview. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 5-26.	1.1	147

#	Article	IF	CITATIONS
1479	The roles of class I histone deacetylases (HDACs) in memory, learning, and executive cognitive functions: A review. Neuroscience and Biobehavioral Reviews, 2017, 83, 63-71.	2.9	27
1480	Neuroinflammation in Alzheimer's Disease. Advances in Protein Chemistry and Structural Biology, 2017, 108, 33-57.	1.0	129
1481	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. Annals of Neurology, 2017, 82, 503-513.	2.8	133
1482	Family-based association analysis of NAV2 gene with the risk and age at onset of Alzheimer's disease. Journal of Neuroimmunology, 2017, 310, 60-65.	1.1	11
1483	PC-FACS. Journal of Pain and Symptom Management, 2017, 53, 971-977.	0.6	0
1484	Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 7146-7165.	2.9	18
1485	Cellulose Orodispersible Films of Donepezil: Film Characterization and Drug Release. Pharmaceutical Chemistry Journal, 2017, 51, 707-715.	0.3	6
1486	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Medical Genomics, 2017, 10, 29.	0.7	28
1487	Genetic variants associated with risk of Alzheimer's disease contribute to cognitive change in midlife: The Atherosclerosis Risk in Communities Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 269-282.	1.1	19
1488	Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women. Reproductive Sciences, 2017, 24, 355-368.	1.1	25
1489	Speech rhythm alterations in Spanish-speaking individuals with Alzheimer's disease. Aging, Neuropsychology, and Cognition, 2017, 24, 418-434.	0.7	23
1490	Effect of the Goals of Care Intervention for Advanced Dementia. JAMA Internal Medicine, 2017, 177, 24.	2.6	205
1491	Progression from normal cognition to mild cognitive impairment in a diverse clinicâ€based and communityâ€based elderly cohort. Alzheimer's and Dementia, 2017, 13, 399-405.	0.4	67
1492	Inflammation and Microbiota and Gut Reconditioning. , 2017, , 1609-1660.		1
1493	The Endocannabinoid System and Human Brain Functions. , 2017, , 115-186.		3
1494	Neuropathology of dementia., 2016,, 94-122.		5
1495	Contribution of Nucleic Acids in the Pathogenesis of Alzheimer's Disease. , 2017, , 129-162.		0
1496	Is it Alzheimer's Disease?. , 2017, , 2-24.		O

#	ARTICLE	IF	CITATIONS
1497	Neuroprotective Actions of Dietary Choline. Nutrients, 2017, 9, 815.	1.7	154
1498	Epigenomics of Alzheimer's Disease. , 2017, , 227-278.		2
1499	Targeting Transition Metals forÂNeuroprotection inÂAlzheimer's Disease. , 2017, , 193-215.		2
1500	Markers of Alzheimer's Disease in Primary Visual Cortex in Normal Aging in Mice. BioMed Research International, 2017, 2017, 1-10.	0.9	7
1501	Epileptic Seizures Prediction Using Machine Learning Methods. Computational and Mathematical Methods in Medicine, 2017, 2017, 1-10.	0.7	130
1502	Neural Regeneration as a Disease-Modifying Therapeutic Strategy for Alzheimer's Disease. , 2017, , 3-29.		0
1503	Role of BACE1 in Alzheimer's synaptic function. Translational Neurodegeneration, 2017, 6, 23.	3.6	80
1504	Evaluation of Different Factors Leading to the Genesis of Alzheimer's Disease: Research Proposal on Dementia. Epidemiology (Sunnyvale, Calif ), 2017, 07, .	0.3	0
1505	Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan. Current Neuropharmacology, 2017, 15, 459-470.	1.4	88
1506	The growing challenge of dementia and its impact on patients, their caregivers, and providers. Annals of Palliative Medicine, 2017, 6, 299-301.	0.5	0
1507	Validation of the Delayed Matching-to-Sample Task 48 (DMS48) in Elderly Chinese. Journal of Alzheimer's Disease, 2018, 61, 1611-1618.	1.2	2
1508	Myxobacterial natural products: An under-valued source of products for drug discovery for neurological disorders. NeuroToxicology, 2018, 66, 195-203.	1.4	24
1509	Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function. Journal of Alzheimer's Disease, 2018, 63, 655-664.	1.2	11
1510	Prevalence of preclinical Alzheimer disease. Neurology, 2018, 90, e1682-e1691.	1.5	82
1511	A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults. Journal of Nutrition, Health and Aging, 2018, 22, 837-846.	1.5	16
1512	Effect of human serum on the electrical detection of amyloid- $\hat{l}^2$ fibrils in biological environments using azo-dye immobilized field effect transistor (FET) biosensor. Sensing and Bio-Sensing Research, 2018, 17, 25-29.	2.2	16
1513	Advance Care Planning in Community-Dwelling Patients With Dementia. Journal of Pain and Symptom Management, 2018, 55, 1105-1112.	0.6	35
1514	Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer's Disease Affected Brain. ACS Chemical Neuroscience, 2018, 9, 1503-1514.	1.7	11

#	Article	IF	CITATIONS
1515	Neurologic Disorders and Maxillofacial Surgery. , 2018, , 243-262.		1
1516	2018 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2018, 14, 367-429.	0.4	1,522
1517	Clinical genetic strategies for early onset neurodegenerative diseases. Molecular and Cellular Toxicology, 2018, 14, 123-142.	0.8	20
1518	Pilot test of a six-week group delivery caregiver training program to reduce sleep disturbances among older adults with dementia (Innovative practice). Dementia, 2018, 17, 234-243.	1.0	14
1519	The Role of Education in the Relationship Between Age of Migration to the United States and Risk of Cognitive Impairment Among Older Mexican Americans. Research on Aging, 2018, 40, 411-431.	0.9	24
1520	A retrospective analysis of care in patients with dementia hospitalized at a tertiary medical center. Aging and Mental Health, 2018, 22, 773-777.	1.5	2
1521	Dementia as a predictor of mortality in adult trauma patients. American Journal of Surgery, 2018, 215, 48-52.	0.9	7
1522	Insulin resistance and cognitive test performance in elderly adults: National health and nutrition examination survey (NHANES). Journal of the Neurological Sciences, 2018, 388, 97-102.	0.3	12
1523	Statin use and risk of Alzheimer disease. Neurology, 2018, 90, 103-104.	1.5	4
1524	Qualitative analysis of the capacity to consent to treatment in patients with a chronic neurodegenerative disease: Alzheimer's disease / Analisi qualitativa sulla capacità a prestare consenso al trattamento in pazienti con malattie cronico degenerative neuropsicoorganiche: Demenza di Alzheimer, International Iournal of Social Psychiatry, 2018, 64, 26-36.	1.6	6
1525	The Role of Mental Health Disease in Potentially Preventable Hospitalizations. Medical Care, 2018, 56, 31-38.	1.1	8
1526	Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimer's and Dementia, 2018, 14, 121-129.	0.4	309
1527	Intermittent hypoxia training: Powerful, non-invasive cerebroprotection against ethanol withdrawal excitotoxicity. Respiratory Physiology and Neurobiology, 2018, 256, 67-78.	0.7	13
1528	Depressive symptoms and cognitive functioning among older adults with cancer. Aging and Mental Health, 2018, 22, 1465-1470.	1.5	13
1529	Periodontal disease exacerbates Alzheimer's disease. Journal of Japanese Society of Periodontology, 2018, 60, 147-152.	0.1	0
1530	Association between Alzheimer's Disease and Cancer Risk in South Korea: an 11-year Nationwide Population-Based Study. Dementia and Neurocognitive Disorders, 2018, 17, 137.	0.4	22
1531	Alterations of Graphic Properties and Related Cognitive Functioning Changes in Mild Alzheimer's Disease Revealed by Individual Morphological Brain Network. Frontiers in Neuroscience, 2018, 12, 927.	1.4	13
1532	Neuroprotective Potentials of Ayurvedic Rasayana Desmodium triquetrum on Brain Aging and Chemically Induced Amnesia in Animal Models Relevant to Dementia. Journal of Traditional Medicine & Clinical Naturopathy, 2018, 07, .	0.1	1

#	Article	IF	CITATIONS
1533	InÂVivo Systems: Animal Models of Neurodegeneration. , 2018, , 424-441.		0
1534	Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNFα, RANTES and IP-10. Scientific Reports, 2018, 8, 16423.	1.6	17
1535	Impact of MRI Protocols on Alzheimer's Disease Detection. , 2018, , .		0
1537	Effect of long-term lifestyle intervention on mild cognitive impairment in hypertensive occupational population in China. Medicine (United States), 2018, 97, e11975.	0.4	11
1538	An Initial Study of Alexithymia and Its Relationship With Cognitive Abilities Among Mild Cognitive Impairment, Mild Alzheimer's Disease, and Healthy Volunteers. Journal of Nervous and Mental Disease, 2018, 206, 628-636.	0.5	13
1539	Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism. BioMed Research International, 2018, 2018, 1-8.	0.9	78
1540	Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI. Frontiers in Aging Neuroscience, 2018, 10, 292.	1.7	14
1541	Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline. Frontiers in Neurology, 2018, 9, 910.	1.1	46
1542	Dehydroepiandrosterone (DHEA) and DHEA Sulfate: Roles in Brain Function and Disease., 0,,.		2
1543	Particular CSF sphingolipid patterns identify iNPH and AD patients. Scientific Reports, 2018, 8, 13639.	1.6	24
1544	The Relationship between Obstructive Sleep Apnea and Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, S255-S270.	1.2	128
1545	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimer's Disease: The TEAM-AD VA Cooperative Study. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 177-185.	1.2	39
1546	Effect of Qingxin Kaiqiao Fang on Hippocampus mRNA Expression of the Inflammation-Related Genes IL-1 <i>β√ i&gt;, GFAP, and A⟨i⟩ ²⟨ i&gt;in an Alzheimer's Disease Rat Model. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-7.</i>	0.5	8
1547	Evolution of Social Identity Terms in Lay and Academic Sources: Implications for Research and Public Policy. Analyses of Social Issues and Public Policy, 2018, 18, 323-352.	1.0	O
1548	The Self-Care Needs and Behaviors of Dementia Informal Caregivers: A Systematic Review. Gerontologist, The, 2019, 59, e565-e583.	2.3	38
1549	Classification and Molecular Aspects of Neurotraumatic Diseases. , 2018, , 1-40.		1
1550	Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline. JAMA Neurology, 2018, 75, 1198.	4.5	136
1551	Biomarker for Alzheimer's Disease. , 2018, , 333-349.		1

#	Article	IF	CITATIONS
1552	Cognitive Impairment and Glycemic Control in Elderly Patients Under Health-Care Case Management. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 265-270.	1.2	6
1553	Relation between alcohol consumption in midlife and dementia in late life. BMJ: British Medical Journal, 2018, 362, k3164.	2.4	4
1554	Highâ€fat diet protects the blood–brain barrier in an Alzheimer's disease mouse model. Aging Cell, 2018, 17, e12818.	3.0	37
1555	Chemical Characterization, Analgesic, Antioxidant, and Anticholinesterase Potentials of Essential Oils From Isodon rugosus Wall. ex. Benth. Frontiers in Pharmacology, 2018, 9, 623.	1.6	50
1556	Modulation of the ATP-Binding Cassette B1 Transporter by Neuro-Inflammatory Cytokines: Role in the Pathogenesis of Alzheimer's Disease. Frontiers in Pharmacology, 2018, 9, 658.	1.6	16
1557	Detecting spatiotemporal clusters of dementia mortality in the United States, 2000–2010. Spatial and Spatio-temporal Epidemiology, 2018, 27, 11-20.	0.9	16
1558	Integration of Nanobots Into Neural Circuits As a Future Therapy for Treating Neurodegenerative Disorders. Frontiers in Neuroscience, 2018, 12, 153.	1.4	8
1559	Age-Related Changes in the Behavior of Apolipoprotein E Knockout Mice. Behavioral Sciences (Basel,) Tj ETQq1 1	0.784314	4 rgBT /Overl
1560	Differences in road-crossing decisions between healthy older adults and patients with Alzheimer's disease. Journal of Safety Research, 2018, 66, 81-88.	1.7	6
1561	The Cognitive Cytokine Effect of Nonsteroidal Antiinflammatory Drugs in the Treatment of Elderly Patients with Osteoarthritis. Advances in Gerontology, 2018, 8, 26-32.	0.1	2
1562	The Prevalence of Mild Cognitive Impairment in China: A Systematic Review., 2018, 9, 706.		124
1563	Validity and reliability of the Persian version of general practitioner assessment of cognition (P-GPCOG). Aging and Mental Health, 2019, 23, 961-965.	1.5	6
1564	An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer's Disease. Neurochemical Research, 2019, 44, 12-21.	1.6	4
1565	Introduction to Neurogenetics. American Journal of Medicine, 2019, 132, 142-152.	0.6	7
1566	Medial temporal lobe atrophy is independently associated with behavioural and psychological symptoms in Alzheimer's disease. Psychogeriatrics, 2019, 19, 46-54.	0.6	16
1567	Cerebrospinal Fluid (CSF) Proteomics. Methods in Molecular Biology, 2019, , .	0.4	0
1568	A cognitive stress test for prodromal Alzheimer's disease: Multiethnic generalizability. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 550-559.	1.2	16
1569	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182

#	Article	IF	CITATIONS
1570	Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer's disease. Pharmacological Research, 2019, 147, 104342.	3.1	21
1571	Normal-pressure hydrocephalus: A critical review. Dementia E Neuropsychologia, 2019, 13, 133-143.	0.3	64
1572	Population projections for U.S. counties by age, sex, and race controlled to shared socioeconomic pathway. Scientific Data, 2019, 6, 190005.	2.4	62
1573	Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present). Current Medicinal Chemistry, 2019, 26, 5684-5710.	1.2	31
1574	A Cross-Sectional Study of Blood Ethylmercury Levels and Cognitive Decline Among Older Adults and the Elderly in the United States. Journal of Alzheimer's Disease, 2019, 72, 901-910.	1.2	5
1575	Proteomic Identification of Pathways Responsible for the Estradiol Therapeutic Window in AD Animal Models. Frontiers in Cellular Neuroscience, 2019, 13, 437.	1.8	4
1576	Dementia in China (2015–2050) estimated using the 1% population sampling survey in 2015. Geriatrics and Gerontology International, 2019, 19, 1096-1100.	0.7	30
1577	Characterization of Alzheimer's Disease Micro-RNA Profile in Exosome-Enriched CSF Samples. Methods in Molecular Biology, 2019, 2044, 343-352.	0.4	3
1578	The effects of soy on scopolamine-induced spatial learning and memory impairments are comparable to the effects of estradiol. Hormone Molecular Biology and Clinical Investigation, 2019, 39, .	0.3	5
1579	CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain, 2019, 142, 3243-3264.	3.7	156
1580	In Vitro and in Silico Human Monoamine Oxidase Inhibitory Potential of Anthraquinones, Naphthopyrones, and Naphthalenic Lactones from <i>Cassia obtusifolia</i> Linn Seeds. ACS Omega, 2019, 4, 16139-16152.	1.6	22
1581	Ellagic acid a multi-target bioactive compound for drug discovery in CNS? A narrative review. European Journal of Medicinal Chemistry, 2019, 183, 111724.	2.6	62
1582	Differences in service utilization at an urban tribal health organization before and after Alzheimer's disease or related dementia diagnosis: A cohort study. Alzheimer's and Dementia, 2019, 15, 1412-1419.	0.4	10
1583	Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer's disease. Central Nervous System Agents in Medicinal Chemistry, 2019, 19, 154-170.	0.5	48
1584	Geriatric Care Issues. Physician Assistant Clinics, 2019, 4, 217-238.	0.1	0
1587	Polysorbate 80 Coated Gold Nanoparticle as a Drug Carrier for Brain Targeting in Zebrafish Model. Journal of Cluster Science, 2019, 30, 897-906.	1.7	12
1588	Non-conventional compounds with potential therapeutic effects against Alzheimer's disease. Expert Review of Neurotherapeutics, 2019, 19, 375-395.	1.4	12
1589	2019 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2019, 15, 321-387.	0.4	1,633

#	Article	IF	Citations
1590	Rethinking Cognitive Impairment in the Management of Older Patients With Cardiovascular Disease. Journal of the American Heart Association, 2019, 8, e011968.	1.6	8
1591	Icariin and Its Metabolites as Potential Protective Phytochemicals Against Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 271.	1.6	66
1592	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10.	4.4	61
1593	Antibody-based therapeutics. Drug Metabolism and Pharmacokinetics, 2019, 34, 1-2.	1.1	1
1594	Quality of Life with Lateâ€Stage Dementia: Exploring Opportunities to Intervene. Journal of the American Geriatrics Society, 2019, 67, 1189-1196.	1.3	10
1595	The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population. Journal of Alzheimer's Disease, 2019, 67, 1181-1186.	1.2	11
1596	Challenges Faced by Older Adults With Cognitive Impairment and Their Caregivers in a Care Home. International Journal of Social Work, 2019, 6, 33.	0.4	0
1597	Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review. Current Psychiatry Research and Reviews, 2019, 15, 132-142.	0.1	1
1598	Effects of Alzheimer's Disease on Reach-to-Pinch Performance with Multimodal Sensory Feedbacks., 2019,,.		0
1599	Dementia assessment and diagnostic practices of healthcare workers in rural southwestern Uganda: a cross-sectional qualitative study. BMC Health Services Research, 2019, 19, 1005.	0.9	17
1600	Comparative Analysis of Various Technologies used for the People Enduring through Alzheimer's Disease: A Survey. , 2019, , .		2
1601	Diagnosis and Treatment of Alzheimer's Disease in Elderly and Senile Age. Advances in Gerontology, 2019, 9, 439-446.	0.1	0
1602	Geriatric models of care for neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 57-72.	1.0	1
1603	Application of Biomedical Engineering in Neuroscience. , 2019, , .		1
1604	Methionine sulfoxide reductase (Msr) dysfunction in human brain disease. Free Radical Research, 2019, 53, 1144-1154.	1.5	17
1605	Accessible Interface for Context Awareness in Mobile Devices for Users With Memory Impairment. International Journal of Biomedical and Clinical Engineering, 2019, 8, 1-30.	0.2	1
1606	The Immune System Drives Synapse Loss During Lipopolysaccharide-Induced Learning and Memory Impairment in Mice. Frontiers in Aging Neuroscience, 2019, 11, 279.	1.7	35
1607	Future Therapeutic Perspectives into the Alzheimer's Disease Targeting the Oxidative Stress Hypothesis. Molecules, 2019, 24, 4410.	1.7	67

#	ARTICLE	IF	CITATIONS
1608	Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases. Processes, 2019, 7, 940.	1.3	7
1609	The Biology of mRNA: Structure and Function. Advances in Experimental Medicine and Biology, 2019, , .	0.8	3
1610	A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of Aβ1–42, α-synuclein, and amylin amyloid fibrils as well as amyloid-containing Staphylococcus aureus biofilms. Analytical and Bioanalytical Chemistry, 2019, 411, 251-265.	1.9	2
1611	Relational autonomy in action: Rethinking dementia and sexuality in care facilities. Nursing Ethics, 2019, 26, 1654-1664.	1.8	11
1612	Alkaloids as Potential Multi-Target Drugs to Treat Alzheimer's Disease. Studies in Natural Products Chemistry, 2019, , 301-334.	0.8	18
1613	Sex Differences in Alzheimer's Disease: Where Do We Stand?. Journal of Alzheimer's Disease, 2019, 67, 35-60.	1.2	30
1614	Synthesis, crystal structure, DFT calculations and molecular docking of l-pyroglutamic acid. Journal of Molecular Structure, 2019, 1178, 436-449.	1.8	31
1615	The fear of Alzheimer's disease: mediating effects of anxiety on subjective memory complaints. Aging and Mental Health, 2020, 24, 308-314.	1.5	19
1616	Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration. Cellular and Molecular Neurobiology, 2020, 40, 313-345.	1.7	11
1617	Connected Health in Smart Cities. , 2020, , .		5
1618	Clinical factors associated with activities of daily living and their decline in patients with severe dementia. Psychogeriatrics, 2020, 20, 327-336.	0.6	5
1619	The flash visual evoked potential-P2 and the detection of amnestic mild cognitive impairment: A review of empirical literature. International Journal of Psychophysiology, 2020, 155, 162-167.	0.5	9
1620	Inpatient diagnoses of idiopathic normal pressure hydrocephalus in the United States: Demographic and socioeconomic disparities. Journal of the Neurological Sciences, 2020, 418, 117152.	0.3	3
1621	Epigenetics and Lead Neurotoxicity. , 2020, , .		1
1622	Racial and ethnic patterns and differences in health care expenditures among Medicare beneficiaries with and without cognitive deficits or Alzheimer's disease and related dementias. BMC Geriatrics, 2020, 20, 482.	1.1	9
1623	Defining and predicting transdiagnostic categories of neurodegenerative disease. Nature Biomedical Engineering, 2020, 4, 787-800.	11.6	22
1624	Effects of rosmarinic acid on nervous system disorders: an updated review. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1779-1795.	1.4	53
1625	Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 877-883.	1.2	3

#	Article	IF	CITATIONS
1626	New naphthalene derivative for cost-effective AChE inhibitors for Alzheimer's treatment: In silico identification, in vitro and in vivo validation. Computational Biology and Chemistry, 2020, 89, 107378.	1.1	20
1627	Health Care Costs of Alzheimer's and Related Dementias Within a Medicare Managed Care Provider. Medical Care, 2020, 58, 833-841.	1.1	4
1628	Effect of escitalopram on $\hat{Al^2}$ levels and plaque load in an Alzheimer mouse model. Neurology, 2020, 95, e2666-e2674.	1.5	35
1629	Sex differences in risk of Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12084.	1.2	12
1630	Impact of dementia on informal care: a systematic review of family caregivers' perceptions. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002242.	0.8	91
1631	Implications of Medicare Advantage for Patients With Alzheimer Disease and Related Dementias. JAMA Network Open, 2020, 3, e201853.	2.8	2
1632	Green Tea Seed Isolated Theasaponin E1 Ameliorates AD Promoting Neurotoxic Pathogenesis by Attenuating $\hat{Al^2}$ Peptide Levels in SweAPP N2a Cells. Molecules, 2020, 25, 2334.	1.7	11
1633	Pharmacological exploration of traditional plants for the treatment of neurodegenerative disorders. Phytotherapy Research, 2020, 34, 3089-3112.	2.8	25
1634	What Can We Learn From the Past About the Future of Gerontology: Using Natural Language Processing to Examine the Field of Gerontology. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1828-1837.	2.4	6
1635	Low vision and the risk of dementia: a nationwide population-based cohort study. Scientific Reports, 2020, 10, 9109.	1.6	32
1636	Peripheral Circulating Exosomal miRNAs Potentially Contribute to the Regulation of Molecular Signaling Networks in Aging. International Journal of Molecular Sciences, 2020, 21, 1908.	1.8	15
1637	2020 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2020, 16, 391-460.	0.4	1,802
1638	The prevalence of Alzheimer's disease in the Chinese Han population: a meta-analysis. Neurological Research, 2020, 42, 291-298.	0.6	13
1639	The Development and Psychometric Validation of a Comprehensive Measure Assessing Fear of Incompetence among Adults Who Have a Family Member with Dementia. International Journal of Alzheimer's Disease, 2020, 2020, 1-15.	1.1	0
1640	Good Cop, Bad Cop: Defining the Roles of î"40p53 in Cancer and Aging. Cancers, 2020, 12, 1659.	1.7	22
1641	Are Advances in Survival Among the Oldest Old Seen Across the Spectrum of Health and Functioning?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 2354-2360.	1.7	4
1642	Health Care Utilization, Care Satisfaction, and Health Status for Medicare Advantage and Traditional Medicare Beneficiaries With and Without Alzheimer Disease and Related Dementias. JAMA Network Open, 2020, 3, e201809.	2.8	42
1643	EEG multifractal analysis correlates with cognitive testing scores and clinical staging in mild cognitive impairment. Journal of Clinical Neuroscience, 2020, 76, 195-200.	0.8	24

#	Article	IF	CITATIONS
1644	In vitro neuroprotective effects of farnesene sesquiterpene on alzheimer's disease model of differentiated neuroblastoma cell line. International Journal of Neuroscience, 2021, 131, 745-754.	0.8	23
1645	The role of magnetic fields in neurodegenerative diseases. International Journal of Biometeorology, 2021, 65, 107-117.	1.3	20
1646	Knockdown of astrocytic TREM2 in the hippocampus relieves cognitive decline in elderly male mice. Behavioural Brain Research, 2021, 397, 112939.	1.2	3
1647	Impact of the Physician Orders for Life-Sustaining Treatment (POLST) Program Maturity Status on the Nursing Home Resident's Place of Death. American Journal of Hospice and Palliative Medicine, 2021, 38, 812-822.	0.8	3
1648	Musical instrument training program improves verbal memory and neural efficiency in novice older adults. Human Brain Mapping, 2021, 42, 1359-1375.	1.9	21
1649	Severity Distribution of Alzheimer's Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. Journal of Alzheimer's Disease, 2021, 79, 807-817.	1.2	18
1650	Hydrogen sulfide and mesenchymal stem cellsâ€extracted microvesicles attenuate LPSâ€induced Alzheimer's disease. Journal of Cellular Physiology, 2021, 236, 5994-6010.	2.0	22
1651	Recommended resources on the neuroscience of aging. , 2021, , 567-574.		0
1652	Bacopa monnieri (Brahmi)., 2021,, 243-256.		2
1653	Effects of traditional Chinese exercise on patients with cognitive impairment: A systematic review and Bayesian network metaâ€analysis. Nursing Open, 2021, 8, 2208-2220.	1.1	14
1654	Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. International Journal of Molecular Sciences, 2021, 22, 2805.	1.8	8
1655	Sex Differences in Cardiovascular Disease and Cognitive Dysfunction in Rural West Elderly Texans. Journal of Alzheimer's Disease Reports, 2021, 5, 213-226.	1.2	2
1656	Geriatric Care Managers., 2021,, 180-184.		0
1657	Interplay Between Microglia and Alzheimer's Diseaseâ€"Focus on the Most Relevant Risks: APOE Genotype, Sex and Age. Frontiers in Aging Neuroscience, 2021, 13, 631827.	1.7	23
1658	DFT Calculations and Molecular Docking Studies on a Chromene Derivative. Journal of Chemistry, 2021, 2021, 1-17.	0.9	13
1659	Intergenerational Montessori Program for Adults With Memory Concerns. American Journal of Speech-Language Pathology, 2021, 30, 1090-1099.	0.9	1
1660	Understanding the Representation and Representativeness of Age in Al Data Sets., 2021,,.		10
1661	"2-step MCI-AD― a simple scoring system to predict rapid conversion from mild cognitive impairment to Alzheimer dementia. Archives of Gerontology and Geriatrics, 2021, 94, 104359.	1.4	2

#	Article	IF	CITATIONS
1662	A Study of Changes of Physical Functions According to Changes in Cognitive Functions in Community-Dwelling Elderly People Who Participated in an Exercise Program. Journal of Sports Science and Medicine, 2021, 20, 474-481.	0.7	1
1663	Molecular dynamics study of water channels in natural and synthetic amyloid- $\hat{l}^2$ fibrils. Journal of Chemical Physics, 2021, 154, 235102.	1.2	0
1664	The Association of Cultural Participation and Social Engagement With Self-Reported Diagnosis of Memory Problems Among American Indian and Alaska Native Elders. Journal of Aging and Health, 2021, 33, 60S-67S.	0.9	2
1665	Comprehensive investigations for a potential natural prophylaxis—A cellular and murine model for apple cider vinegar against hydrogen peroxide and scopolamine induced oxidative stress. Drug Development Research, 2021, , .	1.4	7
1666	A Simple Method for Simulating Dementia Onset and Death within an Existing Demographic Model. Medical Decision Making, 2022, 42, 0272989X2110168.	1.2	1
1667	Role of Withaferin A and Its Derivatives in the Management of Alzheimer's Disease: Recent Trends and Future Perspectives. Molecules, 2021, 26, 3696.	1.7	22
1668	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within community dwelling populations. The Cochrane Library, 2021, 2021, CD010079.	1.5	3
1669	Threshold Effects of Total Copper Intake on Cognitive Function in US Older Adults and the Moderating Effect of Fat and Saturated Fatty Acid Intake. Journal of the Academy of Nutrition and Dietetics, 2021, 121, 2429-2442.	0.4	6
1670	Mini-Cog for the detection of dementia within a community setting. The Cochrane Library, 2021, 2021, CD010860.	1.5	6
1671	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within a secondary care setting. The Cochrane Library, 2021, 2021, CD010772.	1.5	4
1672	Investigation of nootropic potential of ethanol extract of Elettaria cardamomum Maton fruit (Cardamom): a spice of India. Clinical Phytoscience, 2021, 7, .	0.8	0
1673	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within a general practice (primary care) setting. The Cochrane Library, 2021, 2021, CD010771.	1.5	1
1674	The neurogenic niche in Alzheimer's disease. Neuroscience Letters, 2021, 762, 136109.	1.0	7
1675	Sepsis and Cognitive Assessment. Journal of Clinical Medicine, 2021, 10, 4269.	1.0	5
1676	Aortic valve replacement among patients with Alzheimer's disease and related dementias. Journal of the American Geriatrics Society, 2021, 69, 3468-3475.	1.3	1
1677	Potential neuroprotection by Dendrobium nobile Lindl alkaloid in Alzheimer's disease models. Neural Regeneration Research, 2022, 17, 972.	1.6	25
1678	Effects of expressive arts therapy in older adults with mild cognitive impairment: A pilot study. Geriatric Nursing, 2021, 42, 129-136.	0.9	14
1679	Relationship Between Physical Performance and Mild Cognitive Impairment in Chinese Community-Dwelling Older Adults. Clinical Interventions in Aging, 2021, Volume 16, 119-127.	1.3	23

#	ARTICLE	IF	CITATIONS
1680	Conjugal Alzheimer Disease. Archives of Neurology, 2008, 65, 373-8.	4.9	37
1683	Understanding and Treating Alzheimer's Disease. , 2006, , 49-70.		1
1684	Mindfulness-Based Elder Care: Communicating Mindfulness to Frail Elders and Their Caregivers. , 2009, , 431-445.		8
1685	Cholesterol—A Janus-Faced Molecule in the Central Nervous System. , 2007, , 151-170.		2
1686	Pathogenesis of Prion Diseases. , 2007, , 125-146.		1
1687	Living Longer, Healthier Lives., 2007,, 53-78.		2
1688	Cognitive Impairment., 0,, 99-126.		3
1689	How Biochemical Pathways for Disease May be Triggered by Early-Life Events. , 2009, , 205-214.		1
1690	What Have We Learned from the Tau Hypothesis?., 2009,, 49-62.		5
1692	Early Memory Loss Clubs: A Novel Approach for Stimulating and Sustaining Cognitive Function. , 2011, , 381-400.		1
1693	Gene- and Cell-Based Approaches for Neurodegenerative Disease. Advances in Experimental Medicine and Biology, 2010, 671, 117-130.	0.8	10
1694	Zinc and Zinc Transport and Sequestration Proteins in the Brain in the Progression of Alzheimer's Disease. Advances in Neurobiology, 2011, , 669-693.	1.3	1
1695	Metabolic Syndrome as a Risk Factor for Alzheimer Disease., 2013,, 281-341.		3
1696	Brain Imaging and Cognition. , 2014, , 235-256.		5
1697	Assistive Technologies for Improving Quality of Life. Autism and Child Psychopathology Series, 2014, , 1-20.	0.1	7
1698	Assistive Technology for People with Alzheimer's Disease. Autism and Child Psychopathology Series, 2014, , 219-250.	0.1	7
1699	A Case of Alzheimer's Dementia in Uganda. , 2015, , 247-254.		3
1700	Brain Oxidative Stress in the Pathogenesis and Progression of Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 99-118.	0.4	1

#	Article	IF	CITATIONS
1701	Toward Uniform Smart Healthcare Ecosystems: A Survey on Prospects, Security, and Privacy Considerations., 2020,, 75-112.		10
1702	RNA Granules and Their Role in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2019, 1203, 195-245.	0.8	19
1703	A Comparative Study on Epileptic Seizure Detection Methods. Advances in Intelligent Systems and Computing, 2021, , 3-8.	0.5	1
1704	Physical Activity and Chronic Disease Prevention. Contemporary Pediatric and Adolescent Sports Medicine, 2016, , 163-179.	0.0	5
1706	Improving Prognostic Prediction from Mild Cognitive Impairment to Alzheimer's Disease Using Genetic Algorithms. Advances in Intelligent Systems and Computing, 2017, , 180-188.	0.5	6
1707	The Importance of the Environment in Brain Aging: Be Happy, Live Longer!. , 2012, , 79-94.		2
1709	Behavior and Personality Disturbances. , 2012, , 73-91.		1
1710	Importance of tau in cognitive decline as revealed by developmental exposure to lead. Toxicology Letters, 2018, 284, 63-69.	0.4	7
1711	Noninvasive Brain Stimulation for the Study of Memory Enhancement in Aging. European Psychologist, 2016, 21, 41-54.	1.8	14
1713	Implications of Skinner's verbal behavior for studying dementia The Journal of Speech and Language Pathology, Applied Behavior Analysis, 2010, 5, 48-58.	0.2	3
1715	Altruism and Informal Care for Dementia. International Journal of Social Science Studies, 2013, 2, .	0.0	2
1716	Dementia Population Risk Tool (DemPoRT): study protocol for a predictive algorithm assessing dementia risk in the community. BMJ Open, 2017, 7, e018018.	0.8	9
1717	COMPLEXITY OF MOLECULAR SIGNALING NETWORKS FOR VARIOUS TYPES OF CANCER AND NEUROLOGICAL DISEASES CORRELATES WITH PATIENT SURVIVABILITY. , 2014, , .		1
1718	Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease. Journal of Diabetes Research, 2020, 2020, 1-12.	1.0	93
1719	Predicting cognitive decline in healthy older adults. American Journal of Geriatric Psychiatry, 2005, 13, 735-40.	0.6	36
1720	Public awareness, knowledge, and attitude toward Alzheimer's disease in Aseer region, Saudi Arabia. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020, 56, .	0.4	7
1721	Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 419-434.	0.4	115
1722	Diagnosis and treatment of Alzheimer's disease. Neurology, 2005, 64, S34-9.	1.5	116

#	Article	IF	CITATIONS
1723	Moderate to severe Alzheimer disease. Neurology, 2005, 65, .	1.5	13
1724	Cost consequences and cost benefits of treating patients with moderate to severe Alzheimer disease. Neurology, 2005, 65, .	1.5	4
1725	FAD Mutations in Amyloid Precursor Protein Do Not Directly Perturb Intracellular Calcium Homeostasis. PLoS ONE, 2010, 5, e11992.	1,1	17
1726	Loss of Caveolin-1 Accelerates Neurodegeneration and Aging. PLoS ONE, 2010, 5, e15697.	1.1	155
1727	${\rm A\hat{l}^240~Oligomers~Identified~as~a~Potential~Biomarker~for~the~Diagnosis~of~Alzheimer's~Disease.~PLoS~ONE,~2010,~5,~e15725.}$	1.1	96
1728	Rivastigmine Lowers ${\sf A}\hat{\sf I}^2$ and Increases sAPPÎ $\pm$ Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons. PLoS ONE, 2011, 6, e21954.	1.1	58
1729	Different Patterns of White Matter Degeneration Using Multiple Diffusion Indices and Volumetric Data in Mild Cognitive Impairment and Alzheimer Patients. PLoS ONE, 2012, 7, e52859.	1.1	68
1730	Identification of Unstable Network Modules Reveals Disease Modules Associated with the Progression of Alzheimer's Disease. PLoS ONE, 2013, 8, e76162.	1.1	41
1731	KIAA1462, A Coronary Artery Disease Associated Gene, Is a Candidate Gene for Late Onset Alzheimer Disease in APOE Carriers. PLoS ONE, 2013, 8, e82194.	1,1	9
1732	A Network Based Method for Analysis of IncRNA-Disease Associations and Prediction of IncRNAs Implicated in Diseases. PLoS ONE, 2014, 9, e87797.	1.1	150
1733	Analyses of the Binding between Water Soluble C60 Derivatives and Potential Drug Targets through a Molecular Docking Approach. PLoS ONE, 2016, 11, e0147761.	1.1	23
1734	Structural and functional connectional fingerprints in mild cognitive impairment and Alzheimer's disease patients. PLoS ONE, 2017, 12, e0173426.	1.1	24
1735	Electronic cigarette use and subjective cognitive complaints in adults. PLoS ONE, 2020, 15, e0241599.	1.1	18
1736	The Epidemiological Scale of Alzheimer's Disease. Journal of Clinical Medicine Research, 2015, 7, 657-666.	0.6	53
1737	Micro and nanocrystalline cellulose based oral dispersible film; preparation and evaluation of in vitro/in vivo rapid release studies for donepezil. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	3
1739	Association study of the PLXNA4 gene with the risk of Alzheimer's disease. Annals of Translational Medicine, 2016, 4, 108-108.	0.7	6
1740	Economic considerations in the management of Alzheimer's disease. Clinical Interventions in Aging, 2006, 1, 143-154.	1.3	82
1741	Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2007, 3, 245-258.	1.0	35

#	Article	IF	CITATIONS
1742	The Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease. Current Pharmaceutical Design, 2014, 20, 2506-2519.	0.9	30
1743	Increased Alzheimer's Disease Neuropathology is Associated with Type 2 Diabetes and ApoE & Carrier Status. Current Alzheimer Research, 2013, 10, 654-659.	0.7	57
1744	Epidemiology and Etiology of Alzheimer's disease: From Genetic to Non- Genetic Factors. Current Alzheimer Research, 2013, 10, 852-867.	0.7	174
1745	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. Current Alzheimer Research, 2017, 14, 1190-1197.	0.7	39
1746	Neuroprotective Effect of $\hat{l}^2$ -secretase Inhibitory Peptide from Pacific Hake (Merluccius productus) Fish Protein Hydrolysate. Current Alzheimer Research, 2019, 16, 1028-1038.	0.7	11
1747	Interactions between Personality, Depression, Anxiety and Cognition to Understand Early Stage of Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2020, 20, 782-791.	1.0	9
1748	Impact of the CD40-CD40L Dyad in Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 149-155.	0.8	33
1749	An Overview on Potential Neuroprotective Compounds for Management of Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2013, 11, 1006-1011.	0.8	10
1750	Link Between Chronic Bacterial Inflammation and Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1140-1147.	0.8	48
1751	Computer-Based Driving in Dementia Decision Tool With Mail Support: Cluster Randomized Controlled Trial. Journal of Medical Internet Research, 2018, 20, e194.	2.1	6
1752	Biomarkers to advance drug development for Alzheimer's disease. Future Neurology, 2006, 1, 409-415.	0.9	1
1753	Positron emission tomography in Alzheimer's disease: early prediction and differentiation. Future Neurology, 2009, 4, 23-38.	0.9	1
1754	Mitochondrial toxins and neurodegenerative diseases. Frontiers in Bioscience - Landmark, 2007, 12, 986.	3.0	53
1755	Functional foods and bioactive compounds: Roles in the prevention, treatment and management of neurodegenerative diseases. GSC Biological and Pharmaceutical Sciences, 2020, 11, 297-313.	0.1	7
1756	Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in Clinical Neuroscience, 2009, 11, 111-128.	1.8	855
1757	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	1.8	38
1758	Diagnosis of Alzheimer's disease with [18F]PET in mild and asymptomatic stages. Behavioural Neurology, 2009, 21, 101-15.	1.1	17
1759	Alzheimer's Disease Prevalence can be Lowered with Non-Invasive Testing. Journal of Alzheimer's Disease, 2008, 14, 353-359.	1.2	32

#	Article	IF	Citations
1760	Testing the Neurovascular Hypothesis of Alzheimer's Disease: LRP-1 Antisense Reduces Blood-brain Barrier Clearance, Increases Brain Levels of Amyloid-β Protein, and Impairs Cognition. Journal of Alzheimer's Disease, 2009, 17, 553-570.	1.2	111
1761	Role Change Experienced by Family Caregivers of Adults with Alzheimer's Disease. Californian Journal of Health Promotion, 2004, 2, 82-91.	0.3	1
1762	A Review on Current Strategies and Future Perspective in Respect to Alzheimer's Disease Treatment. Current Research in Neuroscience, 2015, 6, 1-15.	0.0	4
1763	Memory and Brain Neurotransmitter Restoring Potential of Hydroalcoholic Extract of Ipomoea aquatica Forsk on Amyloid Beta Aβ (25-35) Induced Cognitive Deficits in Alzheimer's Mice. International Journal of Pharmacology, 2016, 12, 52-65.	0.1	3
1764	Spaced Retrieval for Enhancing Memory: Implications for Nursing Practice and Research. Journal of Gerontological Nursing, 2007, 33, 46-52.	0.3	21
1765	Individualized Skills Training Program for Community-Dwelling Adults with Mild Alzheimer's Disease. Journal of Gerontological Nursing, 2011, 37, 20-31.	0.3	2
1766	Struggling to Do the Right Thing: Stories from People Living with Alzheimer's Disease. Journal of Psychosocial Nursing and Mental Health Services, 2005, 43, 13-16.	0.3	8
1767	Review of Exemplar Programs for Adults with Early-Stage Alzheimer's Disease. Research in Gerontological Nursing, 2008, 1, 295-304.	0.2	14
1768	Pilot Study of a Brief Behavioral Sleep Intervention for Caregivers of Individuals with Dementia. Research in Gerontological Nursing, 2010, 3, 19-29.	0.2	18
1769	Behavioral Symptoms of Dementia: A Dyadic Effect of Caregivers' Stress Process?. Research in Gerontological Nursing, 2011, 4, 168-184.	0.2	9
1770	Aerobic Training for Older Men with Alzheimer's Disease: Individual Examples of Progression. Research in Gerontological Nursing, 2011, 4, 243-250.	0.2	11
1771	Sleep Disturbance, Nocturnal Agitation Behaviors, and Medical Comorbidity in Older Adults With Dementia: Relationship to Reported Caregiver Burden. Research in Gerontological Nursing, 2014, 7, 206-214.	0.2	12
1772	Towards defining the Mechanisms of Alzheimer's disease based on a contextual analysis of molecular pathways. AIMS Genetics, 2016, 03, 025-048.	1.9	3
1773	Alzheimer disease: Time to improve its diagnosis and treatment. Cleveland Clinic Journal of Medicine, 2009, 76, 49-58.	0.6	53
1774	Attitudes and expectations of technologies to manage wandering behavior in persons with dementia. Gerontechnology, 2007, 6, .	0.0	19
1775	Korean Red Ginseng Tonic Extends Lifespan in D. melanogaster. Biomolecules and Therapeutics, 2013, 21, 241-245.	1.1	19
1776	Sex Differences in Cardiovascular Risk Factors for Dementia. Biomolecules and Therapeutics, 2018, 26, 521-532.	1.1	25
1777	Alzheimer's Disease A Century Later. Journal of Clinical Psychiatry, 2006, 67, 1784-1800.	1.1	99

#	Article	IF	CITATIONS
1778	Spontaneous Social Behaviors Discriminate Behavioral Dementias From Psychiatric Disorders and Other Dementias. Journal of Clinical Psychiatry, 2008, 69, 60-73.	1.1	55
1779	Practical Diagnosis and Management of Dementia Due to Alzheimer's Disease in the Primary Care Setting. primary care companion for CNS disorders, The, 2013, 15, .	0.2	20
1780	Alzheimer's Disease in the Family Practice Setting. Primary Care Companion To the Journal of Clinical Psychiatry, 2004, 6, 234-238.	0.6	8
1781	A Systematic Review of Assessment and Treatment of Moderate to Severe Alzheimer's Disease. Primary Care Companion To the Journal of Clinical Psychiatry, 2006, 8, 158-9.	0.6	40
1782	Changing the Course of Alzheimer's Disease. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 32-41.	0.6	31
1783	Treatment Guidelines for Alzheimer's Disease. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 113-121.	0.6	51
1784	The complexities underlying age-related macular degeneration: could amyloid beta play an important role?. Neural Regeneration Research, 2017, 12, 538.	1.6	34
1785	Evaluation of Demographics and Medication Use in Patients with Dementia in Assisted Living and Skilled Nursing Facilities. The Consultant Pharmacist, 2005, 20, 584-591.	0.4	4
1786	Scientific Rigor Recommendations for Optimizing the Clinical Applicability of Translational Research. Journal of Neurology & Neurophysiology, 2012, 03, .	0.1	19
1787	Toxic Exposure and Life Style Factors on Ageing Brain Neurodegenerative Disease, Alzheimer's and Parkinson's: Role of Natural Antioxidants to Ameliorate the Condition. Journal of Alcoholism and Drug Dependence, 2018, 06, .	0.2	1
1788	The Potential Role of Epigenetics in Alzheimer?s Disease Etiology. Biological Systems, Open Access, 2012, 02, .	0.1	3
1789	Iterative Image Processing for Early Diagnostic of Beta-Amyloid Plaque Deposition in Pre-Clinical Alzheimer's disease Studies. Journal of Applied Bioinformatics & Computational Biology, 2017, 06, .	0.2	8
1790	Global Proteomics: Pharmacodynamic Decision Making via Geometric Interpretations of Proteomic Analyses. Journal of Proteomics and Bioinformatics, 2008, 01, 315-328.	0.4	6
1791	Predictors of hospitalization and institutionalization in Medicaid patient populations with Alzheimer's Disease. Advances in Alzheimer's Disease, 2013, 02, 74-82.	0.3	3
1792	Options for Evaluating Treatment Benefit in MCI and Prodromal Alzheimer's Disease: Content Validity of the Perceived Deficits Questionnaire (PDQ) in Patients with Early Symptoms of Cognitive Decline. Advances in Alzheimer's Disease, 2014, 03, 1-10.	0.3	2
1793	Association between Caregiver Quality of Life and the Care Provided to Persons with Alzheimer's Disease: Systematic Review. Advances in Alzheimer's Disease, 2014, 03, 44-53.	0.3	11
1794	Recent progress and concerns in dementia: Distinguishing Alzheimer's disease and dementia with Lewy bodies via biochemical markers in the cerebrospinal fluid. Advances in Biological Chemistry, 2012, 02, 176-190.	0.2	10
1795	The interrelationship between insulin resistane and Alzheimer development. Journal of Biomedical Science and Engineering, 2013, 06, 754-773.	0.2	2

#	Article	IF	Citations
1796	Dying of Boredom: An Exploratory Case Study of Time Use, Apparent Affect, and Routine Activity Situations on Two Alzheimer's Special Care Units. American Journal of Occupational Therapy, 2009, 63, 337-350.	0.1	80
1797	Drivers With Dementia and Outcomes of Becoming Lost While Driving. American Journal of Occupational Therapy, 2010, 64, 225-232.	0.1	58
1798	Semiparametric accelerated failure time model for length-biased data with application to dementia study. Statistica Sinica, 2014, 24, 313-333.	0.2	15
1799	Validation of Arabic Version of Saint - Louis - University - Mental - Status (SLUMS) - Examination and Prevalence of Cognitive Impairment in Community Dwelling Egyptian Older Adults. Middle East Journal of Age and Ageing, 2014, 11, 11-19.	0.0	10
1801	Disparities in Subjective Cognitive Impairment by Sexual Orientation and Gender in a National Population Based Study of U.S. Adults, 2013–2018. Journal of Aging and Health, 2022, 34, 519-528.	0.9	11
1802	Letter Concerning <i>Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease</i> by Moghavem, Henderson, and Greicius. Annals of Neurology, 2021, 90, 1004-1006.	2.8	0
1803	Voting and the Cognitively Impaired. SSRN Electronic Journal, 0, , .	0.4	0
1804	Dementia-Specific Respite: The Key to Effective Caregiver Support. North Carolina Medical Journal, 2005, 66, 50-54.	0.1	3
1805	Alzheimer's Disease and the Family Caregiver: The Cost and Who Pays?. North Carolina Medical Journal, 2005, 66, 18-25.	0.1	2
1806	Alzheimer's Disease and Other Dementias at End of Life. Caring for the Ages, 2005, 6, 8-13.	0.0	0
1807	Nutrition, Brain Aging, and Alzheimer's Disease. Oxidative Stress and Disease, 2005, , 409-441.	0.3	0
1809	PET in Neurology. , 2006, , 217-236.		0
1810	The Oldest Old. , 2006, , 191-204.		1
1812	Air Pollution and Human Brain Pathology. , 2006, , 331-350.		1
1813	Improving Function Through Research. Journal of Gerontological Nursing, 2006, 32, 4-5.	0.3	2
1814	The Role of Sex Steroids in Alzheimer's Disease: Prevention and Treatment. , 2007, , 295-306.		0
1815	Primary Vision Care in Geriatrics: An Overview., 2007,, 1-30.		1
1817	Neurodegenerative disorders., 2007,, 395-412.		0

#	Article	IF	CITATIONS
1818	Morbidity and Mortality Changes with Hormone Therapy., 2007,, 627-636.		0
1819	The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics. , 2007, , 194-211.		0
1820	The U.S. Population — Looking Forward from the Past. , 2007, , 35-62.		0
1821	Alzheimer's Disease: A Complex Paradigm. Medical Psychiatry, 2007, , 1-34.	0.2	0
1826	Title is missing!. Journal of Lipid Nutrition, 2008, 17, 7-18.	0.1	0
1827	Enabling Ageing in Place through Visitor Recognition and Monitoring Technology. The International Journal of Science in Society, 2009, 1, 15-30.	0.2	0
1829	Questionnaire Versus Performance-Based Functional Assessment in Dementia. Psi Chi Journal of Undergraduate Research, 2009, 14, 99-106.	0.3	0
1830	Strategic Planning and Its Epidemiological Basis. , 2009, , 151-177.		0
1831	Early-Stage Alzheimer's Disease: Using Evidence to Advance the Science of Care. Journal of Gerontological Nursing, 2009, 35, 3-4.	0.3	0
1832	Visual Hallucinations in Neurodegenerative Disorders. , 2010, , 51-64.		0
1834	<b>Chapter 17</b> Neurological Disorders. , 2010, , .		0
1835	Enhancing the Communication Flow Between Alzheimer Patients, Caregivers, and Neuropsychologists. Advances in Experimental Medicine and Biology, 2010, 680, 601-607.	0.8	2
1836	Progression of Atrophy in Alzheimer's Disease and Related Disorders. , 2012, , 167-174.		0
1840	Neurologic and Cognitive Changes in the Elderly. , 2011, , 321-338.		0
1841	Health Inequalities, General Trends in Mortality and Morbidity, and Associated Factors., 2012,, 271-361.		0
1842	Individualized Skills Training Program for Community-Dwelling Adults with Mild Alzheimer's Disease. Journal of Gerontological Nursing, 2011, 37, 20-29.	0.3	0
1844	Clinical Trials of AD Delay of Onset: Enrichment by a Prognostic Genetic Biomarker. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 141-160.	0.6	0
1845	Brain Aging: Influence of Early–Life Events on Late-Life Brain Disorders. , 2012, , 67-78.		0

#	Article	IF	CITATIONS
1846	Understanding Mechanism of Action of Herbal Drugs in Age Related Degenerative Brain Disorders. , 2012, , 159-176.		0
1847	Now Where Was I Going? The Challenge of Care Transitions for the Cognitively Impaired. North Carolina Medical Journal, 2012, 73, 58-60.	0.1	1
1849	Assessment of Alzheimer's Disease. , 2013, , 271-280.		1
1850	Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease. Frontiers in Neuroscience, 2012, , 87-102.	0.0	0
1853	Aging, dementia, and disorders of cognition. , 2013, , 835-862.		1
1854	Progression of Atrophy in Alzheimer's Disease and Related Disorders. , 2013, , 185-192.		0
1855	A Study of the Indoor Walking Navigation System for Patients with Early-stage Alzheimer's Disease. , 2013, , .		3
1857	The Relationship Between Aortic Stiffness, Microvascular Disease in the Brain and Cognitive Decline: Insights into the Emerging Epidemic of Alzheimer's Disease. , 2014, , 307-320.		3
1859	HemeOxygenase-1: Transducer of Sterol Dys-Regulation in Alzheimer Disease. Journal of Glycomics & Lipidomics, 2014, 04, .	0.4	0
1860	Dementia, Delirium, and Depression. , 2014, , 73-87.		0
1861	Race-Ethnicity and Gender in Older Adults. , 2014, , 65-83.		2
1862	Role of MFG-E8 in the Brain. , 2014, , 173-187.		0
1863	AN IN SILICO EVALUATION OF COCCINIA GRANDIS FRUITS AGAINST ALZHEIMERS DISEASE. Journal of Pharmaceutical and Scientific Innovation, 2014, 3, 328-332.	0.1	0
1864	Nutrition at the End of Life. , 2015, , 303-312.		0
1869	New Frontiers in Alzheimer's Disease Diagnosis. , 0, , .		0
1870	Sex Steroids and Mood in Women. , 2015, , 147-169.		O
1871	Alcohol and Cognition. , 2016, , 79-96.		0
1873	Multidisciplinary/interdisciplinary actions in the care of elderly with Alzheimer's Disease. Revista Da Rede De Enfermagem Do Nordeste, 2016, 17, 144.	0.2	6

#	Article	IF	CITATIONS
1874	Functional NeuroCognitive ImagingTM and Notus NeuroCogsTM: A Novel Use of fMRI in the Assessment of Cognitive Function in Major Neurocognitive Disorder. Journal of Neuroimaging in Psychiatry & Neurology, 2017, 02, .	0.4	1
1875	1.8 DELIRIUM and DEMENTIA DELIRIUM. Journal of Hospital Medicine, 2017, 12, .	0.7	1
1877	Dietary Intake of AGEs and ALEs and Inflammation: Nutritional Aspects., 2017,, 309-328.		0
1878	A Risk Coefficient for Radiation-Induced Dementia. Advances in Alzheimer's Disease, 2018, 07, 13-35.	0.3	1
1879	Mitochondrial Function and Neurodegenerative Diseases. , 2018, , 369-414.		1
1880	The optimized time of 18F-THK5351 PET/CT in normal Thai population. , 2018, , .		0
1884	Memory Dysfunction Correlates with the Dysregulated Dopaminergic System in the Ventral Tegmental Area in Alzheimer's Disease. , 2019, , 85-98.		0
1885	Tau Pathology. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 217-234.	0.1	0
1886	Drug Classifications and Pharmacologic Actions. , 2019, , 181-261.		0
1888	A Smart System for the People Enduring through Alzheimer's Disease. , 2019, , .		0
1889	Transitions in financial autonomy and risk for financial elder abuse. , 2020, , 87-107.		0
1890	Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 2257-2279.	0.9	4
1891	Herbal Drugs Used In Treatment Of Alzimer's Disease. American Journal of PharmTech Research, 2020, 10, 66-87.	0.2	0
1892	Development of Chinese Versions of Quality of Life in Late-Stage Dementia and Cognitive Tests for Severe Dementia. Dementia and Geriatric Cognitive Disorders Extra, 2021, 10, 172-181.	0.6	1
1893	Is there an association between oral health-related quality of life and Alzheimer's disease?. Evidence-Based Dentistry, 2020, 21, 124-125.	0.3	1
1895	Latinos and Dementia: Prescriptions for Policy and Programs that Empower Older Latinos and Their Families. , 2020, , 385-401.		3
1896	Acupuncture Treatment is Associated with a Decreased Risk of Dementia in Patients with Depression: A Propensity Score-Matched Cohort Study. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3255-3266.	1.0	2
1897	Are the benefits of NSAIDs to decrease the risk of Alzheimer's disease a MIRAGE?. Therapy: Open Access in Clinical Medicine, 2005, 2, 375-380.	0.2	0

#	Article	IF	CITATIONS
1898	Therapy of vascular dementia: perspectives and milestones. Therapy: Open Access in Clinical Medicine, 2005, 2, 649-658.	0.2	1
1899	Physical function parameters that predict the onset of mild cognitive impairment one year later in community-dwelling elderly women. Japanese Journal of Health Promotion and Physical Therapy, 2020, 10, 117-123.	0.1	0
1900	Obesity, the deadly quartet and the contribution of the neglected daily organ rest - a new dimension of un-health and its prevention. Hepatobiliary Surgery and Nutrition, 2015, 4, 278-88.	0.7	4
1901	Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical Interventions in Aging, 2008, 3, 211-25.	1.3	319
1902	Beyond the Black Box: What is The Role for Antipsychotics in Dementia?. Current Psychiatry, 2008, 7, 50-65.	1.7	15
1909	Cost evaluation of a coordinated care management intervention for dementia. American Journal of Managed Care, 2009, 15, 521-8.	0.8	35
1910	Attitudes on aging well among older African Americans and whites in South Carolina. Preventing Chronic Disease, 2009, 6, A113.	1.7	5
1911	Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease. American Journal of Translational Research (discontinued), 2009, 1, 131-47.	0.0	12
1912	Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behavioural Neurology, 2009, 21, 3-12.	1.1	24
1914	Are clinician's ever biased in their judgments of the capacity of older adult's to make medical decisions?. Generations, 2009, 33, 78-91.	1.0	10
1916	FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 250-64.	0.4	32
1917	Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evidence, 2006, 1, 195-219.	4.7	21
1918	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Current Opinion in Investigational Drugs, 2010, 11, 80-91.	2.3	18
1919	Integrative analysis of common neurodegenerative diseases using gene association, interaction networks and mRNA expression data. AMIA Summits on Translational Science Proceedings, 2012, 2012, 62-71.	0.4	11
1921	Linguistic adaptation of the clinical dementia rating scale for a Spanish-speaking population: a focus group approach. Puerto Rico Health Sciences Journal, 2010, 29, 102-8.	0.2	5
1922	Relationship between oral health and its impact on the quality life of Alzheimer's disease patients: a supportive care trial. International Journal of Clinical and Experimental Medicine, 2013, 6, 766-72.	1.3	35
1924	Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?. American Journal of Cardiovascular Disease, 2013, 3, 197-226.	0.5	126
1925	Melatonin and abeta, macular degeneration and alzheimers disease: same disease, different outcomes?. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2012, 1, 24-32.	0.4	3

#	Article	IF	CITATIONS
1928	Diagnosis and Management of Mild Cognitive Impairment in the Community: What is the Role of Primary Care Physician? Malaysian Family Physician, 2011, 6, 74-8.	0.2	3
1931	Next Generation House Call. Cerebrum: the Dana Forum on Brain Science, 2017, 2017, .	0.1	0
1932	Cost of dementia in Medicare managed care: a systematic literature review. American Journal of Managed Care, 2019, 25, e247-e253.	0.8	10
1933	<i>SCN2B</i> , a possible crucial molecule involved in the aging associated Alzheimer's disease., 2019, 5, 26-32.		0
1934	Evaluating Residual Cognition in Advanced Cognitive Impairment: The Residual Cognition Assessment. Dementia and Geriatric Cognitive Disorders, 2021, 50, 460-472.	0.7	0
1935	Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation, 2022, 145, CIR000000000001052.	1.6	2,561
1936	The New Frontier of Perioperative Cognitive Medicine for Alzheimer's Disease and Related Dementias. Neurotherapeutics, 2022, 19, 132-142.	2.1	2
1937	The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases. Neuroscience and Biobehavioral Reviews, 2022, 135, 104541.	2.9	4
1938	Reassessing Diabetes and APOE Genotype as Potential Interacting Risk Factors for Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2022, 37, 153331752110709.	0.9	1
1939	White Matter Lesions May Aid in Differentiating Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 851-862.	1.2	4
1940	Mechanical Ventilation and Survival in Patients With Advanced Dementia in Medicare Advantage. Journal of Pain and Symptom Management, 2022, , .	0.6	0
1941	Two new metabolites from Portulaca oleracea and their anti-inflammatory activities. Phytochemistry Letters, 2022, 48, 114-119.	0.6	6
1942	The prevalence of cognitive impairment in older Indian persons with cancer and brain metastases. Ecancermedicalscience, 0, 16, .	0.6	0
1943	Directional DBS of the Fornix in Alzheimer's Disease Achieves Long-Term Benefits: A Case Report. Frontiers in Aging Neuroscience, 2022, 14, 809972.	1.7	3
1944	Contribution of socioeconomic, lifestyle, and medical risk factors to disparities in dementia and mortality. SSM - Population Health, 2021, 16, 100979.	1.3	3
1945	CURVED MULTIFORMAT IMAGING OF STRUCTURAL MRI AS A BIOMARKER FOR PROFILING OF VARIOUS DEMENTIA – AN ALGORITHMIC APPROACH WITH MR/PET. Asian Journal of Psychiatry, 2022, 73, 103094.	0.9	1
1946	Palliative Care for Patients with Alzheimer's Dementia: Advance Care Planning Across Transition Points., 2007,, 144-156.		0
1947	Familial Neurodegenerative Diseases and Single Nucleotide Polymorphisms. , 2008, , 463-478.		0

#	Article	IF	CITATIONS
1970	Relationships Between Cognitive Screening Composite Scores and Pain Intensity and Pain Disability in Adults With/At Risk for Knee Osteoarthritis. Clinical Journal of Pain, 2022, 38, 470-475.	0.8	7
1974	Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations. Microorganisms, 2022, 10, 1326.	1.6	6
1975	A Systematic Review and Meta-Analysis of Cerebrospinal Fluid Amyloid and Tau Levels Identifies Mild Cognitive Impairment Patients Progressing to Alzheimer's Disease. Biomedicines, 2022, 10, 1713.	1.4	5
1976	The Incidence and Burden of Risk Factors for Mild Cognitive Impairment in Older Rural Chinese Persons. Gerontology and Geriatric Medicine, 2022, 8, 233372142211145.	0.8	2
1977	Angiotensin Receptor Blockers and Dementia Prevention: Do Not RAS to a Conclusion Yet. Hypertension, 2022, 79, 2170-2172.	1.3	1
1978	Gut Microbiome and Diet: Promising Approach for Treatment of Cognitive Impairment. , 2022, , 195-209.		0
1979	Dementia diagnosis with EEG using machine learning. , 2023, , 107-129.		1
1980	Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs. Medicinal Chemistry, 2023, 19, 311-324.	0.7	4
1981	Leisure, Mental Health, and Life Satisfaction among Older Adults with Mild Cognitive Impairment. American Journal of Health Behavior, 2022, 46, 477-487.	0.6	6
1982	Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	7
1983	EEG coherence as a marker of functional connectivity disruption in Alzheimer's disease. Aging and Health Research, 2022, 2, 100098.	0.5	7
1984	Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers. Diagnostics, 2022, 12, 2425.	1.3	2
1985	Tibolone Improves Memory and Decreases the Content of Amyloid-β Peptides and Tau Protein in the Hippocampus of a Murine Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 1437-1447.	1.2	1
1986	Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversity. Alzheimer's and Dementia, 2023, 19, 1841-1848.	0.4	6
1987	Candesartan â $\in$ " the next anti-amyloid drug?. Brain Communications, 0, , .	1.5	0
1988	Neuron-targeted Knockout of APE1 Forces Premature Cognitive Impairment and Synaptic Dysfunction in Adult Mice., 2022, 13, 1862.		3
1990	Flipping the Default: A Novel Approach to Cardiopulmonary Resuscitation in End-Stage Dementia. Journal of Clinical Ethics, 2007, 18, 122-139.	0.1	36
1991	A Forced Choice: The Value of Requiring Advance Directives. Journal of Clinical Ethics, 2008, 19, 127-140.	0.1	1

#	Article	IF	CITATIONS
1992	Effect of Aqueous Extract of Allium Canadense on the Activity of the Inhibited Acetylcholinesterase Enzyme by Organophosphate Diazinon. Majallah-i DÄnishgÄh-i 'UlÅ«m-i PizishkÄ«-i ĪlÄm, 2022, 30, 95-103.	0.1	0
1994	The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development., 2011,, 1-14.		o
1995	Systemic GDF11 attenuates depression-like phenotype in aged mice via stimulation of neuronal autophagy. Nature Aging, 2023, 3, 213-228.	5.3	9
1996	Post-traumatic stress disorder in Alzheimer's disease. , 2017, 32, 58-69.		5
1997	Nanobots: Self-Regulated Electronics for Health Care. , 2023, , 643-649.		1
1998	Young Astrocytic Mitochondria Attenuate the Elevated Level of CCL11 in the Aged Mice, Contributing to Cognitive Function Improvement. International Journal of Molecular Sciences, 2023, 24, 5187.	1.8	2
1999	Association of common infections with cognitive performance in the Baltimore Epidemiologic Catchment Area study followâ€up. Alzheimer's and Dementia, 2023, 19, 4841-4851.	0.4	6
2003	Effects of adenosine A2A receptors on cognitive function in health and disease. International Review of Neurobiology, 2023, , .	0.9	O
2006	The Early Stage of Abnormal Aging: Cognitive Impairment. Advances in Experimental Medicine and Biology, 2023, , 149-155.	0.8	0